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Kristin N. Hollister 
 
ELUCIDATING THE ROLE OF BCL6 IN HELPER T CELL ACTIVATION, 
PROLIFERATION, AND DIFFERENTIATION 
 
The transcriptional repressor BCL6 has been shown to be essential for the differentiation 
of germinal center (GC) B cells and follicular T helper (TFH) cells.  The interaction of 
TFH and GC B cells is necessary for the development of high affinity antibodies specific 
for an invading pathogen.  Germline BCL6-deficient mouse models limit our ability to 
study BCL6 function in T cells due to the strong inflammatory responses seen in these 
mice.  To overcome this, our lab has developed a new BCL6 conditional knockout (cKO) 
mouse using the cre/lox system, wherein the zinc finger region of the BCL6 gene is 
flanked by loxP sites.  Mating to a CD4-Cre mouse allowed us to study the effects of 
BCL6 loss specifically in T cells, without the confounding effects seen in germline 
knockout models.  Using this cKO model, we have reaffirmed the necessity of BCL6 for 
TFH differentiation, including its role in sustained CXCR5 surface expression, a 
signature marker for TFH cells.  This model also allowed us to recognize the role of 
BCL6 in promoting the expression of PD-1, another key surface marker for TFH cells.  
Without BCL6, CD4+ T cells cannot express PD-1 at the high levels seen on TFH cells.  
Our discovery of DNMT3b as a target for BCL6 suggests BCL6-deficient T cells have 
increased DNA methyltransferase activity at the PD-1 promoter.  This data establishes a 
novel pathway for explaining how BCL6, a transcriptional repressor, can activate genes.  
Experiments with the BCL6 cKO model have also established a role for BCL6 in naïve 
CD4+ T cell activation.  Furthermore, we did not observe increased differentiation of 
other helper T cell subsets, in contrast to what has been reported elsewhere with 
germline BCL6-deficient models.  Unexpectedly, we found decreased T helper type 2 
(Th2) cells, whereas mouse models with a germline mutation of BCL6 have increased 
Th2 cells.  These results indicate that BCL6 activity in non-T cells is critical for controlling 
T cell differentiation.  Finally, using an HIV-1 gp120 immunization model, we have, for 
the first time, shown BCL6-dependent GCs to be limiting for antibody development and 
affinity maturation in a prime-boost vaccine scheme.  
 
 
Alexander L. Dent, Ph.D., Chairman 
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CHAPTER 1 – A GENERAL INTRODUCTION TO THE IMMUNE RESPONSE 
 
 
Immune System Origins 
 
The immune response of mammals is a system which has been developed and fine-
tuned by evolution over millions of years (1, 2).  It enables higher order beings to survive 
in a world where bacteria and viruses cover nearly every surface.  More than half a 
billion years ago, a genetic mutation took place which enabled jawed vertebrates, of 
which mammals are one type, to enhance their immune response by rearranging the 
genes of their immune cells (1).  From that point forward, all descendants of this 
ancestral animal phylum were better suited to protect themselves from the dangers of 
infection, which is a main objective for any immune response (1).  A second, and equally 
important attribute for immune cells, is to distinguish between self and non-self (2).  Only 
by being able to recognize a foreign pathogen, while limiting damage to self-tissues, can 
an immune response be effective and lifesaving (2).  
 
In humans, and mice (the animal used as a surrogate for humans in research studies), 
the immune response is broken down into two defined, but cooperative, parts: the innate 
and adaptive immune responses.  Cells constituting both arms of the immune system 
develop through a process known as hematopoiesis, wherein self-renewing stem cells 
can give rise to progenitor cells, which, in turn, differentiate into mature immune cells (3-
5).  This process enables patients who must undergo radiation for cancer treatment, to 
have their entire immune system reconstituted from a stem cell transplant. 
 
 
The Innate Immune Response 
 
The first, and most important, layer of defense we have against pathogens is our outer 
anatomical barriers.  Skin and mucosal surfaces are essential for protecting us from 
viruses, bacteria, and other pathogens in the outside world.  In the event that this 
physical defense is compromised, such as from a cut in the skin, pathogens can gain 
entry into the body.  When this occurs, innate immune cells detect the antigen and 
attempt to remove it.  These cells all develop from a common myeloid progenitor cell (3-
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5).  Environmental cues will cause these progenitors to become either monocytes, 
neutrophils, basophils, eosinophils, or mast cells.  Working together, these cells can help 
clear the majority of infections faced on a daily basis.  By using their general defense 
mechanisms, these innate cells will eliminate pathogens before a person realizes he or 
she has been infected. 
 
Granulocytes 
 
Eosinophils, neutrophils, basophils, and mast cells are all considered granulocytes and 
differentiate from a precursor of the same name.  These cells are so named because of 
the distinct granules visible when viewed under a microscope.  Granules in eosinophils 
contain cytokines and enzymes, such as peroxidase and neurotoxin (6).  Once they 
receive stimulating factors from the environment, in particular interleukin (IL)-5, these 
cells will release the contents of their granules, a process called degranulation (6).  
Those contents will then facilitate killing of infected cells and tissues or directly affect the 
pathogen.  Dysregulation of these cells has been shown in a number of diseases, 
including asthma (6).   
 
In the case of neutrophils, the cytokines contained within their granules can exacerbate 
the inflammatory response by recruiting additional immune cells to the point of infection 
(7).  Also, release of reactive oxygen species facilitates killing of infected tissue.  Unlike 
eosinophils, these cells also have the ability to phagocytose microorganisms or particles 
which have been marked for removal by other components of the immune response (7).   
 
Mast cells and basophils share similar functions and, historically, basophils have been 
mistaken for a type of mast cell (8).  However, more recent research has shown these 
two cells to be distinct linages of myeloid cells.  While both cell types are rare, basophils 
are relatively short-lived, while mast cells can persist in tissues for weeks to months (8, 
9).  Both cell types play a role in allergy and inflammation.  Among other things, the 
granules in these cells contain histamine, and, upon their release, can both mediate and 
exacerbate allergic responses.  Furthermore, basophils help mediate the T helper type 2 
(Th2) response (8, 9), which will be described further in a later section.   
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Monocytes, macrophages, dendritic cells 
 
Monocytes are a unique type of innate cell in that they exit the bone marrow into 
circulation as a mature cell, but continue to differentiate into additional types of immune 
cells in the periphery.  Once they leave the blood circulation and enter into tissues, such 
as spleen and lymph nodes, environmental cues will trigger these cells to differentiate 
into macrophages (MΦ) or dendritic cells (DC) (10, 11).  These cells are phagocytes 
which present ingested antigen to T and B cells.  The unique ability of these cells to 
present antigen to T helper (Th) cells classifies them as professional antigen presenting 
cells (APC) (12). 
 
Major histocompatibility complex class II molecules 
 
A requisite for professional APCs to present antigen to Th cells is their expression of 
major histocompatibility complex class II (MHC II) molecules on their cell surface.  Unlike 
MHC class I (MHC I) molecules, which are expressed on every nucleated cell, MHC II 
expression is reserved to only professional APCs, of which MΦ and DCs are two types 
(13).  Within the APC, the MHC II molecule is composed of an alpha and beta heavy 
chain and is assembled in the endoplasmic reticulum (ER).  To stabilize the two 
subunits, a protein called invariant chain binds the groove where antigen will be loaded 
(13-15).  This full-length protein is then cleaved, leaving only a small peptide, known as 
CLIP, within the antigen binding groove.  After leaving the ER and trafficking through the 
Golgi apparatus, the MHC II molecule will migrate into the cytoplasm in an endosome.  
Meanwhile, pathogens are taken up from the outside, via phagocytosis, into 
phagosomes (13-15).  Within phagosomes, pathogen is digested into peptide fragments.  
When an endosome containing an assembled MHC II molecule binds with a 
phagosome, another protein, called DM, will bind to MHC II, causing the release of CLIP.  
With the binding groove of the MHC II molecule available, peptide is loaded onto the 
complex and trafficked to the cell surface, where the antigen can then be presented to 
Th cells in the context of the MHC II molecule (13-15).   
 
Natural killer cells 
 
A final cell type imperative for the innate immune response is the natural killer (NK) cell.   
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Unlike APCs and granulocytes, NK cells are derived from a different progenitor cell in 
the bone marrow and, thus, are more closely related to cells of the adaptive response.  
NK cells survey the body, looking for cells which have decreased or no MHC I surface 
expression (16).  This function evolved from the ability of pathogens, particularly viruses, 
to trigger down-regulation of MHC I on the surface of infected cells.  Therefore, this is an 
efficient way for NK cells to detect infected cells, and when this occurs, NK cells release 
granules which contain enzymes that kill the infected cell (16). 
 
 
The Adaptive Immune Response 
 
Professional APCs are essential for the immune response because they serve as a link 
between the innate and the adaptive responses.  Activation of this second layer of 
immunity is required if innate responses cannot clear an antigen.  The acquired 
response is made up of two major cell types: B cells and T cells.  They differentiate, as 
do NK cells, from a common lymphoid progenitor (4).  While B cells develop in the bone 
marrow and further mature in the blood, T cells exit the bone marrow in their precursor 
form and traffic to the thymus, where they will undergo further maturation and selection 
processes.  For a more detailed description of this process, please see the introduction 
of Chapter 3.  T cells are activated by APCs, which acquire antigen from the periphery, 
typically from the site of infection, and travel to the nearest draining lymph node.  
Secondary lymphoid organs, such as the spleen and lymph nodes, are organized into 
different areas important for different aspects of the acquired immune response.  Within 
a lymph node, professional APCs will interact with naïve Th cells, which are also referred 
to as CD4+ T cells due to the expression of this particular co-receptor on their surface, in 
the T cell zone (Figure 1A).  It is here where naïve Th cells are activated and, depending 
on the antigen presented and the cytokine environment, differentiate into one of several 
different Th subsets.  Each Th subset, under the control of a unique master transcription 
factor, will secrete cytokines that facilitate removal of the specific pathogen present 
(Figure 2).  
 
T helper type 1, type 2, type 17, and type 9 cells 
 
During a viral infection, T helper type 1 (Th1) cells differentiate in the presence of IL-12 
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Figure 1.  Germinal center development.  A. Naïve CD4+ Th cells are activated by 
professional APCs, such as DCs, within the T cell zone of secondary lymphoid organs.  
B. Once activated a subset of Th cells will up-regulate the transcriptional repressor 
BCL6 as well as the surface chemokine receptor, CXCR5.  This allows them to follow 
the chemokine gradient of CXCL13, the ligand for CXCR5, toward the B cell follicle.  
Follicular dendritic cells (FDC) and stromal cells (FSC) secrete this chemokine to attract 
Th cells.  C. While naïve Th cells are being activated and migrating toward the T-B cell 
border zone, B cells are also being activated by APCs within the B cell follicle.  Once 
activated, these cells will also migrate to the border zone where they can interact with Th 
cells (D).  E. The surface proteins necessary for these cognate interactions include MHC 
II/TCR, ICOSL/ICOS, CD40/CD40L, and SLAM/SLAM+SAP.  SAP is an intracellular 
protein which signals downstream from the SLAM intracellular tail.  SAP signaling is 
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crucial to maintain prolonged interactions between Th and B cells at this border zone.  
These interactions will license Th and B cells to take part in the germinal center (GC) 
reaction.  F. If cells are not licensed to become part of the GC, the Th cells will down-
regulate BCL6, migrate away from the B cell follicle, and differentiate into another Th 
subset.  B cells not able to become GC B cells can also exit the follicle, where they will 
receive help from other Th cells and become extra-follicular plasma cells, which secrete 
lower affinity antibodies.  G. Th and B cells which are properly licensed will up-regulate 
BCL6 and migrate back into the follicle to form transient structures known as GCs.  H. B 
cells will up-regulate additional surface proteins, such as GL7, Fas, and different 
cytokine receptors.  Th cells, now known as TFH cells, will up-regulate PD-1, IL-21R, as 
well as begin to secrete different cytokines, including their signature cytokine, IL-21, to 
influence changes in the GC B cells. 
 
 
in response to viral peptides presented by MHC II molecules on APCs (17, 18).  The 
master transcription factor of Th1 cells, Tbet, works with Signal Transducer and Activator 
of Transcription (STAT) 4 to clear the infection by secretion of Interferon gamma (IFNγ) 
(Figure 2).  Th2 cells will differentiate in the presence of IL-4 during extracellular parasite 
infections (18, 19).  Up-regulation of their master transcription factor, GATA3, in 
conjunction with STAT6 activity leads to secretion of signature cytokines, such as IL-4, 
IL-5, and IL-13 (Figure 2).  Th2 cells have also been shown to play a substantial role in 
allergic responses.  Antifungal and antimicrobial responses require T helper type 17 
(Th17) differentiation, whose master transcription factor is RAR-related orphan receptor 
gamma (RORγt) (17, 18, 20) (Figure 2).  Th17 cells have also been shown to trigger 
inflammation through the cytokines they secrete, including IL-17A and IL-22.  T helper 
type 9 (Th9) cells are a relatively recently studied subset which have been shown to 
clear helminth infections.  Th9 cells secrete their namesake cytokine, IL-9 (17, 20) 
(Figure 2).  For a more detailed description of Th subsets and their functions, please see 
the introduction of Chapter 4.   
 
Th-B cell interactions 
 
Th cell subsets will interact with activated B cells to trigger isotype class switching, via 
cytokine signaling, and the differentiation of B cells into plasma cells.  Plasma cells, 
whose sole job is to secrete antibodies to aid in clearing the infection, are a final 
differentiation state for B cells (21).  The interactions of Th cells and B cells take place in 
the T cell zone and are referred to as extra-follicular antibody responses.  The antibodies 
produced are not highly specific for the infecting antigen.  However, these responses 
can arise quite quickly.  In this way, extra-follicular antibodies can help to control the  
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Figure 2.  Different CD4+ Th cell subsets.  Upon activation by a professional APC, 
naïve Th cells can differentiate into one of several subsets.  The type of antigen being 
presented and cytokine environment will help direct these cells into a specific subset.  
Each subset is controlled by its own master transcription factor, and in some cases, 
specific STAT signaling.  Additionally, each subset secretes its own signature cytokine.  
Only follicular Th cells (TFH) are defined by their location, rather than just their master 
transcription factor and cytokines.  Regulatory T cells (Treg) are also unique in that they 
are responsible for repressing the activity of other Th subsets, rather than helping to 
activate the immune response. 
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infection, while more specific antibodies, which take longer to develop, are induced 
within the GC. 
 
Regulatory Th cells 
 
Regulatory T (Treg) cells play a slightly different role in the immune response.  Natural 
Tregs, or nTreg cells, develop from the thymus and are responsible for maintaining the 
responses of other T cells via suppressive cytokines (17, 19).  This ensures tolerance 
and limits auto-reactive T cell activity.  A second set of Tregs, induced Tregs (iTreg), can 
differentiate from naïve Th cells in the periphery in the presence of polarizing cytokines.  
Induced Tregs cells have the same responsibilities as nTregs.  Both types of Tregs are 
under the control of the same master transcription factor, forkhead box P3 (Foxp3) 
(Figure 2).  Induced Treg cells have been shown to be differentiated in vitro in the 
presence of transforming growth factor beta (TGF-β) (17, 18). 
 
Follicular T helper cells 
 
The final subset of Th cells, follicular T helper (TFH) cells, is quite unique in that it 
performs its functions in a completely different area of the secondary lymphoid organ, 
compared to other Th subsets.  Upon infection, TFH cells will differentiate regardless of 
what the antigen is or what the surrounding cytokine environment is in vivo.  During 
initial activation, a subset of Th cells will up-regulate the transcription factor B cell 
lymphoma 6 (BCL6), as well as the chemokine receptor C-X-C chemokine receptor type 
5 (CXCR5) (Figure 1B) (22, 23).  This enables Th cells to follow the C-X-C motif 
chemokine 13 (CXCL13) chemokine gradient, which is secreted by follicular dendritic 
cells and stromal cells, toward the B cell follicle.  Upon reaching the T/B cell border 
zone, these activated Th cells will have cognate interactions with activated B cells 
(Figure 1C-D) (24, 25).  In addition to MHC II presentation of antigen to the T cell 
receptor (TCR), CD40/CD40Ligand (CD40L), ICOS/ICOSL, and SLAM/SLAM 
interactions are crucial to this process (Figure 1E).  In particular the Slam Associated 
Protein (SAP) is a Th cell intracellular protein which has been shown to be necessary to 
prolong physical contact between the Th and B cells.  These interactions are a licensing 
process in which some of the Th cells will become TFH cells and some B cells will travel 
back into the B cell area to have further interactions with TFH cells (23, 26).  Without 
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SAP, this licensing event cannot take place, and TFH cells will not develop.  Those Th 
cells which do not become TFH cells will down-regulate BCL6 and CXCR5, travel away 
from the border region, and differentiate into another type of Th subset (Figure 1F) (22, 
25).  Additionally, B cells not chosen to further interact with TFH cells can exit the B cell 
follicle and take part in extra-follicular interactions with other Th cells, as described 
above. 
 
 
Germinal Centers 
 
Germinal center development 
 
The Th cells selected to become TFH cells at the border region will further up-regulate 
CXCR5 and the master transcription factor for TFH cells, BCL6.  At this time, it is unclear 
what attributes a Th cell must have to be licensed to become a TFH cell, however one 
study has suggested the affinity of the TCR for the antigen being presented by the 
border region B cells is the deciding factor (27).  TFH cells will then migrate into the B 
cell follicle and begin to form the structures known as germinal centers (GCs) (Figure 
1G).  GCs are transient structures which arise within the B cell area and are composed 
of TFH and B cells (28).  It is here that GC B cells will undergo somatic hypermutation, 
making the antibodies they produce highly specific for the antigen present.  Furthermore, 
isotype class switching takes place within GCs, which is a critical modification process to 
antibodies and is necessary to ensure efficient clearance of the pathogen. 
 
After being licensed, TFH cells will be the first cell type to form the GC (22, 23).  During 
their migration into the B cell follicle, these cells will up-regulate TFH signature surface 
markers, such as ICOS, programmed cell death protein 1 (PD-1), SLAM, CD40L, IL-21 
receptor (IL-21R), and IL-6 receptor (IL-6R) (Figure 1H).  The most commonly used 
markers to identify TFH cells are CXCR5 and PD-1.  One day after TFH cells migrate 
into the B cell follicle, licensed B cells from the T/B border zone will likewise migrate 
back into the B cell area and join the TFH cells (22, 23).  Like TFH cells, GC B cells 
highly express BCL6 (29).  In addition to up-regulating IL-21R, ICOSL, and SLAM, the 
signature surface markers for GC B cells, Fas and GL7 become highly up-regulated 
once these cells have reached the GC (Figure 1H) (28). 
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Figure 3.  Antibody development.  A. Antibodies are comprised of a heavy chain (H) 
and light chain (L), each with a variable region (VH and VL) and constant region (CH and 
CL).  These components are all held together with disulfide bonds.  The variable region 
will bind antigens, while the constant region is recognized by immune cells.  B. The B 
cell receptor (BCR), which will become antibodies in plasma cells, is first formed by 
random gene rearrangement and selection of one variable region allele, one diversity 
allele, and one joining region allele.  This is mediated by the recombination activating 
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gene, or RAG 1 and RAG 2 enzymes.  In order to further diversity the BCR, and future 
antibodies, point mutations are introduced into the selected variable region.  This is 
mediated by activation-induced deaminase, or AID, and is referred to as somatic 
hypermutation.  C. The constant region of the BCR can be one of eight isotypes in mice.  
They are IgM (Cμ), IgD (Cδ), IgG3 (Cγ3), IgG1 (Cγ1), IgG2b (Cγ2b), IgG2a (Cγ2a), IgE 
(Cε), and IgA (Cα).  The genes for the isotypes are arrayed along the Ig heavy chain 
locus, as shown in the diagram.  Naïve B cells will express both IgM and IgD on their 
surface.  Upon activation, cells will undergo isotype class switching, in which AID will 
recombine out intermediate constant genes, leaving the desired isotype gene directly 
following the VDJ segments.  Once a particular constant gene is removed, the cell can 
no longer express that isotype.   
 
 
Somatic hypermutation and isotype class switching of B cells  
 
Within the GC, the antibody genes of B cells will undergo two very important maturation 
steps that lead to efficient clearance of a pathogen: somatic hypermutation and isotype 
class switching (28).  Somatic hypermutation is the process by which small mutations 
are introduced into the variable region of the B cell receptor (BCR) (Figure 3 A-B).  
These genetic changes will alter the affinity the BCR has for a given epitope.   
 
Isotype class switching refers to the process by which B cells, under the instruction of 
cytokine signals, change their BCR to the form which will best suit the antibody-mediated 
clearance of a pathogen.  Naïve B cells will initially express two BCR immunoglobulin 
(Ig) isotypes: IgD and IgM (Figure 3C).  Upon activation, naïve B cells will lose the ability 
to express IgD, thus making them only IgM positive (30).  From there, B cells can 
undergo additional switching to other isotypes.  These isotypes are IgM, IgG3, IgG1, 
IgG2b, IgG2a, IgE, and IgA (31).  It is important to realize that, while a B cell can 
undergo additional isotype switching, it can never return to an earlier form, as that part of 
the gene has been permanently recombined out (30).  For example, if an activated B cell 
mutates from IgM to IgG1, it can never again become IgM or IgG3 positive (Figure 3C).  
Additional changes will only lead to isotypes further down the Ig heavy chain locus, such 
as IgG2a or IgE.  Cytokine signaling from the environment, and particularly from Th 
cells, can trigger further isotype class switching (31).  Because certain antibodies are 
required for clearance of particular antigens, this is how Th cells are responsible for 
clearance of particular pathogens, albeit indirectly.  For example, Th1 cells are cited as 
being responsible for clearance of certain bacteria.  In the presence of IFNγ, which is 
secreted by Th1 cells, B cells will switch to an IgG2a isotype.  However, in the presence 
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of Th2 cells, which secrete IL-4 in the presence of some parasites, B cells will adopt an 
IgG1 isotype.  TFH cells have the unique ability to secrete the signature cytokines of all 
Th subsets, enabling them to direct GC B cell isotype switching, regardless of what 
antigen is being presented.   
 
Germinal center structure 
 
The GC itself is organized into two distinct areas: the dark zone and light zone (Figure 
4).  Within the dark zone, activated GC B cells will undergo clonal expansion and 
somatic hypermutation, which leads to increased numbers of B cells with enhanced 
affinity for the antigen (28, 32).  TFH cells reside within the light zone where they interact 
with GC B cells, providing survival signals and secreting cytokines to direct isotype class 
switching of the BCR.  GC B cells will continue to cycle back and forth between the light 
and dark zones, acquiring further affinity maturation and additional isotype switching, if 
necessary (28, 33).  At some point, the GC B cells will cease cycling and exit the GC, as 
either memory B cells or plasma cells secreting the high affinity antibody that was 
developed during the GC process (28).  The intracellular steps necessary to halt the 
cycling process and exit the GC are not well defined at this time.  What is known is both 
memory B cells and plasma cells must down-regulate BCL6 in order to differentiate from 
a GC B cell state (33).  This entire process, of GC formation, light/dark zone cycling, and 
development of memory B cells and plasma cells, takes several days to weeks.  
Typically, the peak of the GC response occurs between seven to ten days after infection 
or immunization.  Once the antigen is cleared, the GC will dissipate, with its cells 
becoming either memory cells or dying by apoptosis (28).  There is currently some 
evidence that TFH cells can become long-lived memory T cells in circulation (34). 
 
Regulating the germinal center response 
 
Regulation of the GC cycling process is crucial, as GC B cells which somatically mutate 
away from affinity for the presented antigen can be a hindrance to the immune response.  
If lower affinity B cells were allowed to survive and proliferate, they would take resources 
away from those cells progressing toward a more specific conformation.  Furthermore, if 
a B cell were to somatically hypermutate and gain affinity for self-antigens, an 
autoimmune response would rapidly develop (28).  For these reasons, the GC response 
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must be tightly controlled.  To do so, the GC has at least two layers of mediation.  First, if 
the somatic hypermutations of the GC B cells leads to lowered affinity for the antigen, 
these cells will not receive survival signals from TFH cells upon their return to the light 
zone, leading to apoptosis of the B cell (28).  Secondly, a special subset of Th cells 
exists to control the TFH reaction.  Follicular regulatory T (TFR) cells are a recently 
described subset which possess traits of both TFH and Treg cells (35, 36).  These Th 
cells, like TFH cells, highly express BCL6 and CXCR5, and can migrate from the T cell 
zone into the GC.  Their job is to regulate TFH responses, by suppressing auto-reactive 
T cells via the same methods as Treg cells.  While TFR cells express BCL6, they also 
express the master transcription factor of Treg cells, Foxp3, at high levels.  At this time,  
 
  
Figure 4.  Germinal center cycling and regulation.  The GC is comprised of a dark 
zone and a light zone.  Within the dark zone, B cells will undergo clonal expansion as 
well as somatic hypermutation.  Cells acquiring increased affinity via the somatic 
hypermutation will continue to receive help and survival signals from TFH cells.  Further 
isotype class switching of the BCR is also done in the light zone, triggered by cytokines 
secreted from TFH cells.  Those cells which decrease their affinity due to somatic 
hypermutation will not receive those signals, and thus are removed from the GC via 
apoptosis.  This cycling from light to dark zone will continue until B cells down-regulate 
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BCL6 and exit the GC to become either memory B cells or plasma cells secreting high 
affinity antibodies.  TFR are responsible for regulating TFH cells. 
research into this subset suggests they are Treg cells which acquire the ability to 
express BCL6 and migrate into the GC (35, 36).   
 
 
Goals of Research 
 
While the role BCL6 plays in B cells, particularly GC B cells, has been extensively 
studied for approximately two decades, it is only in the last few years that researchers 
have begun to appreciate the role of BCL6 in Th cells.  Since the first definitive papers 
describing TFH cells were published (37-40), many groups around the world have 
investigated these cells, what they do, where they migrate to, and how they are 
controlled.  However, many questions remain unexplored.  What are the kinetics of GC 
and TFH development over time?  How do these cells develop?  Does BCL6 play a role 
in other Th cells?  What type of vaccine can enhance GC outcomes?  This thesis seeks 
to address these questions and provide insights into how BCL6 controls gene 
expression, both in TFH and non-TFH Th cells. 
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CHAPTER 2 – DEVELOPMENT OF A NEW BCL6 CONDITIONAL KNOCKOUT 
MOUSE MODEL 
 
 
INTRODUCTION 
 
The transcriptional repressor BCL6 is made up of three major domains (Figure 5).  First, 
the N-terminal Poz (Pox virus and zinc finger) domain binds specific corepressor 
proteins, including SMRT (silencing mediator of retinoid and thyroid receptor), N-CoR 
(nuclear receptor co-repressor), and BCoR (BCL-6 interacting corepressor) (41-44).  
These corepressors facilitate BCL6 repression, in part, by recruiting histone 
deacetylases (HDAC) to chromatin (45, 46).  The BCL6 Poz domain can also directly 
bind HDAC1 (47).  The central region of BCL6, known as repression domain 2 (RD 2), 
has been shown to directly bind MTA3, which is a subunit of the nucleosome remodeling 
and deacetylase (NuRD) complex (48, 49), as well as SIN3A, which, in combination with 
SMRT and HDACs, is part of a deacetylation complex (44, 47).  Association with these 
corepressors and complexes allows BCL6 to effectively repress gene expression 
through chromatin remodeling.  The RD 2 region also has sites for phosphorylation and 
acetylation, thus making this region responsible, in part, for turnover of BCL6 (44, 50).  
Finally, the C-terminal portion of BCL6 is composed of a zinc finger region, with six zinc 
fingers (51-53).  Binding of the zinc fingers to DNA is sequence-specific and mediates 
transcriptional repression of BCL6 target genes (54-58).   
 
Currently, there is no data demonstrating that BCL6 can activate genes directly.  
Therefore, the prevailing theory of how BCL6 can activate genes, particularly in the case 
of TFH and GC B cells, is by repressing other transcriptional repressors or by binding 
these suppressors and sequestering them away from their targets (46, 50).  The exact 
mechanisms by which this is accomplished are not known, however this is one goal of 
my work.  In order to better understand which genes BCL6 represses in a cell, germline 
knockout (GL KO) models have been employed to determine which genes were up-
regulated in the absence of BCL6.  Until now, these GL KO mice were the only models 
available to explore how BCL6 can up-regulate gene expression in primary T cells.   
 
The problem with the BCL6 GL KO approach is the sickly nature of mice lacking both 
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Figure 5.  BCL6 protein.  BCL6 contains a Poz domain which can bind protein, such as 
corepressors including SMRT, N-CoR, and BCoR, as well as directly bind HDAC1.  The 
middle region is referred to as repression domain 2 (RD 2).  It can also bind repression 
complexes via SIN3A and MTA3.  The C-terminus contains six zinc fingers (ZF) and can 
bind DNA. 
 
 
BCL6 alleles in all cell types (29, 59).  To begin with, GL KO mice are too sick to breed 
(60), and, therefore, heterozygous mice must be used for mating purposes.  Based on 
Mendelian probabilities, one quarter of the offspring of these mice should be 
homozygous for the deletion, however, in our hands, usually less than twenty five 
percent of mice born are KOs.  Whether the mice homozygous for deletion die in utero 
or do not survive past birth remains unknown.  In either case, mice lacking both alleles 
are difficult to acquire, and if they do survive, they are extremely sick, suffer from growth 
retardation, and rarely survive past eight weeks (29, 59).  Additionally, they suffer from 
myocarditis and pulmonary vasculitis, which is characterized by an influx of eosinophils 
(29, 59).  Furthermore, this type of inflammation has been described as Th2-mediated, 
as the Th cells from these mice have been shown to produce large amounts of Th2 
cytokines (29, 59).  Therefore, it is not practical to use these mice as in vivo models of 
BCL6 deletion.   
 
To overcome these obstacles, most researchers have utilized different cell transfer 
models to investigate the role of BCL6 in Th cells.  Transfer of mature, but naïve, Th 
cells into healthy recipient mice is a widely used and accepted method for studying loss 
of BCL6 in T cells, however, this strategy brings with it its own set of complications.  For 
instance, it is highly likely the cytokine environment, resulting from Th2 inflammation, in 
GL KO mice has already conditioned the transferred cells to skew toward a Th2 
phenotype (59, 61).  Bone marrow transfers from GL KO mice to healthy irradiated 
recipients also run the risk of cells being preconditioned by the rampant inflammatory 
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disease seen in the GL KO mice and, furthermore, the bone marrow itself still contains 
the hyper-inflammatory myeloid cells which will produce the skewing cytokines in 
recipient mice.  Additionally, these bone marrow chimera models are costly and time 
consuming, thus limiting their practicality.  Therefore, it was necessary to develop a 
conditional KO (cKO) mouse model, in which BCL6 can be functionally deleted in 
specific subsets of cells, rather than globally, to investigate the role of BCL6 in different 
cell subsets. 
 
 
MATERIALS AND METHODS 
 
Mice and immunization 
 
BCL6Neofl/Neofl mice on a mixed C57BL/6-129Sv background were generated at the 
Indiana University School of Medicine Transgenic and Knockout facility.  LoxP sites were 
inserted into the BCL6 gene locus, flanking exons 7-9 encoding the zinc finger domain of 
BCL6, using standard molecular cloning and embryonic stem cell techniques.  CreEIIa 
mice, obtained from Jackson Labs, were used to remove the floxed Neomycin gene from 
the germline of knock-in mice.  The following primer pairs were used to genotype 
different locations and versions of the mutant BCL6 allele as well as CD4 Cre-
recombinase:  
 
Neo-floxed: 
5’ loxP forward (5’ –TGAAGACGTGAAATCTAGATAGGC– 3’)  
5’ loxP reverse (5’ –ACCCATAGAAACACACTATACATC– 3’) 
3’ loxP + Neo gene forward (5’ –GAGGCCACTTGTGTAGCGCCAAGT– 3’)  
3’ loxP + Neo gene reverse (5’ –CTACTCCTAAGCTTCCTTTAACAC– 3’)  
 
Floxed: 
5’ loxP forward (5’ –TGAAGACGTGAAATCTAGATAGGC– 3’)  
5’ loxP reverse (5’ –ACCCATAGAAACACACTATACATC– 3’) 
3’ loxP forward (5’ –TCACCA ATCCCAGGTCTCAGTGTG– 3’)  
3’ loxP reverse (5’ –CTTTGTCATATTTCTCTGGTTGCT– 3’) 
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∆ZF: 
Deletion forward (5’ –TGAAGACGTGAAATCTAGATAGGC– 3’) 
Deletion reverse (5’ –CTACTCCTAAGCTTCCTTTAACAC– 3’)  
 Also ensure mice are negative for “Floxed” genotyping bands 
 
Cre-CD4 
Forward (5’ –ATCGCCATCTTCCAGCAGGCGCACT– 3’) 
Reverse (5’ –ATTTCCGTCTCTGGTGTAGCTGAT– 3’) 
 
Mice were immunized i.p. with 1 x 109 sheep red blood cells (SRBC; Rockland 
Immunochemicals Inc., Gilbertsville, PA) in PBS.  
 
Flow cytometry 
 
Total spleen or thymus cells were incubated with anti-mouse CD16/CD32 (Fcγ receptor) 
for 20 minutes, followed by surface staining for the indicated markers.  A fixable viability 
dye (eFluor 780, eBioscience) was used for all samples; manufacturer’s directions were 
followed.  The following antibodies were used for staining GC B cells: α-mCD19 Alexa 
Fluor 700, clone eBio1D3 (eBioscience); α-mB220 PE, clone RA3-682 (BD Bioscience); 
α-mFas Biotin, cat. # 554256 (BD Bioscience); Streptavidin-PECy7 (Biolegend); α-mGL7 
APC, clone GL7 (BD Bioscience); PNA FITC (Vector Laboratories Inc.).  The following 
antibodies were used to stain TFH cells: α-mCD3 Alexa Fluor 700, clone 500A2 (BD 
Bioscience); α-mCD4 PECy7, clone RM4-5 (BD Bioscience); α-mCXCR5 PerCP-efluor 
710, clone SPRCL5 (eBioscience); α-mPD-1 APC, clone 29F.1A12 (Biolegend); α-
mICOS FITC, clone C398.4A (eBioscience).  Intracellular BCL6 was stained with α-
h/mBCL6 V450, clone K112-9 (BD Horizon) or α-mBCL6 PE, clone mGI191E 
(eBioscience).  Samples were run on a BD LSR II flow cytometer using FACSDiva 
software.  Data was analyzed using FlowJo software. 
 
In vitro stimulation 
 
Total CD4+ T cells or naïve CD4+ T cells were isolated via magnetic bead separation 
(Miltenyi Biotec).  Effector memory cells were isolated via FACS.  Cells were stimulated 
with plate-bound anti-CD3 (5 µg/ml) and anti-CD28 (10 µg/ml) antibodies (BD 
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Biosciences) at 1x106 cells per mL.  Th0 media conditions contain no cytokines or 
blocking antibodies, Th neutral (ThN) conditions contain anti-IFNγ and anti-IL-4 (10 
µg/mL) (BD Biosciences) and TFH conditions contain IL-6 and IL-21 (10 ng/ml each 
(R&D Systems), plus anti-IFNγ, -IL-4 (10 µg/mL) and -TGF-β antibodies (20 µg/mL).    
 
ELISA 
 
Cytokines and antibody titers were measured via ELISA.  Kits from BD Biosciences were 
used to measure cytokines, except IL-17, in which purified and biotin-labeled antibodies 
were used (BD Biosciences).  Unless otherwise stated, both in vitro and ex vivo cells 
were isolated, as described above, and cultured for 5 days; IL-2 was used in all culture 
conditions when expanding cells.  After 5 days, cells were restimulated with anti-CD3 
antibody (5 μg/mL) for 18 – 24 hours, at which time supernatants were collected and 
analyzed. 
 
Histology 
 
Tissues were fixed in formalin and embedded in paraffin.  Standard histological sections 
were cut and stained with hematoxylin and eosin.  Samples were scored blindly on a 1-5 
scale assessment of leukocytic infiltration, with 5 being the most inflamed.  0 = no sign of 
inflammation, 1 = hint of inflammatory cells, 2 = significant but small or rare patches of 
inflammatory cells, 3 = significant foci of inflammatory cells, 4= large foci of inflammatory 
cells taking up more than 50% of tissue, 5 = greater than 80% of tissue is filled with 
inflammatory cells. 
 
Gene expression analysis 
 
Total RNA was prepared using a kit (Qiagen) after lysis of the cells via Trizol (Life 
Technologies); cDNA was prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Quantitative PCR (qPCR) reactions were run by assaying each sample in 
triplicates using the Fast Start Universal SYBR Green Mix (Roche Applied Science) with 
custom primers or specific Taqman assays (ABI).  Assays were run with a Stratagene 
Mx3000P Real-Time QPCR machine.  Levels of mRNA expression were normalized to 
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beta-tubulin mRNA levels, and differences between samples analyzed using the ∆∆CT 
method.  Primers for SYBR Green assays were previously described (14, 19). 
 
Statistical Analysis 
 
Statistical analysis was done using ANOVA with Tukey post hoc analysis on SPSS 
Statistics 20 software.  
 
 
RESULTS 
 
Generation of BCL6Neofl/Neofl mice 
 
To generate a new cKO mouse model for BCL6, a targeting construct containing loxP 
sites and a neomycin (Neo) resistance gene within the zinc finger region was introduced 
into embryonic stem cells (Figure 6 A-B).  Mice initially generated from these embryonic 
stem cells, henceforth referred to as BCL6-Neo-floxed (BCL6Neofl), differ from GL KO 
mice in that they have the entire zinc finger region intact, but flanked by loxP sites 
(“floxed”) with the addition of a Neo gene cassette 3’ of exon 9, whereas the original GL 
KO mice have only exon 9 and part of exon 8 deleted, leading to only partial loss of the 
zinc finger domain (Figure 6 C).  After mating heterozygous floxed mice (BCL6+/Neofl), 
homozygous floxed mice were generated (BCL6Neofl/Neofl).   
 
When heterozygous parents were mated, BCL6Neofl/Neofl mice were born at equivalent 
rates to GL KO mice (−/−), and both mice were born at rates lower than the expected 
Mendelian frequency of twenty five percent (Figure 7 A).  The percent of those 
homozygous mice that survived past weaning to at least eight weeks of age was higher 
for BCL6Neofl/Neofl mice than BCL6−/− mice, with approximately eighty six percent of 
Neofl/Neofl mice and sixty five percent of GL KO mice surviving (Figure 7 B).  When the 
survival rates are taken into consideration along with birth rates, the probability of a GL 
KO mouse being born and surviving to eight weeks significantly drops below twenty five 
percent, while BCL6Neofl/Neofl mice are reduced to an eighteen percent chance (Figure 7 
C).  Phenotypically, BCL6Neofl/Neofl mice also appeared smaller and more hunched than 
littermates, similar to what is seen with GL KO mice.  
 21  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Germline and targeted BCL6.  A. Schematic of the wild type BCL6 allele 
(BCL6+) and a targeting construct containing BCL6 exons 7 through 9 and a Neomycin 
resistance gene (Neo) which was inserted into the wild type allele.  B. The new BCL6-
floxed allele containing a Neo gene (BCL6Neofl).  C. A schematic of BCL6 in the original 
GL KO mouse model (BCL6−) in which part of exon 8 and all of exon 9 were deleted.  
The zinc finger region encoded by exon 7 is still fully intact. 
 
 
Functional testing of BCL6Neofl/Neofl mice  
 
To verify the functionality of the BCL6 gene before mating to a Cre recombinase mouse, 
BCL6Neofl/Neofl mice were immunized with sheep red blood cells (SRBC) and sacrificed ten 
days later.  SRBC were used as an immunization because of their ability to induce
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Figure 7.  Frequencies of BCL6Neofl/Neofl mice compared to BCL6−/− mice.  The 
frequencies of homozygous BCL6Neofl/Neofl and BCL6−/− mice born to heterozygous 
parents, and their deaths, were tracked over one year.  A. The percent of BCL6Neofl/Neofl 
and BCL6−/− mice born in all litters which survived to weaning (3 weeks) when 
genotyping was done.  B. Percentage of homozygous mice born that survived past 8 
weeks.  C. Percent of homozygous mice born and surviving past eight weeks in each 
litter.  Mean ± SE; n = 15 (Neofl) and 30 (−/−) litters.  **p < 0.01 by one sample t test 
(theoretical mean of 25%). 
 
 
strong GC responses.  Surprisingly, BCL6Neofl/Neofl mice had significantly reduced GC B 
cells and TFH cells as compared to wild type (WT) (BCL6+/+) and heterozygous 
(BCL6+/Neofl) mice  (Figure 8 A-C).  Furthermore, BCL6Neofl/Neofl mice had similar levels of 
GC cells to GL KO (BCL6−/−) and unimmunized WT mice.  Flow cytometry analysis of 
BCL6 in immunized mice showed a step-wise decrease in BCL6 protein expression as 
WT alleles were replaced with Neo-floxed alleles (Figure 9 A).  These data would 
suggest that a functional transcript of BCL6 is not being produced with the presence of 
the neomycin resistance gene in the targeting construct.  RNA analysis of ex vivo Th 
cells from immunized mice revealed a steep drop in full length transcript being produced 
in mice containing the targeting construct (Figure 9 B).  In fact, RNA levels were 
comparable to that of cells from GL KO mice.  This would suggest BCL6Neofl/Neofl mice 
may actually be more phenotypically similar to BCL6−/− mice than to WT mice.  Since GL 
KO mice are much smaller than WT mice, the weights of BCL6Neofl/Neofl mice were 
analyzed and found to more be more similar to the sizes of BCL6−/− mice than BCL6+/+ 
mice (Figure 9 C).  However, the total CD4+ T cell and B cell populations in the spleen 
were found to be closer to the levels seen in WT mice (Figure 9 D). 
 
To further investigate the defect in BCL6 transcription, naïve Th cells were isolated from 
unimmunized mice.  When cells from the spleen and thymus were analyzed directly ex 
vivo, without in vitro stimulation, levels of BCL6 exon 8 transcript increased with the  
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Figure 8.  Loss of GCs in BCL6Neofl/Neofl mice.  Wild type (BCL6+/+), heterozygous 
(BCL6+/Neofl), Neo-floxed (BCL6Neofl/Neofl), and GL KO (BCL6−/−) mice were immunized i.p. 
with SRBC and sacrificed on day 10.  BCL6+/+ mice injected with only PBS were used as 
negative controls.  Spleen cells were analyzed via flow cytometry for GCs.  A. 
Representative flow plots of GC B cell populations; gated on B220+ Fas+.  B. 
Representative flow plots of TFH cell populations; gated on CD4+ CXCR5+.  C. Graphs 
of GC B cells and TFH cells shown in A-B.  Mean ± SE; n = 3 – 6.  **p < 0.01, ***p < 
0.001 by ANOVA; Tukey post hoc. 
 
 
introduction of the floxed allele (Figure 10 A).  Activation with anti-CD3 and anti-CD28 
antibodies in Th0 culture conditions also revealed an increase in BCL6 transcript levels 
(Figure 10 B).  Conversely, culturing cells in conditions which skew them toward a  
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Figure 9.  Genotypic and phenotypic 
characterization of BCL6Neofl/Neofl mice.  Mice were 
immunized and sacrificed as in Figure 8.  A. Flow 
cytometry analysis of BCL6 expression in total CD4+ Th 
cells.  MFI of BCL6 protein is listed.  B. Total CD4+ T 
cells were isolated via bead separation and lysed 
directly ex vivo for RNA analysis of BCL6 expression.  
Samples normalized to BCL6+/+ levels (dotted line at 
1.0).  C. Weight of mice on day 10 after immunization.  Mean ± SE.  D. CD4+ T cells and 
total B cells as percentage of total spleen.  T cells gated on CD3+ CD4+; B cells gated on 
B220+.  Mean ± SE; n = 3 – 6. 
 
 
TFH phenotype led to a drop in transcript levels compared to WT mice (Figure 10 C). 
 
Any effects of decreased BCL6 transcription on cytokine secretion, after immunization, 
were abrogated in BCL6Neofl/Neofl mice.  Only IL-17A and IFNγ appeared to be slightly 
increased in the BCL6Neofl/Neofl mice compared to BCL6+/+ mice (Figure 11).  Naïve Th 
cells isolated from uninfected mice and activated for five days in Th0 conditions showed 
a similar result with IL-17A being increased over BCL6+/+ mice (Figure 12).  After five 
days, only BCL6−/− mice showed a substantially different cytokine profile from other mice  
 (Figure 12).  This lack of inflammatory cytokines in BCL6Neofl/Neofl mice likely contributed 
to the absence of disease, as these mice had reduced lung vasculitis compared to GL 
KO mice and only a few BCL6Neofl/Neofl mice had marginally increased myocarditis  
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Figure 10.  BCL6 expression CD4+ T cells.  A. 
Total CD4+ T cells were isolated from thymus and 
spleen of unimmunized mice via bead separation.  
Cells were lysed directly ex vivo for RNA analysis 
of BCL6 exon 8 transcript levels.  Levels are 
normalized to BCL6+/+ mice (dotted line at 1.0).  B 
– C. Naïve CD4+ T cells were isolated from 
untreated mice via bead separation and activated 
with anti-CD3 and anti-CD28 antibodies for 4 
days in (B) Th0 or (C) TFH culture conditions.  On day 4, cells were harvested and 
restimulated with anti-CD3 and anti-CD28 for 5 hours in Th0 media, after which they 
were lysed for RNA analysis.  Transcript levels of different BCL6 exons were measured 
via qPCR.  Levels are normalized to BCL6+/+ levels (dotted line at 1.0).  Mean ± SE.  
 
 
compared to BCL6+/Neofl mice (Figure 13).   
 
Because the transcriptional and functional changes seen in BCL6Neofl/Neofl mice appeared 
to be more of a knock-down rather than full knockout phenotype, we decided to further 
investigate the effects of having decreased levels of BCL6 expression, compared to WT 
and GL KO mice.  Total Th cells were isolated from mice immunized with SRBC and 
sacrificed ten days later.  After culturing for five days in vitro under Th0 conditions, cells 
were briefly restimulated with antibodies before being lysed for RNA analysis.  Because 
cytokine data suggested these ex vivo cells could be skewing toward a Th17 phenotype 
(Figure 11-12), cells were analyzed for transcript levels of rorc, the gene which encodes 
the master transcription factor for Th17 cells.  Interestingly, BCL6Neofl/Neofl Th cells 
showed a large increase in rorc expression over WT mice (Figure 14 A).  Furthermore, 
prdm1, the gene coding for Blimp1, was found to only be marginally increased with loss 
of functional BCL6 transcript (Figure 14 A).  This is particularly interesting because 
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previous work by others has demonstrated the reciprocal expression of Blimp1 and 
BCL6 (62). To further investigate the effects of graded BCL6 expression on Th17 cell  
differentiation, naïve CD4+ T cells were isolated, activated with antibodies, and cultured 
for five days in either Th0 or TFH-skewing culture conditions.  After a brief restimulation, 
cells were lysed and RNA expression measured.  Under the non-skewing conditions of 
Th0 culture, rorc levels were substantially increased over WT in all mouse types, 
whereas under TFH conditions, levels remained comparable to BCL6+/+ mice (Figure 14 
B).  Once again, under both culture conditions, prdm1 did not increase with loss of BCL6 
(Figure 14 B).  This lack of increased prdm1 expression, particularly in GL KO mice, is 
again interesting, considering the established dogma.  
 
Analysis of BCL6Neofl/Neofl mice has thus demonstrated a functional defect in full length 
BCL6 expression.  Not only have we found decreased full transcript of BCL6 being 
generated in BCL6Neofl/Neofl mice (Figure 9B), but the ability for GC B cells and TFH cells 
to develop in these mice is severely and significantly reduced as well (Figure 8).   
 
 
Figure 11.  Cytokine production of CD4+ T cells from immunized mice.  Mice were 
immunized as in Figure 8.  Total CD4+ T cells were isolated via bead separation and 
stimulated for 5 days with anti-CD3 and anti-CD28 antibodies in Th0 media.  On day 5, 
cells were harvested and restimulated overnight with anti-CD3 antibody.  Supernatants 
were analyzed for cytokines via ELISA.  Mean ± SE; n = 2 – 3. 
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Figure 12.  Cytokine production of cultured naïve CD4+ T cells.  Naïve CD4+ T cells 
were isolated via bead separation from unimmunized mice.  Cells were activated with 
anti-CD3 and anti-CD28 antibodies in Th0 culture conditions for 5 days.  Cells were then 
restimulated overnight with anti-CD3 antibody.  Supernatants were analyzed for 
cytokines via ELISA.  Mean ± SE; n = 2 – 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Histology of lung and heart from BCL6Neofl and GL KO mice.  Mice were 
immunized as in Figure 8, and heart and lungs were taken for histological analysis.  
Samples were scored blindly.  Individual scores are shown with the mean. 
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Figure 14.  Changes in rorc and prdm1 expression under different cytokine 
environments.  A. Mice were immunized as in Figure 8.  Total CD4+ T cells were 
isolated via bead separation, activated with anti-CD3 and anti-CD28 antibodies, and 
cultured for 5 days in Th0 culture conditions.  On day 5, cells were restimulated with anti-
CD3 antibody for 5 hours, then lysed for RNA analysis.  Transcript levels of rorc and 
prdm1 are normalized to BCL6+/+ levels (dotted line at 1).  Mean ± SE.  B. Naïve CD4+ T 
cells were isolated and cultured as in Figure 10 B-C.  Transcript levels are normalized to 
BCL6+/+ levels (dotted line at 1.0). 
 
 
Therefore, without modifications to the inserted targeting construct, these mice could not 
be used for further development as a cKO model.   
 
Removal of the neomycin resistance gene 
 
To rectify the defective BCL6 transcription in BCL6Neofl/Neofl mice, it was determined the 
neomycin resistance gene needed to be removed.  To do so, CreEIIa mice were obtained 
from the Jackson Laboratory and mated to BCL6Neofl/Neofl mice.  CreEIIa mice express a 
Cre recombinase under the control of the adenovirus EIIa promoter, which is active early 
in mouse development.  Therefore, the EIIa-Cre recombinase will target and delete 
genomic DNA between two loxP sites in GL lineage cells.  Since our BCL6 Neo-floxed 
construct contains three loxP sites, a total of three different deletions could result.  Either 
the zinc fingers (exons 7 – 9), the Neo gene, or both could be removed (Figure 6 B).  
Two new mouse alleles resulted from this deletion process.  First, a new GL KO mouse 
was generated by deleting the entire zinc finger region and neomycin resistance gene, 
henceforth referred to as BCL6∆ZF/∆ZF mice (Figure 15 A).  Secondly, and more 
importantly, the neomycin resistance gene was successfully deleted, leaving the zinc 
finger region intact, flanked by two loxP sites, creating a floxed-BCL6 (BCL6fl/fl) mouse 
(Figure 15 B). 
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Figure 15.  Alleles of new BCL6 mutant mice.  A. Schematic of new GL KO mouse 
(BCL6∆ZF) developed by mating to a CreEIIa mouse, which resulted in deletion of the 
entire zinc finger region and neomycin resistance gene.  B. Schematic of BCL6 allele in 
new BCL6-floxed mouse (BCL6fl).  The neomycin resistance gene was removed by 
mating to a CreEIIa mouse, which constitutively expresses Cre recombines and will 
remove any segment flanked by two loxP sites.   
 
 
New germline knockout mice – BCL6∆ZF/∆ZF 
 
The novelty of this new GL KO mouse (BCL6∆ZF/∆ZF) is that rather than only having a 
partial deletion of the zinc finger region, as the original GL KO mouse (BCL6−/−) has 
(Figure 6 C), the entire region is now deleted, as well as the neomycin resistance gene 
(Figure 15 A).  To verify this deletion, naïve Th cells were isolated from untreated 
BCL6∆ZF/∆ZF and littermate controls.  Cells were stimulated for two days with anti-CD3 
and anti-CD28 antibodies in Th0 culture conditions, then lysed for RNA analysis.  As 
shown in Figure 16 A, transcript levels of BCL6 exons 2/3 were reduced in BCL6∆ZF/∆ZF 
mice compared to the levels seen in littermate controls; as expected, exon 8 transcripts 
were nonexistent.    
 
Work by several groups, including our own, has consistently shown the original BCL6 GL 
KO mouse (BCL6−/−) to skew toward a Th2-like phenotype and to develop systemic 
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inflammation.  To assess the phenotype of our new GL KO mice, naïve BCL6∆ZF/∆ZF and 
littermate control mice were sacrificed and analyzed.  Like the original GL KOs, 
BCL6∆ZF/∆ZF mice were smaller than littermate controls (Figure 16 B).  Spleen cells were 
then isolated and analyzed.  No differences in T or B cell populations were observed in 
BCL6∆ZF/∆ZF mice compared to controls (Figure 16 C).  When naive Th cells were isolated 
and activated with anti-CD3 and anti-CD28 antibodies for four days in Th0 culture 
conditions, the cytokines produced after an overnight restimulation showed a slightly 
different pattern than expected.  Like traditional GL KO mice, Th cells fromBCL6∆ZF/∆ZF 
mice produced increased levels of IL-17A and IL-10 (Figure 17 A).  Unlike BCL6−/− mice, 
activated naïve Th cells from BCL6∆ZF/∆ZF mice showed a reduction in IFNγ secretion, as 
the GL KO typically has similar levels of this cytokine to WT mice.  Most interestingly, 
however, was the lack of increased IL-4 production; amounts produced by BCL6∆ZF/∆ZF 
mice were equivalent to control mice.  
 
In a separate experiment, effector memory (EM) cells (CD44hi CD62L−) from BCL6+/+, 
BCL6Neofl/Neofl, and BCL6∆ZF/∆ZF mice were isolated via FACS and stimulated for 24 hours 
with anti-CD3 and anti-CD28 antibodies in Th0 culture conditions.  Like the four day 
culture with naïve Th cells, EM cells failed to show increased IL-4 secretion in 
 
 
 
 
Figure 16.  Genotypic and phenotypic characterization of BCL6∆ZF/∆ZF mice.  A. 
Naïve CD4+ T cells were isolated from unimmunized BCL6∆ZF/∆ZF mice and littermate 
controls.  Control mice were a mixture of BLC6+/+ and BCL6+/∆ZF mice.  Cells were 
activated with anti-CD3 and anti-CD28 antibodies in Th0 media for 48 hours, then lysed 
for RNA analysis.  Transcript levels are normalized to littermate control levels (dotted 
line at 1.0).  Mean ± SE.  B. Weights of unimmunized BCL6∆ZF/∆ZF mice and littermate 
controls.  Mean ± SE.  C – D. CD4+ T, CD8+ T, and B cell populations were analyzed via 
flow cytometry from the spleen of unimmunized mice.  T cells gated on CD3+ and CD4+ 
or CD3+ CD8+; B cells gated on B220+ CD19+.  Mean ± SE. 
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Figure 17.  Cytokine skewing of CD4+ T cells 
from BCL6∆ZF/∆ZF mice.  A.  Naïve CD4+ T cells 
were isolated via bead separation from the 
spleens of the BCL6∆ZF/∆ZF and littermate control 
mice in Figure 16.  Cells were activated with anti-
CD3 and anti-CD28 antibodies in Th0 culture 
conditions for 4 days, after which they were restimulated overnight with anti-CD3 and 
anti-CD28 antibodies.  Supernatants were collected and cytokine levels measured via 
ELISA.  Mean ± SE.  B. Effector memory (EM) CD4+ T cells (CD44+ CD62L−) were 
isolated via FACS from the spleens of unimmunized BCL6+/+, BCL6Neofl/Neofl, and 
BCL6∆ZF/∆ZF mice.  EM cells were stimulated for 24 hours via anti-CD3 and anti-CD28 
antibodies in Th0 media.  Supernatant cytokine levels were measured via ELISA.  Mean 
± SE. 
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Figure 18.  Functional analysis of BCL6fl/fl 
mice.  A. BCL6+/+, BCL6fl/fl, BCL6Neofl/Neofl, and 
BCL6−/− mice were immunized i.p. with SRBC and sacrificed on day 9.  Spleen CD4+ T 
cells were analyzed for BCL6 protein expression via flow cytometry MFI of BCL6 protein 
is shown.  B. Representative flow plots of mice immunized in (A).  GC B cells (top) were 
gated on B220+ CD19+ Fas+.  TFH cells (bottom) were gated on CD3+ CD4+ CXCR5+.  C. 
EM CD4+ T cells (CD44+ CD62L−) were isolated via FACS from the spleens of 
unimmunized BCL6+/+, BCL6fl/fl, and BCL6Neofl/Neofl mice.  EM cells were stimulated for 24 
hours via anti-CD3 and anti-CD28 antibodies in Th0 media.  Supernatant cytokine levels 
were measured via ELISA.  Mean ± SE. 
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BCL6∆ZF/∆ZF mice, while IL-10 levels remained increased (Figure 16 B).  IFNγ in EM cells 
was equivalent to BCL6+/+ mice.  Of interest was the seemingly step-wise increase in IL- 
17A levels with the disruption of the zinc finger region (Figure 17 B).  This cytokine data 
would suggest that our new GL KO mouse, with the entire zinc finger removed, does not 
skew toward a Th2 phenotype. 
 
 
BCL6fl/fl mice 
 
After BCL6Neofl/Neofl mice were mated to CreEIIa mice, some offspring were found to have 
only the neomycin resistance gene deleted, leaving the zinc fingers, flanked by two loxP 
sites, intact (Figure 15 B).  These mice, termed BCL6fl/fl, needed to be tested in order to 
assess whether the lack of GCs seen in BCL6Neofl/Neofl was indeed due to the presence of 
the neomycin resistance gene or because of some other factor.  To test the functionality 
of the BCL6 allele in homozygous BCL6fl/fl mice, SRBC were again injected i.p. and mice 
were sacrificed on day nine.  Removal of the neomycin resistance gene successfully 
restored BCL6 protein, as measured by flow cytometry (Figure 18 A).  Functionality of 
the gene was also reestablished, as GC B cell and TFH populations were present at WT 
levels in BCL6fl/fl mice (Figure 18 B).  When EM Th cells were isolated from naïve mice 
and activated for 24 hours with antibodies in Th0 culture conditions, the cytokine profile 
of BCL6fl/fl mice more closely resembled that of WT mice, rather than BCL6Neofl/Neofl mice 
(Figure 18 C).  The increased IL-17A secretion from BCL6Neofl/Neofl effector memory Th 
cells seen here supports the earlier findings which suggest BCL6Neofl/Neofl mice may be 
skewing toward a Th17 phenotype.  With the restoration of BCL6 protein and function, 
these BCL6fl/fl mice are a functional floxed mouse which can be used for conditional 
deletion. 
 
 
DISCUSSION 
 
Due to the complexities associated with using the original BCL6 GL KO mouse (BCL6−/−) 
a cKO mouse model needed to be developed to better understand the role of BCL6 in 
different cell subsets.  Here, using a targeting construct containing loxP sites flanking the 
zinc finger region of the gene, we have created a new mouse model which can do just 
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that.  The first version of these mice, BCL6-Neo-floxed (BCL6Neofl/Neofl) mice proved to be 
unusable for our purposes of cKO.  However, they, in themselves, seem to be a novel 
BCL6 knock-down model.  These mice are perplexing in that they lack BCL6 function in 
vivo, but show increases in transcript expression in ex vivo uncultured cells and in Th0 
cultured cells.  One reason for the increase in exon 8 expression could be due to 
transcription of the neomycin resistance gene.  As shown in Figure 6, the Neo gene 
actually runs in an antisense direction to the rest of the BCL6 gene.  Therefore, 
transcription of this gene could result in exons 8 and 9 being transcribed as well.  Also, 
BCL6 self-represses its own transcription, and if functional protein is not being produced, 
this self-repression cannot take place.  Therefore BCL6Neofl/Neofl T cells may have 
increased BCL6 RNA levels due to lack of self-repression, even at basal levels.  
However, in ex vivo cells from immunized mice and in Th cells cultured in TFH-skewing 
conditions, we show a decrease in BCL6 transcript compared to BCL6+/+ mice.  This may 
have more to do with the ability of WT cells to increase BCL6, rather than a decrease in 
BCL6 transcription in BCL6Neofl/Neofl mice.  In TFH-skewing cultures and in immunized 
mice, Th cells will be pushed to up-regulate BCL6.  Therefore, cells which are impeded 
from doing so, i.e. T cells from BCL6+/Neofl, BCL6Neofl/Neofl, and BCL6−/− mice, will not be 
able to achieve the normal increase seen in BCL6+/+ T cells.  Therefore, the decrease in 
transcript expression in BCL6Neofl/Neofl mice likely has more to do with WT cells raising the 
threshold.   
 
The lack of functional BCL6 expression in BCL6Neofl/Neofl mice, while having a devastating 
effect on GCs, had few effects on Th cell cytokine secretion.  IL-4 was not substantially 
increased, as is typically seen with GL KO mice.  The one cytokine that stood out, 
though, was IL-17A.  It was increased in ex vivo cultured Th cells (Figure 11), in naïve 
Th cells, in vitro cultured cells (Figure 12) and in in vitro stimulated effector memory cells 
(Figure 18 C).  Ex vivo Th cells showed a more than two-fold increase in rorc 
expression, the master transcription factor for Th17 cells.  This increase was also seen 
in Th0 cultured naïve Th cells.  When comparing BCL6−/−, BCL6Neofl/Neofl mice, and 
BCL6+/+ mice, it appeared BCL6Neofl/Neofl mice have an intermediate phenotype, as they 
have reduced body weight, lack of GCs, and reduced BCL6 protein, similar to GL KO 
mice.  However, their Th cell cytokine profile matched more closely to WT mice, and 
their inflammation, as determined by histology, was more of an intermediate level 
(Figure 13).  Based on this, I would propose a model wherein graded BCL6 expression 
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results in the differentiation of different Th subsets.  High BCL6 leads to TFH cells, while 
complete loss of BCL6 protein leads to Th2 cell development, as has been previously 
published (59, 61).  Finally, an intermediate level of BCL6 transcript leads to TH17 
differentiation (Figure 19).  Because TFH cells and Th17 cells have been shown to share 
some characteristics, such as reliance on IL-6 and STAT3 for differentiation, utilization of 
c-maf, and secretion of IL-21(17, 19, 24, 63), this model seems plausible.   
 
One caveat to the graded expression model, though, is the development and analysis of 
a new GL KO mouse (BCL6∆ZF/∆ZF).  These mice failed to show the Th2-type skewing 
seen in the original KO mice (BCL6−/−).  The observations made with BCL6∆ZF/∆ZF mice 
suggests multiple explanations for the phenotype seen in BCL6−/− mice.  First of all, 
having only partial zinc finger deletion, as is the case with BCL6−/− mice, could result in a 
BCL6 protein with partial nucleic acid binding capabilities.  What the binding capabilities 
of this truncated protein are has not been investigated, and thus cannot be ruled out as a 
possible explanation for the Th2 phenotype in these mice.  Secondly, the background of 
the mice may play a larger role in the skewing of Th cells than previously appreciated, as 
the original GL KO mice, while on a mixed background, are slightly different than our 
new mice, which are mixed C57BL/6-129Sv.  Therefore, having 129Sv genes may 
somehow be affecting Th cell cytokine production.  Furthermore, the endogenous 
microbiota/microflora found in these mice likely plays a role in augmenting the immune 
response, and since our new GL KO mice are housed in a somewhat different 
environment (subtle changes in mouse housing and feeding) than the original KO mice, 
this difference may be a contributing factor to the differences seen.  In any case, the 
conclusions about BCL6 function using BCL6−/− mice must be revaluated using the new 
GL KO and, more importantly, with our new cKO mouse, as these cKO mice will be able 
to control for extrinsic effects from other cells on the cells of interest, which is not 
possible in a GL KO of any kind.  This is the major reason we developed these new 
BCL6fl/fl mice.  Now researchers can tightly control which cells have BCL6 deleted and 
know any effects they see are due solely to loss of the gene in those cells. 
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Figure 19.  Proposed model for graded BCL6 expression in different Th subsets.  
Published data has established BCL6 as the master transcription factor for TFH cells.  
These cells also express BCL6 at the highest levels of all the Th subsets.  Conversely, 
reports have shown BCL6 to repress GATA3, the master transcription factor for Th2 
cells.  Thus, little-to-no BCL6 is expressed in these cells.  Data presented here has 
demonstrated BCL6Neofl/Neofl mice to be a BCL6 knock-down model, rather than knockout.  
Based on RNA and cytokine analysis of these mice, showing increased rorc expression 
and IL-17A secretion, both signature markers for TH17 cells, it seems plausible that an 
intermediate level of BCL6 could lead a cell to skew toward a Th17 phenotype. 
 
  
BCL6 
TFH Th17 Th2 
 37  
 
CHAPTER 3 – BCL6 IS NECESSARY FOR EFFICIENT NAÏVE CD4+ T CELL 
ACTIVATION 
 
 
INTRODUCTION 
 
Like all immune cells, CD4+ T cells originate from a process known as hematopoiesis, 
wherein hematopoietic stem cells, which have the ability to self-renew, differentiate into 
multipotent progenitors (MMP) (Figure 20) (64-66).  These cells can then give rise to 
myeloid cells via a common myeloid progenitor (CMP), or to lymphocytes, including B 
cells, by differentiating into a common lymphoid progenitor (CLP) (66-68).  The CLP can 
exit the bone marrow and migrate to the thymus, where terminal T cell development 
commences (64, 66, 67, 69).  First, cells referred to as double negative (DN), because 
they express neither CD4 nor CD8, differentiate from the CLP (69-72).  From there, cells 
are selected for and become double positive (DP), as they begin to express both CD4 
and CD8 on the cell surface (69-72).  Further environmental signals will enable these 
cells to become single positive (SP) for either CD4 or CD8 (69, 70, 72, 73).  At this point, 
T cells are considered mature and can exit the thymus into circulation (69, 70, 72).  
These mature, but naïve, T cells can enter secondary lymphoid organs, such as the 
spleen and lymph nodes, where they sample antigens being presented by APCs (74).  If 
the TCR of a T cell, in this case that of a CD4+ T cell, is specific for the presented 
antigen, it will be activated, begin to proliferate, and carry out effector functions to aid in 
pathogen clearance.   
 
For a CD4+ T cell to be properly activated, a complicated signal cascade must take 
place.  First, the TCR binds the MHC II/antigen complex on an APC (Figure 21) (74-76).  
At the same time, CD4, functioning as a coreceptor, must bind to the MHC II molecule 
presenting the antigen (77, 78).  TCR engagement triggers the mobilization and 
recruitment of the lymphocyte-specific protein tyrosine kinase (Lck) to the CD4 
intracellular tail (71, 75-78).  Lck will then become phosphorylated, converting it to an 
active state (77).  Activated Lck will phosphorylate the zeta chain of the CD3 complex, 
thus recruiting another protein kinase, Zap70 (71, 75-78).  Once relocated to the CD3 
zeta chain, Zap70 becomes phosphorylated, either by Lck or via auto-phosphorylation 
(71, 78).  Now in an active state, Zap70 will trigger a cascade of  
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Figure 20.  Development of CD4+ T cells.  All immune cells originate from 
hematopoietic stem cells (HSC) in the bone marrow (BM).  These self-renewing cells 
can differentiate into mulitpotent progenitors (MPP), which will, in turn, differentiate into 
common myeloid progenitors (CMP).  These cells give rise to monocytes, granulocytes, 
and mast cells.  Alternately, MMPs can differentiate into common lymphoid progenitors 
(CLP), which will become immune cells of the acquired response.  If the CLP does not 
differentiate into the B cell linage within the BM, a CLP can exit the marrow and migrate 
to the thymus, where it will give rise to T cells.  First, a CLP will differentiate into what is 
known as a double negative (DN) T cell, as these cells do not express either of the 
coreceptors, CD4 or CD8.  However, expression of the TCR β chain, along with other 
surface markers, denotes them as T cells.  Environmental signals will next trigger 
surface expression of both CD4 and CD8 on these cells, leading them to become double 
positive (DP) cells.  Finally, further environmental signals and selection events in the 
thymus will cause these cells to cease expressing one of the coreceptors and become 
single positive (SP) for either CD4 or CD8.  These cells are now considered mature 
naïve T cells, and will exit the thymus into the circulation.  Frequent encounters with 
APCs allow T cells the chance to become activated and take part in pathogen clearance.  
For CD4+ T cells, this typically occurs in secondary lymphoid organs, such as the spleen 
or lymph nodes.  These activated T cells can then acquire effector functions to aid in the 
clearance of the pathogen. 
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Figure 21.  Early signaling events in TCR stimulation.  When an APC presents 
antigen to a CD4+ Th cell in the context of the MHC class II molecule, several cascade 
events must take place for proper signaling and activation of the T cell.  First, the TCR, 
made up of an α and β chain, will bind the antigen and make contact with the MHC class 
II molecule.  Additionally, the CD4 coreceptor must bind the MHC class II molecule on 
the APC for proper signaling.  This leads to recruitment of the intracellular protein kinase 
called lymphocyte-specific protein tyrosine kinase, or Lck.  The intracellular tail of CD4 
will phosphorylate (P) Lck, thus transforming it into its active state.  This kinase can then 
phosphorylate the tail of the CD3 zeta (ζ) chain.  CD3 is a signature surface marker for T 
cells.  It is composed of several different chains and clusters around the TCR.  In the 
context of CD4+ T cells, these chains are typically the epsilon (ε), delta (δ) and zeta (ζ) 
chains.  Phosphorylation of the zeta chain leads to recruitment of the zeta-chain-
associated protein kinase 70 (Zap70).  Once localized to CD3, Zap70 is phosphorylated 
by Lck, thus activating it.  From here, Zap70 will trigger a cascade of downstream 
phosphorylation events, eventually leading to the activation of transcription factors which 
will trigger T cell proliferation and differentiation. 
 
 
sequential phosphorylation events (76-78).  Downstream factors, such as MAP kinases, 
are essential parts of this signal cascade (76, 77), which culminates in the activation of 
critical gene expression pathways, such as NFAT, fos, and jun transcription factors.  
These, in turn, trigger up-regulation of activation markers, such as IL-2, IL-2 receptor 
alpha (IL-2Rα), cytotoxic T-lymphocyte antigen 4 (CTLA4), CXCR5, and CD69 (74, 76, 
77, 79, 80).  These activated CD4+ T cells will then differentiate into one of several 
subsets, depending on the antigen and cytokine environment, to carry out effector 
functions (Figure 2). 
 
At this time, a role for BCL6 in naïve Th cell activation has not been established.   
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Although CXCR5 has been shown to be up-regulated early after activation, research has 
demonstrated this to be independent of BCL6 expression (81).  Recently, two 
publications have shown BCL6 to become up-regulated very early after activation, but do 
not show data that BCL6 is essential for activation (22, 23).  Using our new cKO mouse 
model, we investigated the activation status of CD4+ T cells in multiple in vivo and in 
vitro models. 
 
 
MATERIALS AND METHODS 
 
Mice and immunizations 
 
Bcl6fl/fl mice were mated to CD4-cre mice (82) to generate Bcl6fl/fl CreCD4 mice.  Mice with 
the wild type BCL6 allele were bred to CD4-Cre mice for use as controls (BCL6+/+ CreCD4).  
The floxed allele was genotyped by PCR using the following primers:  
5’ loxP forward (5’ – TGAAGACGTGAAATCTAGATAGGC – 3’)  
5’ loxP reverse (5’ – ACCCATAGAAACACACTATACATC – 3’)  
3’ loxP forward (5’ –TCACCA ATCCCAGGTCTCAGTGTG–3’)  
3’ loxP reverse (5’ – CTTTGTCATATTTCTCTGGTTGCT–3’) 
 
Cre-CD4 transgene was genotyped using the following primers: 
Forward (5’ –ATCGCCATCTTCCAGCAGGCGCACT– 3’) 
Reverse (5’ –ATTTCCGTCTCTGGTGTAGCTGAT– 3’) 
 
Mice were immunized i.p. with 1 x 109 sheep red blood cells (SRBC; Rockland 
Immunochemicals Inc., Gilbertsville, PA) in PBS. 
 
Chimera mice 
 
For mixed bone marrow chimera experiments, RAG-1-deficient mice (83) were sub-
lethally irradiated with 350 rads.  The following day, bone marrow from Bcl6fl/fl CreCD4 
(CD45.2+) and BoyJ (CD45.2−) mice was harvested and cells mixed in equal amounts.  
Irradiated RAG mice received tail vein injections of 5x106 cells.  Mice were rested for 
approximately three months before immunization.  Mice were bred under specific 
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pathogen-free conditions at the laboratory animal facility at IUSM and were handled 
according to protocols approved by the IUSM Animal Use and Care Committee.  
 
Flow cytometry 
 
Total spleen or thymus cells were incubated with anti-mouse CD16/CD32 (Fcγ receptor) 
for 20 minutes, followed by surface staining for the indicated markers.  A fixable viability 
dye (eFluor 780, eBioscience) was used for all samples.  The following antibodies were 
used to stain naïve and memory T cells: α-mCD3 Alexa Fluor 700, clone 500A2 (BD 
Bioscience); α-mCD4 PECy7, clone RM4-5 (BD Bioscience); α-mCD8a APC, clone 53-
6.7 (BD Bioscience); α-mCD44 PE, clone IM7 (eBioscience); α-mCD62L FITC, clone 
MEL-14 (BD Bioscience).  CD25+ cells were stained using α-mCD25 PE CF594, clone 
PC61 (BD Horizon).  CD69+ cells were stained with α-mCD25 PerCPCy 5.5, clone 
H1.2F3 (Biolegend).  The GL3 Ab (Biolegend) was used to detect γδ T cells and NKT 
cells were identified with α-galactosylceramide-loaded CD1d tetramers obtained from the 
NIH tetramer core facility.   
 
For chimera experiments, the following antibodies were used: Bone marrow – α-mCD3 
Alexa Fluor 700, clone 500A2 (BD Bioscience); α-mB220 PE, clone RA3-6B2 (BD 
Bioscience); α-mCD11b Biotin, clone M1/70 (eBioscience) with Streptavidin-PECy7 
(Biolegend); α-mCD45.2 PerCPCy 5.5, clone 104 (BD Bioscience); Thymus –  α-mCD3 
Alexa Fluor 700, clone 500A2 (BD Bioscience); α-mCD4 FITC, clone H129.19 (BD 
Bioscience); α-mCD8a APC, clone 53-6.7 (BD Bioscience), α-mCD45.2 PerCPCy 5.5, 
clone 104 (BD Bioscience); Spleen – α-mCD3 Alexa Fluor 700, clone 500A2 (BD 
Bioscience); α-mCD4 PerCPCy 5.5, cloneRM4-5 (eBioscience); α-mCD8a APC, clone 
53-6.7 (BD Bioscience); α-mCD44 PE, clone IM7 (eBioscience); α-mCD62L FITC, clone 
MEL-14 (BD Bioscience); α-mCD45.2 PECy7, clone 104 (Biolegend).  Samples were run 
on a BD LSR II flow cytometer using FACSDiva software.  Data was analyzed using 
FlowJo software. 
 
In vitro stimulation 
 
Total CD4+ T cells were isolated via magnetic bead separation (Miltenyi Biotec); Cells  
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were stimulated with plate-bound anti-CD3 (5 µg/mL) and anti-CD28 (10 µg/mL) 
antibodies (BD Biosciences) for 24 hours at 1x106 cells/mL in Th0 media conditions, 
which contain no cytokines or blocking antibodies. 
 
Gene expression analysis 
 
Total RNA was prepared using a kit (Qiagen) after lysis of the cells via Trizol (Life 
Technologies); cDNA was prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Quantitative PCR (qPCR) reactions were run by assaying each sample in 
triplicates using the Fast Start Universal SYBR Green Mix (Roche Applied Science) with 
custom primers or specific Taqman assays (ABI).  Assays were run with a Stratagene 
Mx3000P Real-Time QPCR machine.  Levels of mRNA expression were normalized to 
beta-tubulin mRNA levels, and differences between samples analyzed using the ∆∆CT 
method.  Primers for SYBR Green assays were previously described (14, 19). 
 
Microarrays 
 
Naïve CD4+ T cells were isolated via FACS using the following surface markers: CD3+ 
CD4+ CD62L+ CD44−.  A cell viability gate was also used.  Cells were activated in vitro 
with anti-CD3 and anti-CD28 antibodies, as described above, in Th0 or TFH media 
conditions.  TFH conditions contain IL-6 and IL-21 [10 ng/ml each (R&D Systems)], plus 
anti-IFNγ (10 μg/mL), anti-IL-4 (10 μg/mL), and anti–TGF-β (20 µg/mL) antibodies.  Cells 
were cultured for 20 hours.  Cells were lysed, RNA prepared using an RNeasy kit 
(Qiagen), and cDNA prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Affymetrix gene expression microarrays were carried out by Center for Medical 
Genomics at the Indiana University School of Medicine. 
  
Statistical analysis 
 
Statistical analysis was done using IBM SPSS Statistics 21 software.  Statistics for 
microarray data was done using GraphPad Prism software.  In all figures, *p < 0.05, **p 
< 0.01, ***p < 0.001. 
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RESULTS 
 
Efficient and complete deletion of BCL6 zinc finger exons in BCL6+/fl CreCD4 mice 
 
After BCL6fl/fl mice were generated and found to be able to form normal GC responses, 
these mice were mated to CD4-Cre mice.  CD4-Cre mice express a Cre recombinase 
enzyme under the control of the CD4 promoter.  This means that the floxed zinc fingers 
of BCL6 (Figure 22 A) will be deleted in all T cells, since CD4 expression is turned on 
during early T cell development in the thymus.  After the first mating, heterozygous 
BCL6+/fl CreCD4 mice were generated.  Spleen cells from these mice were FACS sorted 
for B cells and CD4+ T cells.  PCR analysis revealed efficient deletion of the zinc fingers 
in CD4+ T cells, but not in B cells, of Cre-expressing mice (Figure 22 B).  Heterozygous 
mice were then mated to produce BCL6fl/fl CreCD4 offspring. 
 
Skewed naïve and effector memory CD4+ T cell populations in BCL6fl/fl CreCD4 mice 
 
Eight week old, untreated BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were first analyzed 
for T cell development.  Thymic cells were analyzed for proportions of double positive 
CD4 CD8 cells (Figure 23 A), single positive CD4 and CD8 cells (Figure 23 B), natural 
killer T cells, and gamma delta T cells (Figure 23 C).  The spleens of eight to twelve 
week old untreated mice were also analyzed for Treg populations (Figure 23 D).  In all 
cases, no differences in T cell populations were found between BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice.  Unimmunized mice were also assessed for naïve and effector 
memory T cell populations in the spleen.  In the case of CD8+ T cells, no differences 
were found between the two mouse strains (Figure 23 E).  However, naïve CD4+ T cells 
were significantly increased in the spleen of BCL6fl/fl CreCD4 mice as compared to 
BCL6+/+ CreCD4 mice.  After immunizing mice i.p. with SRBC and sacrificing nine days 
later, the naïve CD4+ T cell population in BCL6fl/fl CreCD4 mice remained significantly 
increased (Figure 23 G – H), while no differences in total CD4+ or CD8+ T cells were 
found (Figure 23 F).  Furthermore, while CD8+ T cells showed no differences in naïve or 
effector memory cells in either mouse type, the BCL6fl/fl CreCD4 mice now showed a 
significant loss in the CD4+ effector memory cell population (Figure 23 G – H).  These 
data suggest that BCL6, specifically in CD4+ T cells, plays a role in naïve Th cell 
activation.  
 44  
 
As mice age, they are exposed to more environmental antigens, and thus, trend toward 
having more activated T cells.  To see if the skewing of naïve and effector memory cell 
populations seen in BCL6fl/fl CreCD4 mice decreased with age, BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice were aged to thirteen months and sacrificed without immunizing.  
Still, at this advanced age, BCL6fl/fl CreCD4 mice continued the trend of having increased 
naïve and decreased effector memory CD4+ T cells (Figure 24). 
 
Skewed naive and effector CD4+ T cell populations confirmed in mixed bone 
marrow chimera model 
 
The finding that naïve and effector memory Th cell populations were skewed in the 
absence of BCL6 was further verified in a mixed bone marrow chimera model.  Bone  
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Conditional deletion of 
BCL6 in T cells.  A. Schematic of the 
BCL6 floxed construct.  B. BCL6fl/fl mice 
were mated to Cre-CD4 expressing mice 
to create offspring heterozygous for the 
BCL6fl allele, and expressing a Cre 
recombinase driven by the CD4 
promoter.  B cells and CD4+ T cells were 
sorted via FACS and analyzed for BCL6 
expression.  B cells were gated on 
CD19+ B220+ CD3− CD4−.  CD4+ T cells 
were gated on CD19− B220− CD3+ CD4+.  
B cells expressed both a wild type allele (germline) and floxed allele (5’ loxP and 3’ 
loxP), regardless of Cre expression.  CD4+ T cells not expressing a Cre-CD4 
recombinase also expressed both versions of the BCL6 allele.  However, cells from 
those mice mated to CreCD4 mice expressed a wild type allele but not a floxed allele, as 
evidenced by the lack of a band in both the 5’ loxP and 3’ loxP regions.  This 
demonstrates successful conditional knockout of the BCL6 zinc finger region in T cells. 
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Figure 23.  BCL6fl/fl CreCD4 mice have increased naïve and decreased effector 
memory CD4+ T cell populations.  Untreated 8 week old BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice were sacrificed and analyzed for T cell populations.  A. Double positive T 
cells in thymus.  B. Single positive CD4 and CD8 T cells in thymus.  C. Natural killer T 
cells (NKT) and gamma delta T cells (γδ) in thymus.  D. Treg cells in spleen of 
unimmunized mice.  Shown as percent of total CD3+ CD4+ T cells.  E. Naïve and effector 
memory cell populations in the spleen of unimmunized mice.  CD4+ and CD8+ cells 
gated on CD3+.  Naïve cells gated on CD62L+ CD44−.  Effector memory cells gated on 
CD62L− CD44hi.  N = 3 – 4; mean ± SE.  F – H. Mice were immunized i.p. with SRBC 
and sacrificed on day 9.  F. T cell populations in spleen.  Cells gated on CD3+.  G. Naïve 
and effector memory cells in spleen.  Cells gated as in (E).  N = 4; mean ± SE.  H. 
Representative flow plots of CD4+ cells in (G).  Cells gated on CD3+ CD4+.  **p < 0.01 by 
t test. 
 
 
marrow from BCL6fl/fl CreCD4 and BoyJ mice was harvested, mixed equally, and 
transferred via tail vein injections into irradiated RAG-deficient mice.  After resting the 
mice for approximately three months, mice were immunized i.p. with SRBC and 
sacrificed nine days later.  Both the bone marrow and spleen reconstituted equally with 
A. B. C. 
E. 
D. 
F. G. 
C
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Figure 24.  Naïve and effector memory cell differences in aged BCL6fl/fl CreCD4 mice 
remain in aged mice.  BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were left untreated and 
aged to 13 months.  Mice were sacrificed and spleen cells analyzed for naïve and 
effector memory CD4+ T cells.  Cells gated as in Figure B.  N = 3; bar = mean. 
 
 
BCL6fl/fl CreCD4 (CD45.2+) and BoyJ (CD45.2−) cells (Figure 25 A).  Only the thymus 
showed slightly, but significantly, more cells coming from the BoyJ donor cells 
(CD45.2−).  Within the bone marrow, the B cells repopulated evenly from both donor 
marrows, however, macrophage and T cell populations were found to be 
disproportionally of CD45.2+ and CD45.2− origins, respectively (Figure 25 B).  Most 
thymus T cells were of equal CD45.2+ and CD45.2− proportions (Figure 25 C).  Only the 
CD4+ T cells in the thymus were shown to be proportionally more of CD45.2− origin.  
However, when the cell populations were calculated as a percent of the total thymus 
cells, any differences were equalized (Figure 25 D), suggesting these differences were 
negligible.  Within the spleen, T cells from BoyJ donor marrow (CD45.2−) made up a 
significantly larger proportion of CD8+ and CD4+ T cells, as well as a significantly higher 
percentage of T cells in the total spleen (Figure 25 E – F).  These data, combined with 
the increase in CD45.2− T cells in the bone marrow (Figure 25 B), suggest BCL6 plays a 
role in the survival of T cells exiting the thymus into circulation. 
 
When CD4+ naïve and effector memory cell populations were analyzed in the spleen, the 
phenotype of the earlier experiment repeated.  Even though the BoyJ cells (CD45.2−) 
made up a significantly larger proportion and percent of the total CD4+ T cells in the 
spleen, BCL6fl/fl CreCD4 (CD45.2+) T cells constituted a significantly larger proportion of 
the naïve cell population, while still lacking the ability to make effector memory cells 
(Figure 25 G).  Because BoyJ cells disproportionally constituted a larger percentage of T 
cells in the spleen, we employed a different gating strategy to eliminate this bias and 
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Figure 25.  BCL6fl/fl CreCD4 have similar naïve/effector 
memory cell phenotype in a competitive chimera 
model.  Bone marrow from BCL6fl/fl CreCD4 (CD45.2+) and 
Boy/J (CD45.2−) mice was harvested, mixed in equal 
proportions, and transferred i.v. to irradiated RAG−/− 
mice.  After resting for 3 months, mice were immunized 
i.p. with SRBC and sacrificed on day 9.  A. Percent 
reconstitution of bone marrow, thymus, and spleen.  B. 
Proportion of each donor cell type found in CD3, B220, and CD11b cell subsets in bone 
marrow.  C. Proportion of each donor cell type constituting double negative (DN) cells, 
double positive (DP), CD4+, and CD8+ cell populations in the thymus.  Cells gated on live 
cells (DN), live cells, CD4+, and CD8+ (DP), live cells and CD4+, or live cells and CD8+, 
respectively.  D. Percent of each cell type of total thymus cells.  Cells gated as in (C).  E. 
Proportion of each donor cell type constituting the spleen CD8+ T cell population (left) 
and percent of each donor CD8+ T cell population in the total spleen (right).  Cells gated 
on CD3+ CD8+.  F. Same populations as (E), except for CD4+ T cells.  Cells gated on 
CD3+ CD4+.  G. Proportion of each donor cell type constituting splenic naïve and effector 
memory CD4+ T cells.  Cells gated for naïve and memory populations as in Figure B.  H. 
Percent of each donor CD4+ T cell population which were naïve or effector memory 
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cells.  Cells gated, in order, on CD3+ CD4+ CD45.2+/−, followed by naïve and memory 
gates used in Figure B.  Shown as percent of CD3+ CD4+ CD45.2− or CD3+ CD4+ 
CD45.2+ cells.  N = 5; mean ± SE. **p< 0.01, ***p < 0.001 by t test.  I. Representative 
flow plots of naïve and effector memory cells in (H). 
 
 
investigate the ability of each donor cell type to remain naïve or become activated 
effector memory cells.  To do this, spleen cells were first gated on total CD3+ CD4+ cells, 
then on CD45.2 expression.  Next, each CD45.2 population was gated on naïve and 
effector memory cells, thus allowing us assess the percentage of these cell types within 
the context of each donor.  When this was done, cells from BCL6fl/fl CreCD4 (CD45.2+) 
mice were still shown to have significantly more naïve cells and fewer effector memory 
cells compared to the proportions found in the BoyJ cell population (Figure 25 H – I).  
This data demonstrates an intrinsic role for BCL6 in the activation of naïve CD4+ T cells.  
 
Naïve/effector memory CD4+ T cell phenotype seen early after immunization and 
only exacerbates over time 
 
Next, we wanted to test the differences in these cell populations early after immunization 
to see if at any time the two cell populations are equivalent in +/+ and fl/fl mice.  BCL6+/+ 
CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed one, 
three, and five days after.  On all days, the total CD4+ T cell population was the same in 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Effector cell defect is consistent throughout immune response in 
BCL6fl/fl CreCD4 mice.  BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. with 
SRBC and sacrificed 1, 3 and 5 days after immunization.  Spleen cells were analyzed.  
A. CD4+ T cells in spleen at each time point.  Percent of total spleen.  Cells gated on 
CD3+.  B. Naïve cells at each time point.  Cells gated on CD3+ CD4+ CD62L+ CD44−.  
Shown as percent of Th cells.  C. Effector memory cells at each time point.  Cells gated 
on CD3+ CD4+ CD62L− CD44hi.  Shown as percent of Th cells.  Mean ± SE; n = 3 – 4 per 
group, per time point.  *p < 0.05, **p < 0.01 by t test. 
A. B. C. 
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both mice (Figure 26 A).  However, like day nine, the naïve Th cells in BCL6fl/fl CreCD4 
were increased at all time points, while the effector memory population was significantly 
decreased on all days tested (Figure 26 B – C).  This data shows that the differences in 
naïve and effector memory cell populations between BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 
mice are seen before immunization and only increase over time after immunization. 
 
Differences in T cell activation markers in BCL6fl/fl CreCD4 mice 
 
To further investigate the activation defect in T cells lacking functional BCL6, 
unimmunized BCL6+/+ CreCD4 mice and BCL6fl/fl CreCD4 mice were analyzed for surface 
markers of activation on CD4+ T cells (Day 0).  While the percentage of total CD4+ and 
CD4+ naïve T cells expressing CD25, also known as IL-2Rα, was not different between 
+/+ and fl/fl mice (Figure 27 A), another activation marker, CD69, decreased among total 
and naïve CD4+ T cells in BCL6fl/fl CreCD4 mice (Figure 27 B).  Therefore, while naïve 
BCL6fl/fl CreCD4 mice do not have decreases in CD25+ Th cells, they do have fewer naïve 
and total CD4+ cells expressing the activation marker CD69.   
 
After immunizing with SRBC, mice were again assessed for activation markers.  On day 
nine after immunization, naïve CD4+ T cells from BCL6fl/fl CreCD4 mice had significantly 
less CD25 expression, as well as significantly fewer Th cells expressing CD69, both total 
CD4+ and naïve CD4+ T cells (Figure 27 A – B).  Therefore, after immunization, BCL6fl/fl 
CreCD4 mice had fewer T cells expressing surface activation markers compared to 
BCL6+/+ CreCD4 mice.  To assess activation markers at the RNA level early after 
immunization, mice were immunized and sacrificed as in Figure 26.  Analysis of total 
CD4+ T cells revealed significant decreases at the RNA level of il2rα (Figure 27 C) and 
ctla4 across several early time points.  Transcripts of il2, however, were not decreased 
until day five (Figure 27 C).  Taken together, this data strengthens the earlier findings 
that BCL6 plays a role in naïve CD4+ T cell activation. 
 
Levels of activation differ between in vitro and in vivo stimulation 
 
In order to better understand the global gene changes in CD4+ T cells in our cKO mice, 
two microarray analyses were done.  Naïve BCL6+/+ CreCD4 mice and BCL6fl/fl CreCD4 
mice were sacrificed and naïve CD4+ T cells isolated from spleen via FACS.  T cells  
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Figure 27.  Decreased activation marker expression in 
BCL6fl/fl CreCD4 mice.  A – B. BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice were either sacrificed unimmunized (Day 0), 
or 9 days post i.p. immunization with SRBC.  A. CD25 (IL-
2Rα) positive cells in total Th cell (top) and naïve Th cell 
(bottom) populations.  Th cells gated on CD3+ CD4+; naïve 
cells additionally gated on CD44− CD62L+.  B. CD69 
positive cells in total Th cell and naïve Th cell populations.  
Cells gated as in (A).  Mean ± SE; n = 3 – 5   C. Mice were 
immunized i.p. with SRBC and sacrificed 1, 3, and 5 days 
after.  Total CD4+ T cells were isolated via bead separation and lysed for RNA directly ex 
vivo.  All samples normalized to +/+ Day 1 (dotted line at 1.0).  Mean ± SE; n = 3 – 4 per 
group, per time point.  *p < 0.05, **p < 0.01, ***p < 0.001 by t test. 
 
 
were then activated in vitro with anti-CD3 and anti-CD28 antibodies in either Th0 or TFH 
culture conditions.  After an overnight stimulation, cells were lysed for RNA analysis.  As 
shown in Table 1, both culture conditions yielded similar numbers of genes significantly 
changed (p < 0.05) in fl/fl mice, compared to +/+ controls.  Furthermore, the majority of 
those genes were down-regulated in fl/fl mice (< -1.1 fold), with only one quarter to one 
third being increased (> 1.1 fold).  With fewer up-regulated genes in activated naïve 
CD4+ T cells from BCL6-deficient mice, the case for BCL6 having a role in naive cell 
activation is strengthened.  
 
Specific activation markers were analyzed in the microarrays (Figure 28 A).  While il2 
and il2rα were shown to be significantly reduced in BCL6fl/fl CreCD4 mice over time 
A. B. C. 
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Table 1.  Summary of microarray data with BCL6fl/fl CreCD4 T cells  
 Th0 conditions TFH conditions 
# genes changed (p < 0.05) 3255 3502 
# genes increased > 1.1 fold 824 (25%) 1102 (34%) 
# genes decreased < -1.1 fold 1495 (46%) 1476 (42%) 
Using Affymetrix gene expression arrays for total mouse genome, analyzing ~ 35,000 
genes, naïve CD4 T cells were activated for 20 hours with anti-CD3 and anti-CD28 
antibodies under either Th0 culture conditions (no cytokines or blocking antibodies), or 
TFH culture conditions (+IL-6 +IL-21, blocking antibodies to IFNγ, IL-4 and TGFβ).  Fold 
increase/decrease in BCL6fl/fl CreCD4 cells relative to BCL6+/+ CreCD4 cells. 
 
 
(Figure 27 C), the microarray gave mixed results, with il2 being significantly reduced in  
TFH conditions, while il2rα was either unchanged or slightly increased under TFH 
polarizing conditions (Figure 28 A).  CXCR5, a surface marker up-regulated on many Th 
cells after initial activation, was shown to be decreased, specifically under Th0 
conditions.  The transcription factors fos and jun were also shown to be significantly 
reduced under TFH culture conditions.  Lck, the protein kinase responsible for 
downstream signaling of TCR stimulation, was significantly reduced in both culture 
conditions, suggesting efficient TCR signaling is not being achieved.  The gene encoding 
Zap70 kinase, a direct downstream target phosphorylation target of Lck kinase and 
critical for TCR signaling, was also significantly reduced in TFH conditions.  One gene, 
however, atf3, was significantly increased in both in vitro conditions.  Because ATF3 has 
been shown to limit cell proliferation, this further adds credence to the limited activation 
potential of naïve Th cells in BCL6fl/fl CreCD4 mice.  Interestingly, the changes seen 
overnight with antibody stimulation of naïve Th cells was not necessarily replicated in 
vivo in total Th cells.  As already shown, il2rα was significantly decreased 24 hours after 
immunization in total CD4+ T cells (Figure 27 C), but the microarray shows it unchanged 
or slightly increased in certain culture conditions.  Likewise, while atf3 and fos were 
shown to be significantly up and down-regulated, respectively, during the in vitro 
stimulation, total CD4+ T cells analyzed ex vivo 24 hours after mouse immunization show 
this trend not to hold true for T cells of mixed activation states (Figure 28 B).  In fact, atf3 
is shown to be decreased in BCL6fl/fl CreCD4 mice over time, while fos never reaches 
significant differences at any time point after immunization.  Only cxcr5, whose initial 
expression has been shown to be BCL6-independent, but prolonged expression reliant 
on BCL6, is consistent with the microarray data.  Total Th cells had lowered cxcr5  
 52  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28.  Differences in activation marker expression 
are dependent on type of naive CD4+ T cell stimulation.  
A.  Naïve CD4+ T cells were isolated via FACS from 
unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice.  
Cells were activated in vitro under Th0 or TFH culture conditions.  After 20 hours, cells 
were lysed for RNA analysis via microarray.  Bars represent gene expression in BCL6fl/fl 
CreCD4 cells in the different culture conditions compared to BCL6+/+ CreCD4 mice.  
Differences are either greater than 1.0 or less than –1.0.  *p < 0.05, **p < 0.01, ***p < 
0.001.  B. Mice were immunized i.p. with SRBC and sacrificed 1, 3, and 5 days after.  
Total CD4+ T cells were isolated via bead separation and lysed for RNA directly ex vivo.  
All samples normalized to +/+ Day 1 (dotted line at 1).  Mean ± SE; n = 3 – 4 per group, 
per time point.  *p < 0.05, **p < 0.01, by t test. 
 
 
mRNA expression twenty four hours after immunization as well as three days after.  As 
these are both early time points, it is likely CXCR5 gene expression is not reliant on 
BCL6.  While overall, in vitro CD4+ T cells from BCL6fl/fl CreCD4 mice had fewer genes 
activated than BCL6+/+ CreCD4 mice, the status of different activation marker genes 
seems to be dependent on the type and duration of stimulation.   
 
 
DISCUSSION 
 
While BCL6 has been shown to be essential for the differentiation of TFH and GC B 
cells, a role for BCL6 in naïve Th cell activation has not yet been established.  
Experiments using GL BCL6-deficient mice have not shown a lack of naïve cell 
activation.  However, this is most likely because of the ongoing inflammatory responses 
in these mice.  Due to this environment, T cells would be poised for activation, and 
A. B. 
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published reports have shown an increase in the effector memory populations in these 
mice, even when unimmunized.  Here, we demonstrate, for the first time, an intrinsic role 
for BCL6 in naïve CD4+ T cell activation. 
 
Even when mice are not immunized and housed in a pathogen-free environment, 
environmental factors still exist which can trigger an immune response.  Therefore, 
unimmunized mice have a measurable effector T cell population.  In this environment, 
BCL6fl/fl CreCD4 mice have a comparable effector memory cell population to BCL6+/+ 
CreCD4 mice, but have significantly more naïve CD4+ T cells (Figure 23 E).  Even over an 
extended period of time, untreated BCL6fl/fl CreCD4 mice trend toward having more naïve 
cells and fewer activated ones (Figure 24).  This would suggest that at basal levels, 
these mice are able to activate cells to environmental factors to the same degree as 
BCL6+/+ CreCD4 mice, while having an increased pool of naïve cells.  Whether this naïve 
population has more cells of greater TCR diversity or just increased cell numbers of 
similar diversity cannot be determined from these studies, however, it is likely the latter. 
 
Soon after immunization, BCL6fl/fl CreCD4 mice fail to enhance their effector population, 
while retaining their naïve Th cell percentages (Figure 26 C).  This would suggest the 
differences seen in naïve and effector memory populations in these mice is in fact due to 
an activation defect, and not because of loss of activated cells.  If naïve cells were in fact 
being activated, but lost soon after to cell death, the effector cell percentages would be 
comparable between fl/fl and +/+ mice at earlier time points, which they are not (Figure 
26 C). 
 
A mixed bone marrow chimera was done to verify the intrinsic nature of the activation 
defect in CD4+ T cells from BCL6fl/fl CreCD4 mice.  In this experiment, the wild type cells 
(BoyJ; CD45.2−) were able to activate a substantial percentage of their CD4+ T cells into 
an effector state, while cells from BCL6fl/fl CreCD4 mice (CD45.2+) retained a much higher 
percentage of naïve cells (Figure 25 H).  These data, which verify the findings of the 
earlier in vivo experiments, demonstrate an intrinsic role for BCL6 in naïve Th cell 
activation.  Furthermore, while the bone marrow of these mice was reconstituted with 
equivalent percentages of each donor cell type and the donor populations were mostly 
similar in the thymus, CD4 T cells in the periphery (spleen and bone marrow) were 
derived significantly more from BoyJ (CD45.2−) donor cells.  While further analysis must 
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be done to confirm, these data would suggest a role for BCL6 in T cell survival after 
exiting the thymus. 
 
To further verify an activation defect in BCL6fl/fl CreCD4 mice, we assessed activation 
marker expression in a variety of in vivo and in vitro models.  CD25, also known as IL-
2Rα, is an early indicator of CD4+ T cell activation.  Th cells from unimmunized mice 
showed no differences in surface expression.  However, after injection with SRBC, CD4+ 
T cells that were very recently presented with antigen, which is to say they are CD25+ 
but also retain naïve surface markers, had significantly fewer cells expressing CD25 
when they were from BCL6fl/fl CreCD4 mice (Figure 27 A).  This would suggest that Th 
cells from the naïve pool in BCL6fl/fl CreCD4 mice are not able to up-regulate this 
activation marker as well as BCL6+/+ CreCD4 Th cells.  Furthermore, another surface 
marker for activation, CD69, was significantly decreased on all CD4+ T cells from BCL6fl/fl 
CreCD4 mice, both before and after immunization, again supporting the finding of an 
activation defect in these mice (Figure 27 B). 
 
At the RNA level, il2rα and il2, a cytokine up-regulated after activation, were down-
regulated over time in BCL6fl/fl CreCD4 Th cells, although not consistently.  In an in vitro 
activation model assessed by microarray, only il2 expression was found to be 
decreased, while il2rα transcripts were up-regulated (Figure 27 C, G A).  These markers, 
however, are not the only marks of activation.  Others, such as CTLA4, CXCR5, Lck, 
Zap70, Fos, and Jun, were all shown to be significantly down-regulated in the Th cells of 
BCL6fl/fl CreCD4 mice, both in in vivo and in vitro models (Figure 27 C, G).  Further 
indication of an activation defect in BCL6fl/fl CreCD4 mice was exhibited by the overall 
results of the microarray, which showed nearly half of all genes were down-regulated in 
BCL6fl/fl CreCD4 Th cells, as compared to BCL6+/+ CreCD4 cells (Table 1).  Together, this 
surface expression data and RNA analysis demonstrates a reduced activation potential 
of CD4+ T cells in BCL6fl/fl CreCD4 mice. 
 
These data are not without limitations.  The Th cells assessed ex vivo are a mixture of 
activated and unactivated cells.  Therefore, RNA data from the time course experiment 
is not useful for demonstrating small nuances in gene expression changes.  Instead, this 
data represents the overriding gene differences seen in cells, regardless of their 
activation status.  Later time points, such as day five, have more activated cells at this 
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time due to clonal expansion.  During in vitro activation, all cells have equal opportunity 
to achieve an active state, regardless of their TCR affinity.  Therefore, data presented in 
the microarray is more representative of the gene changes seen soon after activation, as 
these cells were assessed less than 24 hours after plating.  Microarray analysis is often 
criticized for not being as sensitive to changes as qPCR analysis is, however, many of 
the genes with significant changes in the microarray were confirmed with qPCR, and in 
most cases the differences were exacerbated with this analysis (data not shown).  Taken 
together, the flow analysis of in vivo immunization models and RNA analysis of in vitro 
activated cells demonstrate an inherent activation defect in the naïve Th cells of BCL6fl/fl 
CreCD4 mice. 
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CHAPTER 4 – ROLE OF BCL6 IN Th CELL SUBSETS 
 
 
INTRODUCTION 
 
Nearly thirty years ago researchers recognized that CD4+ Th cells differentiated into 
distinct subsets which secrete specific cytokine profiles and are dependent on the 
antigen and cytokine environment present (84, 85).  The original paradigm of Th1 and 
Th2 cells, secreting IFNγ and IL-4, respectively, has since been expanded to include 
many Th cell subsets, including Th17 (86, 87), Treg (88, 89), TFH (37, 38), Th9 (90, 91), 
and, in humans, Th22 (92, 93).  Each subset has been classified based on their cytokine 
profile, master transcription factors, and, in the case of Treg and TFH cells, their specific 
activity and location (Figure 2).  Because Th9 and Th22 cells are not yet as well defined 
as the other subsets, my work here will focus primarily on Th1, Th2, Th17, Treg, and 
TFH subsets.    
 
As mentioned previously, Th1 cells are controlled by the master transcription factor Tbet, 
whose gene name is tbx21 (17-19, 26).  These cells will mainly respond to intracellular 
pathogens, such as virus and bacteria, and secrete IFNγ in response.  Recent literature 
has shown a role for BCL6 in Th1 cells.  While one group demonstrated repression of 
BCL6 by Tbet (94), another group demonstrated that the interaction of the two 
transcription factors is necessary for proper regulation of IFNγ secretion, whereby BCL6 
represses Tbet-mediated IFNγ transcription in cells already producing IFNγ (95).  Using 
a mixed bone marrow chimera, another group demonstrated an increase in IFNγ 
production by BCL6 KO Th cells, further supporting the findings that BCL6 is crucial for 
proper regulation of IFNγ secretion (39).  However, these studies evaluated the role of 
BCL6 in Th1 cells from the stand point of Tbet KO mice and by using BCL6 GL KO mice.  
Therefore, as yet, no one has characterized the expression of Tbet and IFNγ in a BCL6-
deficient mouse that lacks the pro-inflammatory environment of mice with a GL mutation.  
Our new cKO mouse model will enable us to address this issue.  
 
Th2 cells were originally thought to be the main B cell helpers, however that role has 
since been attributed to TFH cells (26). Th2 cells will differentiate under the control of the 
master transcription factor, GATA3, and secrete the signature cytokine, IL-4 (17-20, 26).  
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Research by us and others has shown a role for BCL6 in Th2 cells, wherein the 
transcriptional repressor will limit GATA3 expression at the post-transcriptional level 
(61).  Furthermore, in the absence of BCL6, Th2 cytokines are substantially increased, 
while over-expression of BCL6 leads to sharp decreases in IL-4 production (59, 61).  
Research using the original GL KO mice has shown a dramatic skewing of Th cells 
toward a Th2 phenotype.  Secretion of inflammatory Th2 cytokines in these mice leads 
to myocarditis and pulmonary vasculitis, which is largely due to an influx of eosinophils 
(29, 59).  However, again, these studies were done using BCL6 GL KO mice and thus 
carry with them the confounding effects of BCL6-deficiency in other cells.  Therefore, our 
new mouse model will allow us to truly recognize the role of BCL6 in this Th cell subset. 
 
The most recent Th cell subset to be fully described is Th17 cells.  CD4+ T cells will 
differentiate into Th17 cells in the presence of IL-6, IL-23 and TGFβ, and, under the 
control of RORγt (rorc), secrete its namesake cytokine, IL-17 (17, 20, 26, 63, 96).  
Existing literature on the role of BCL6 in Th17 cells is somewhat inconclusive.  In our 
work, BCL6 appears to inhibit Th17 differentiation to some degree, but the gene itself is 
up-regulated in a Th17-inducing cytokine environment in vitro (97).  Others have found 
IL-17 secretion to be enhanced in the absence of BCL6 (39).  Finally, using a retroviral 
over-expression model, researchers have shown BCL6 to repress IL-17A and IL-17F 
production in an in vitro setting, while not affecting RORγt transcription (98).  The 
relationship between BCL6, the master transcription factor for TFH cells, and Th17 cells 
is especially interesting when you consider the similarities between TFH and Th17 cells.  
Both cell types require IL-6 for their differentiation, both have been shown to secrete IL-
21, both necessitate the phosphorylation of STAT3 for their differentiation, and both rely 
on c-maf, IRF4, and BATF for down-stream signaling (17, 24, 63, 96, 99, 100).  We hope 
to better understand the relationship between BCL6 and Th17 differentiation with our 
new model. 
 
An interesting dichotomy between the Th1, Th2, and Th17 subsets versus TFH cells is 
the reciprocal expression of BCL6 and Blimp-1.  While BCL6 is highly up-regulated in 
TFH cells, Blimp-1 is repressed.  Furthermore, while in Th1, Th2, and Th17 cells BCL6 is 
only present at low levels, if at all, Blimp-1 is more highly expressed (62, 99).  Extensive 
studies have been done to investigate the role of Blimp-1, encoded by the gene prdm1, 
in Th cell subsets.  For instance, researchers have found Blimp-1 to play a crucial role, 
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in conjunction with BCL6, in regulating the balance between Th1 and Th2 differentiation.  
While BCL6 has been shown to be important in Th1 cells, as mentioned above, Blimp-1 
is not expressed in this subset (101).  Conversely, BCL6 is repressed in Th2 cells by 
Blimp-1, thus allowing GATA3 expression and Th2 differentiation (101).  Using Blimp-1 
KO and cKO models, researchers have found that BCL6 expression is markedly 
enhanced in the absence of Blimp-1, also a transcriptional repressor (101-103).  
Furthermore, using a retroviral vector for over-expressing Blimp-1 in vitro, researchers 
have shown it can severely reduce BCL6 protein levels (62).  Interestingly, most of the 
work regarding BCL6-Blimp-1 interactions has focused around the latter, using Blimp-1 
KO mice and over-expression of Blimp-1.  Once again, our mouse model, wherein BCL6 
is specifically deleted in T cells, enables us to revisit the question of the relationship of 
these two transcriptional repressors and assess how much control BCL6 has over Blimp-
1. 
 
The final non-TFH cell subset to be discussed in this section is Treg cells.  These cells, 
whether they be iTreg or nTreg cells, are dependent on the expression of Foxp3 (19, 
104).  As their name suggests, regulatory Th cells work to limit the immune response by 
eliminating self-reactive T cells in the periphery.  While the processes by which they 
achieve that objective are still not fully understood, one way in which they repress such 
T cells is by secretion of IL-10 (105, 106).  Although not exclusively produced by Treg 
cells, this anti-inflammatory cytokine limits Th cell activity through paracrine or autocrine 
signaling (107).  With regards to BCL6 expression, recently, two groups have published 
evidence of Treg cells up-regulating the transcription factor, which triggered increased 
surface expression of CXCR5, facilitating the migration of these cells into the GC (35, 
36).  Once there, these follicular regulatory Th (TFR) cells added an additional level of 
regulation to the immune response.  Furthermore, BCL6 has been shown to repress 
GATA3 in Treg cells (108).  Therefore, while studies have demonstrated the dual 
expression of both BCL6 and Foxp3, at this time no one has yet to determine whether 
Foxp3 expression is reliant on BCL6, or vice versa.  
 
With the determination that TFH cells are in fact a unique Th cell subset (37, 38, 109), 
and BCL6 their master transcription factor (39, 98), researchers have since worked to 
determine how Th cells differentiate into this subset and what effects BCL6 has in other 
Th subsets.  The relationship between TFH cells and the other subsets is complicated.  
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The ability of TFH cells to produce the signature cytokines of other Th cells, as well as 
the ability for some subsets to express BCL6, particularly Treg cells, has only added to 
the controversy in the field as to whether TFH cells are a distinct subset or if they are 
merely a Th cell which has adopted an altered genotypic and phenotypic profile to 
migrate into the GC (19, 20, 26).  Further complicating things is the plasticity of Th cells 
and their ability to change into, or adopt, partial characteristics of a different subset (17, 
19).  Therefore, fully understanding the role BCL6 plays in the differentiation and 
proliferation of non-TFH subsets may help to settle some of these disagreements 
concerning the plasticity of TFH cells.  Here, we present data which shows little role for 
BCL6 in suppressing the differentiation of Th1, Th2, and Th17 subsets, while its 
expression seems to be essential for IL-4 secretion and expression of Foxp3 by Th cells. 
 
 
MATERIALS AND METHODS 
 
Mice and immunizations 
 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were generated and genotyped as described in 
Chapter 3.  BCL6∆ZF/∆ZF mice were generated and genotyped as described in Chapter 2.  
BCL6fl/fl CreLysM mice were generated by mating BCL6fl/fl mice to B6.129P2-Lyz2tm1(cre)Ifo/J 
mice (LysM-Cre), which were obtained from The Jackson Laboratory (cat. # 004781).  
These mice have a knock-in cre recombinase in the lysosome 2 allele, thus placing cre 
under the control of the Lyz2 promoter.  In this model, BCL6 will be deleted in all myeloid 
cells.  Because the LysM-Cre recombinase is a knock-in allele, only mice heterozygous 
for cre will be functional conditional knockout mice.  Therefore, two different genotypings 
must be done for cre recombinase: one for the wild type allele, and one for the knock-in.   
 
The following primer sets were used for LysM cre typing: 
WT forward (5’ –TTACAGTCGGCCAGGCTGAC– 3’)  
WT reverse (5’ –CTTGGGCTGCCAGAATTTCTC– 3’)  
Knock-in forward (5’ –ATCGCCATCTTCCAGCAGGCGCAC– 3’)  
Knock-in reverse (5’ –ATTTCCGTCTCTGGTGTAGCTGAT– 3’)  
 
The following primer sets were used to detect the BCL6 floxed allele: 
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5’ loxP forward (5’ –TGAAGACGTGAAATCTAGATAGGC– 3’)  
5’ loxP reverse (5’ –ACCCATAGAAACACACTATACATC– 3’) 
3’ loxP forward (5’ –TCACCA ATCCCAGGTCTCAGTGTG– 3’)  
3’ loxP reverse (5’ –CTTTGTCATATTTCTCTGGTTGCT– 3’) 
 
Mice were immunized i.p. with 1 x 109 sheep red blood cells (SRBC; Rockland 
Immunochemicals Inc., Gilbertsville, PA) in PBS. 
 
Flow cytometry 
 
Total spleen or thymus cells were incubated with anti-mouse CD16/CD32 (Fcγ receptor) 
for 20 minutes, followed by surface staining for the indicated markers.  A fixable viability 
dye (eFluor 780, eBioscience) was used for all samples.  The following antibodies were 
used to stain naïve and memory T cells: α-mCD3 Alexa Fluor 700, clone 500A2 (BD 
Bioscience); α-mCD4 PECy7, clone RM4-5 (BD Bioscience); α-mCD8a APC, clone 53-
6.7 (BD Bioscience); α-mCD44 PE, clone IM7 (eBioscience); α-mCD62L FITC, clone 
MEL-14 (BD Bioscience).  For Tbet staining, cells were fixed and permeabilized using 
the Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) according to 
manufacturer guidelines.  Intracellular cytokine staining (ICS) was done as follows: cells 
were stained for surface markers, followed by a fixable viability dye (eBioscience).  Cells 
were fixed for 10 minutes in the dark at room temperature in 2% formaldehyde.  Cells 
were washed 1x with PBS, then 2x in permeabilization buffer (0.1% saponin + 2% BSA 
in PBS).  Cells were then stained for α-mIL-4 APC, clone 11B11 (eBioscience), α-mIL-
17A PE, clone eBio17B7 (eBioscience), α-mIFNγ Alexa Fluor 488 , clone XMG1.2 
(Biolegend), and α-mIL-10 PECy7, clone JES5-16E3 (Biolegend) for 30 minutes at 4 °C 
in permeabilization buffer, washed, and analyzed via flow cytometry.  Samples were run 
on a BD LSR II flow cytometer using FACSDiva software.  Data was analyzed using 
FlowJo software. 
 
Cell isolation and in vitro stimulation 
 
Total CD4+ T cells were isolated via magnetic bead separation (Miltenyi Biotec); effector 
memory cells (EM), central memory cells (CM), and naïve CD4+ T cells were isolated via 
FACS.  EM cells were gated on CD3+ CD4+ CD44hi CD62L−, CM cells gated on CD3+ 
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CD4+ CD44hi CD62L+, and naïve cells gated on CD3+ CD4+ CD44− CD62L+.  Propidium 
iodide was used as a viability gate. 
 
Naïve, EM, and CM cells were stimulated with plate-bound anti-CD3 (5 µg/ml) and anti-
CD28 (10 µg/ml) antibodies (BD Biosciences) for varying times at 1x106 cells/mL.  Total 
spleen cells were stimulated with LPS for 24 hours at 1x107 cells/mL.  Th0 media 
contains no cytokines or blocking antibodies; ThN media contains anti-IFNγ and anti-IL-4 
blocking antibodies (10 μg/mL) (R&D Systems); TFH media contains anti-IFNγ (10 
μg/mL), anti-IL-4 (10 μg/mL) and anti-TGFβ (20 μg/mL) (R&D Systems) blocking 
antibodies, as well as IL-6 and IL-21 cytokines (50 ng/mL each) (PeproTech).  Th1 
media contains anti-IL-4 (10 μg/mL) blocking antibody plus IL-12 (10 ng/mL) 
(PeproTech); Th2 media contains anti-IFNγ (10 ug/mL) blocking antibody plus IL-4 (10 
ng/mL) (PeproTech); Th17 media contains anti-IL-4 and anti-IFNγ (10 ug/mL each) 
blocking antibodies plus IL-6 (10 ng/mL) and TGFβ (1 ng/mL) (PeproTech). 
 
Gene expression analysis 
 
Total RNA was prepared using a kit (Qiagen) after lysis of the cells via Trizol (Life 
Technologies); cDNA was prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Quantitative PCR (qPCR) reactions were run by assaying each sample in 
triplicates using the Fast Start Universal SYBR Green Mix (Roche Applied Science) with 
custom primers or specific Taqman assays (ABI).  Assays were run with a Stratagene 
Mx3000P Real-Time QPCR machine.  Levels of mRNA expression were normalized to 
beta-tubulin mRNA levels, and differences between samples analyzed using the ∆∆CT 
method.  Total cellular RNA was prepared and analyzed for gene expression as 
described in Chapter 2.  Custom primers used with SYBR Green analysis were prdm1, 
il4, ifnγ, il17a, and il10; primers used with Taqman assays were tbx21, rorc, foxp3, and 
gata3.   
 
Microarrays 
 
Naïve CD4+ T cells were isolated via FACS using the following surface markers: CD3+ 
CD4+ CD62L+ CD44−.  A cell viability gate was also used.  Cells were activated in vitro 
with anti-CD3 and anti-CD28 antibodies, as described above, in Th0 or TFH media 
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conditions.  TFH conditions contain IL-6 and IL-21 [10 ng/ml each (R&D Systems)], plus 
anti-IFNγ (10 μg/mL), anti-IL-4 (10 μg/mL), and anti–TGF-β (20 µg/mL) antibodies.  Cells 
were cultured for 20 hours.  Cells were lysed, RNA prepared using an RNeasy kit 
(Qiagen), and cDNA prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Affymetrix gene expression microarrays were carried out by Center for Medical 
Genomics at the Indiana University School of Medicine. 
 
Thymidine incorporation assay 
 
Naïve CD4+ T cells were isolated via FACS; cells were gated on CD3+ CD4+ CD62L+ 
CD44−.  Cells were then activated in Th0 media with different concentrations of anti-CD3 
and anti-CD28 antibodies (BD Bioscience) in round bottom, 96-well plates; 20,000 
cells/well in 100 uL media.  Some cells were e plated without antibodies to measure 
baseline proliferations (0x0).  Other concentration combinations include 1 ug/mL anti-
CD3 + 2 ug/mL anti-CD28, 5 ug/mL anti-CD3 + 2 ug/mL anti-CD28, and 10 ug/mL anti-
CD3 + 10 ug/mL anti-CD28.  After 48 hours, tritiated thymidine was added at 1 uCi per 
well.  Eighteen hours later, plates were frozen and later thawed and assessed for 
thymidine incorporation via a scintillation counter.  Incorporation presented as corrected 
counts per minute (CCPM).  Data points for cells activated with antibodies have 
respective baseline counts (0x0) subtracted. 
  
Statistical analysis 
 
Statistical analysis was done using IBM SPSS Statistics 21 software.  Statistics for 
microarray data was done using GraphPad Prism software. In all figures, *p < 0.05, **p < 
0.01, ***p < 0.001. 
 
 
RESULTS 
 
Transcription levels of BCL6 vary with in vitro and in vivo stimulation 
 
During in vivo immunization, BCL6 is up-regulated in Th cells, particularly in those which 
will become TFH cells.  In BCL6+/+ CreCD4 mice, without immunization (i.e. PBS given as 
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a control injection) we see BCL6 expressed at basal levels in total CD4+ T cells (Figure 
29 A).  Nine days after immunization with SRBC, these T cells, without ex vivo 
stimulation, have a significant increase in BCL6 transcript levels (Figure 29 A).  
Therefore, in vivo immunization with SRBC is a reliable method for inducing BCL6 in 
CD4+ T cells.   
 
In order to assess the effects of stimulating T cells ex vivo after immunization, a time 
course experiment was done to study increases in BCL6 expression over the duration of 
the immune response.  BCL6+/+ CreCD4 mice were immunized with SRBC and sacrificed 
one, three, and five days after the injections.  Total CD4+ T cells were isolated from 
spleen and either lysed directly ex vivo or stimulated in vitro with antibodies for 24 hours 
before being lysed for RNA analysis.  RNA from cells lysed directly ex vivo show levels 
of BCL6 significantly increasing by day five after immunization (Figure 29 B).  However, 
when the same T cells were stimulated overnight, the amount of BCL6 RNA was 
significantly decreased at all time points (Figure 29 B).  This demonstrates the 
detrimental effect in vitro stimulation has on already high levels of BCL6 transcript.  In 
 
 
 
Figure 29.  Induction of BCL6 following immunization.  A. BCL6+/+ CreCD4 mice were 
immunized i.p. with SRBC or PBS as a control.  Mice were sacrificed 9 days after and 
total CD4+ T cells were isolated from spleen via bead separation.  Cells were lysed 
directly ex vivo for RNA analysis.  Samples were analyzed for BCL6 exon 2/3 and exon 
8 expression via qPCR.  Samples normalized to PBS samples for each exon.  Mean ± 
SE; **p < 0.01 by t test.  B. BCL6+/+ CreCD4 mice were immunized i.p. with SRBC and 
sacrificed 1, 3, and 5 days after.  Total CD4+ T cells were isolated from spleen via bead 
separation.  Half the isolated cells were lysed directly ex vivo for RNA analysis and half 
were stimulated for 24 hours with anti-CD3 and anti-CD28 antibodies in Th0 media 
before being lysed for RNA analysis.  Samples were analyzed via qPCR for BCL6 exon 
8 expression.  All samples are normalized to Day 1 ex vivo lysed cells (dotted line at 
1.0).  Mean ± SE; *p < 0.05, **p < 0.01, ***p < 0.001 by 2-way ANOVA; Tukey post hoc. 
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fact, the higher the transcript levels were in the ex vivo samples, the lower the levels 
seem to be in the stimulated samples.  Therefore, this data serves as a caution for the 
interpretation of in vitro stimulated results.  While we expect BCL6 levels to be notably 
high in the Th cells of immunized mice, as is shown in Figure 29 A, in vitro stimulation 
significantly abrogates these levels, and thus could be changing any downstream effects 
of high BCL6 expression.  Therefore, whenever possible, we present data from cells 
harvested directly ex vivo without in vitro stimulation, as this is shown to alter BCL6 
expression in WT Th cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Tbet transcript levels in the absence of BCL6 in vivo.  A. RNA 
expression of tbx21 in total CD4+ T cells from unimmunized BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice.  Total CD4+ T cells isolated via bead separation and lysed for RNA analysis 
directly ex vivo.  B. RNA expression of tbx21 in mice immunized i.p. with SRBC and 
sacrificed on day 9.  Total CD4+ T cells isolated via bead separation and lysed for RNA 
analysis directly ex vivo.  C. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were immunized 
i.p. with SRBC and sacrificed 1, 3, and 5 days after.  Total CD4+ T cells were isolated via 
bead separation.  RNA expression of tbx21 in cells directly ex vivo (top) or after 24 
stimulation with anti-CD3 and anti-CD28 antibodies in Th0 media (bottom).  Samples 
normalized to Day 1 +/+ (dotted line at 1.0).  D. Mice were immunized and sacrificed as 
in (C).  CD4+ T cells were stained for expression of Tbet.  Cells gated on CD3+ CD4+.  E. 
Percent of effector memory (EM) cells expressing Tbet in mice from (D).  Mean ± SE; *p 
< 0.05, **p < 0.01, ***p < 0.001 by t test. 
 
 
A. B. C. 
D. E. 
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The role of BCL6 in Th1 cells 
 
BCL6 has been shown to interact with Tbet in multiple models.  Here, using our new 
cKO mouse model, we show minimal effects of BCL6 loss on Th1 differentiation.  When 
total CD4+ T cells were isolated from unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 
mice and analyzed for Tbet transcript directly ex vivo, BCL6fl/fl CreCD4 mice showed only 
marginally increases in tbx21 levels (Figure 30 A).  The same was seen in Th cells from 
mice immunized with SRBC and sacrificed on day nine (Figure 30 B).  
 
To investigate whether tbx21 transcript levels were significantly increased earlier in the 
immune response, a time course experiment was done in which mice were immunized 
with SRBC and sacrificed one, three, and five days after immunization.  In cells lysed 
directly ex vivo for RNA, tbx21 levels were similar, with cells from BCL6fl/fl CreCD4 mice 
showing slightly decreased levels at earlier time points (Figure 30 C).  When cells were 
stimulated ex vivo for 24 hours, still no differences were seen over five days.   
Interestingly, while cells analyzed ex vivo show a slight increase in tbx21 levels over 
time, those stimulated overnight seemed to have decreased tbx21 transcript over time. 
However, the levels of tbx21 transcript seen in total CD4+ T cells did not replicate at the 
protein level.  When total Th cells were analyzed for Tbet via flow cytometry, BCL6fl/fl 
CreCD4 mice significantly increased protein levels over BCL6+/+ CreCD4 cells beginning on 
day three (Figure 30 D).  When the effector memory (EM) population, which are highly 
activated Th cells, was specifically analyzed, we saw increases in Tbet at all time points 
(Figure 30 E).  Therefore, while tbx21 transcript levels were minimally affected by loss of 
BCL6 in BCL6fl/fl CreCD4 mice, Tbet protein levels were significantly elevated in the 
absence of BCL6.  
 
To fully understand if there is skewing of Th cells toward a Th1 type in BCL6fl/fl CreCD4 
mice, CD4+ T cells were analyzed for IFNγ expression and secretion.  After 
immunization with SRBC, BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were sacrificed on 
day nine.  Total CD4+ T cells were isolated and stimulated with antibodies overnight or 
with PMA and ionomycin for five hours and cytokines analyzed via flow cytometry.  
Analysis of overnight supernatants from +/+ and fl/fl Th cells showed no difference in 
IFNγ concentrations, as was also the case for CD4+ T cells analyzed via flow cytometry 
for intracellular cytokine staining (ICS) (Figure 31 A-C).  When transcript levels of ifnγ  
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Figure 31.  IFNγ expression in the absence of BCL6.  A. BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice were immunized i.p. with SRBC and sacrificed on day 9.  Total CD4+ T cells 
were isolated from spleen via bead separation and stimulated in vitro with anti-CD3 and 
anti-CD28 antibodies in Th0 media for 24 hours.  Supernatants were analyzed for IFNγ 
via ELISA.  B. Mice were immunized and sacrificed as in (A).  Total CD4+ T cells were 
isolated from spleen via bead separation and stimulated for 5 hours in vitro with PMA 
and ionomycin.  IFNγ levels were assessed via ICS.  Cells gated on CD3+ CD4+.  C. 
Representative flow plots of ICS in (B).  D. Mice were immunized, sacrificed, and CD4+ 
T cells isolated as in (A).  T cells were lysed directly ex vivo for RNA analysis.  IFNγ 
transcript levels assessed via qPCR; normalized to +/+.  E. BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice were immunized i.p. with SRBC and sacrificed 1, 3, 5, and 7 days afterward.  
Total CD4+ T cells were isolated via bead separation and stimulated for 24 hours with 
anti-CD3 and anti-CD28 antibodies in Th0 media.  Supernatants were assessed for IFNγ 
via ELISA.  F. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were aged to 13 months and 
sacrificed without immunization.  Total CD4+ T cells were isolated via bead separation 
and stimulated for 24 hours with anti-CD3 and anti-CD28 antibodies in Th0 media.  IFNγ 
levels in supernatants were measured via ELISA.  Mean ± SE. 
 
 
were assessed in total CD4+ cells taken directly ex vivo from the spleen, BCL6fl/fl CreCD4 
T cells showed only a marginal decrease in RNA levels (Figure 31 D).  Therefore, there 
is little difference in IFNγ expression and secretion in the Th cells of BCL6fl/fl CreCD4 mice 
nine days after immunization, as compared to BCL6+/+ CreCD4 mice. 
 
Conversely, to assess changes in IFNγ at earlier time points after immunization, mice 
were injected with SRBC and sacrificed one, three, five, and seven days afterward.  
A. B. 
D. E. F. 
BCL6fl/fl CreCD4 BCL6+/+ CreCD4 
IFNγ 
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While BCL6fl/fl CreCD4 mice did not have significantly higher levels of IFNγ at any time 
point, the CD4+ T cells did trend toward more IFNγ on day seven (Figure 31 E).  
 
To investigate whether Th1 skewing occurs later in the life of BCL6fl/fl CreCD4 mice, both 
cKO and control mice were aged for thirteen months.  Without immunization, total CD4+ 
T cells were isolated from spleen and stimulated overnight with antibodies.  While IFNγ 
levels in the supernatant of BCL6fl/fl CreCD4 mice was slightly increased compared to 
control mice, the difference was not significant (Figure 31 F). 
 
While in vivo modeling is important to understand changes of physiological relevance, 
we also wanted to investigate whether Th1 skewing of BCL6fl/fl CreCD4 naïve Th cells 
occurs in vitro under a variety of culture conditions.  When naïve CD4+ T cells were 
isolated from cKO and control mice, then activated under Th0, ThN, or TFH culture 
conditions overnight, tbx21 transcript levels were found to be significantly increased in 
BCL6fl/fl CreCD4 cells in non-skewing Th0 conditions, while these mice had significantly 
less tbx21 expression under TFH culture conditions (Figure 32 A).  To examine whether 
the increase in tbx21 levels in Th0 culture conditions was due to increased IFNγ 
secretion working in an autocrine fashion, naïve CD4+ T cells were activated with 
antibodies for 24 hours in Th0 media.  No differences in IFNγ secretion from +/+ and fl/fl 
Th cells were found (Figure 32 B).  Therefore, the increase in tbx21 transcript in naïve 
Th cells under non-skewing culture conditions is likely due to intrinsic factors.  When 
naïve Th cells were activated in vitro for five days, a significant decrease in IFNγ 
production was found in the absence of BCL6 (Figure 32 C).  Therefore, while the 
cytokine levels of total CD4+ T cells from in vivo immunized mice were unchanged over 
several time points, it appears IFNγ secretion in in vitro activated cells requires 
expression of BCL6 to sustain its levels over time.  Interestingly, EM cells, which are Th 
cells that have been activated in vivo, from unimmunized mice showed no difference in 
IFNγ levels after overnight in vitro stimulation (Figure 32 B).  Therefore, differences in 
IFNγ secretion by activated Th cells may be altered by the in vitro stimulation itself. 
 
Under neutral culture conditions, i.e. blocking IFNγ and IL-4, Tbet transcript levels 
increased significantly over time in BCL6fl/fl CreCD4 cells compared to BCL6+/+ CreCD4 cells 
(Figure 32 D).  Therefore, in the absence of IFNγ signaling, BCL6 may be working to 
limit tbx21 expression over time.  Finally, when naïve CD4+ T cells were isolated from  
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Figure 32.  Tbet, but not IFNγ, is increased in the absence of BCL6 in in vitro 
cultures.  A.  Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 or BCL6fl/fl CreCD4 
mice via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in Th0, ThN, or 
TFH culture conditions for approximately 20 hours.  RNA expression of tbx21 was 
assessed by microarray (Th0) or qPCR (ThN and TFH) analysis.  B. Naïve and effector 
memory (EM) cells were isolated from unimmunized mice via FACS.  Cells were 
stimulated with anti-CD3 and anti-CD28 antibodies in Th0 culture conditions for 24 
hours.  IFNγ concentrations in supernatants measured via ELSA.  C. Total CD4+ T cells 
were isolated from unimmunized mice via bead separation and activated as in (B) in Th0 
media for 5 days.  After a 6 hour restimulation with anti-CD3 and anti-CD28, 
supernatants were collected and tested for IFNγ secretion via ELISA.  D. Naïve CD4+ T 
cells were isolated via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in 
ThN culture conditions.  Cells were harvested and analyzed 1, 3, and 5 days after 
stimulation for tbx21 RNA expression via qPCR.  E. Naïve CD4+ T cells were isolated via 
FACS and activated with anti-CD3 and anti-CD28 antibodies under Th1 polarizing 
culture conditions for 3 days, then restimulated in Th0 conditions for 6 hours.  RNA 
levels of tbx21 were assessed via qPCR.  F. Cells from (E) were also restimulated in 
Th0 conditions for 18 hours and supernatant collected for analysis via ELISA.  Mean ± 
SE; **p < 0.01 via t test. 
 
 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice and activated under Th1 skewing conditions for 
three days, no differences in tbx21 transcript levels or IFNγ secretion was seen (Figure 
32 E – F). 
 
 
 
A. B. C. 
D. E. F. 
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The role of BCL6 in Th2 cells 
 
Published literature has shown that BCL6 can limit Th2 differentiation.  However those 
studies were done using GL KO mice.  Here, we are able to assess BCL6’s role in these 
Th cells without the confounding effects of the inflammatory environment seen in the 
original GL KO mice.  
 
When total CD4+ T cells were tested for GATA3 transcript in BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice both before and after immunization, no differences in RNA levels were 
seen.  Naïve mice had no significant differences in gata3 expression; however fl/fl mice 
trended toward slightly higher levels (Figure 33 A).  After immunization, on day nine 
(Figure 33 B), as well as earlier in the immune response (Figure 33 C-top), no significant 
differences were seen in gata3 transcript levels.  Stimulating cells overnight with 
antibodies only further equalized the levels between +/+ and fl/fl Th cells (Figure 33 C-
bottom).    
 
 
 
 
 
 
 
 
 
 
Figure 33.  GATA3 transcript levels are unchanged 
in the absence of BCL6 in vivo.  A. RNA expression 
of gata3 in total CD4+ T cells from unimmunized 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice.  Total CD4+ T 
cells isolated via bead separation and lysed for RNA 
analysis directly ex vivo.  B. RNA expression of gata3 
in mice immunized i.p. with SRBC and sacrificed on 
day 9.  Total CD4+ T cells isolated via bead separation 
and lysed for RNA analysis directly ex vivo.  C. BCL6+/+ 
CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. 
with SRBC and sacrificed 1, 3, and 5 days after.  Total CD4+ T cells were isolated via 
bead separation.  RNA expression of gata3 in cells lysed directly ex vivo (top) or after 24 
stimulation with anti-CD3 and anti-CD28 antibodies (bottom) in Th0 media.  Samples 
normalized to Day 1 +/+ (dotted line at 1.0).  Mean ± SE. 
A. B. C. 
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Figure 34.  IL-4 is decreased in BCL6-deficient CD4+ T cells.  A. BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed on day 9.  Total 
CD4+ T cells were isolated from spleen via bead separation and stimulated in vitro with 
anti-CD3 and anti-CD28 antibodies in Th0 media for 24 hours.  Supernatants were 
analyzed for IL-4 via ELISA.  B. Mice were immunized and sacrificed as in (A).  Total 
CD4+ T cells were isolated from spleen via bead separation and stimulated for 5 hours in 
vitro with PMA and ionomycin.  IL-4 levels were assessed via ICS.  Cells gated on CD3+ 
CD4+.  C. Representative flow plots of ICS in (B).  D. Mice were immunized, sacrificed, 
and CD4+ T cells isolated as in (A).  T cells were lysed directly ex vivo for RNA analysis.  
IL-4 transcript levels assessed via qPCR; normalized to +/+.  E. BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed 1, 3, 5, and 7 days 
afterward.  Total CD4+ T cells were isolated via bead separation and stimulated for 24 
hours with anti-CD3 and anti-CD28 antibodies in Th0 media.  Supernatants were 
assessed for IL-4 via ELISA.  F. Mice were immunized and sacrificed as in (E).  Total 
CD4+ T cells were isolated via bead separation.  RNA expression of il4 in cells lysed 
directly ex vivo (left) or after 24 stimulation with anti-CD3 and anti-CD28 antibodies in 
Th0 media (right).  Samples normalized to Day 1 +/+ (dotted line at 1.0).  G. BCL6+/+ 
A. B. 
IL-4 
BCL6fl/fl CreCD4BCL6+/+ CreCD4 C. 
D. E. 
F. G. 
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CreCD4 and BCL6fl/fl CreCD4 mice were aged to 13 months and sacrificed without 
immunization.  Total CD4+ T cells were isolated via bead separation and stimulated for 
24 hours with anti-CD3 and anti-CD28 antibodies in Th0 media.  IL-4 levels in 
supernatants were measured via ELISA.  Mean ± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 
by t test. 
 
 
Immunized mice were also analyzed for IL-4 secretion, as this is the signature cytokine 
for Th2 cells.  Interestingly, total CD4+ T cells from immunized mice showed significant 
decreases in IL-4 production when stimulated either overnight with antibodies (Figure 34 
A) or for several hours with PMA and ionomycin and assessed via ICS (Figure 34 B-C).  
When Th cells from these mice were tested for il4 transcript ex vivo, without stimulation, 
il4 RNA was significantly reduced in the absence of BCL6 (Figure 34 D).  To see if this 
defect in IL-4 production occurs early after immune activation, mice were immunized 
with SRBC and sacrificed one, three, five, and seven days later.  Total CD4+ T cells 
were stimulated overnight with antibodies and supernatants analyzed.  Five days after 
immunization, BCL6fl/fl CreCD4 cells showed increased IL-4, but IL-4 concentrations 
decreased by day seven (Figure 34 E).  Therefore, the decrease on day nine is likely 
due to a continued decrease in production by fl/fl Th cells.  Transcript levels of il4, 
however, did not match the trend seen in protein levels.  While cells from both types of 
mice consistently increased il4 transcript over time, BCL6-deficient Th cells had 
significantly less transcript compared to WT cells (Figure 34 F-left) when assessed 
directly ex vivo.  When cells were stimulated overnight with antibodies, il4 RNA was not 
different between the two groups (Figure 34 F-right), and seemed to match the trends 
seen in IL-4 secretion (Figure 34 E).  Therefore, determining the effects of BCL6 on IL-4 
expression and secretion can be complicated by the type of stimulation used. 
 
Older mice are more prone to disease and have increased numbers of activated T cells.  
Therefore, we wished to assess IL-4 levels in these mice to see if their CD4+ T cells 
would skew toward a Th2 type later in life.  At thirteen months, unimmunized mice were 
sacrificed and total CD4+ T cells isolated.  After an overnight stimulation with antibodies, 
supernatants were tested for IL-4.  While no significant difference was found, BCL6fl/fl 
CreCD4 cells trended toward higher IL-4 secretion (Figure 34 G). 
 
Because we observed altered il4 and gata3 transcript levels with in vitro stimulation, we 
wanted to assess the ability of CD4+ T cells to adopt a Th2-like phenotype in different in 
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vitro culture conditions.  When naïve Th cells were isolated from mice and activated with  
antibodies in Th0, ThN, and TFH culture conditions overnight, gata3 expression was 
increased in fl/fl cells under all conditions, and significantly so in Th0 and ThN media 
(Figure 35 A).  When cells were cultured for up to five days in ThN media, however, fl/fl 
cells had only marginally increased gata3 expression on days one and three after 
activation, and approached a statistical increase by day five (Figure 35 B).  Under non- 
skewing, Th0 conditions, naïve fl/fl cells secreted only slightly increased levels of IL-4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35.  GATA3 is marginally increased in BCL6-deficient CD4+ T cells in in 
vitro cultures.  A.  Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 or BCL6fl/fl 
CreCD4 mice via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in Th0, 
ThN, or TFH culture conditions for approximately 20 hours.  RNA expression of gata3 
was assessed by microarray (Th0 and TFH) or qPCR (ThN) analysis.  B. Naïve and 
effector memory (EM) cells were isolated from unimmunized mice via FACS.  Cells were 
stimulated with anti-CD3 and anti-CD28 antibodies in Th0 culture conditions for 24 
hours.  IL-4 concentrations in supernatants measured via ELISA.  C. Total CD4+ T cells 
were isolated from unimmunized mice via bead separation and activated as in (B) in Th0 
media for 5 days.  After a 6 hour restimulation with anti-CD3 and anti-CD28, 
supernatants were collected and tested for IL-4 secretion via ELISA.  D. Naïve CD4+ T 
cells were isolated via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in 
ThN culture conditions.  Cells were harvested and analyzed 1, 3, and 5 days after 
stimulation for gata3 RNA expression via qPCR.  E. Naïve CD4+ T cells were isolated via 
FACS and activated with anti-CD3 and anti-CD28 antibodies under Th2 polarizing 
culture conditions for 3 days, then restimulated in Th0 conditions for 6 hours.  RNA 
levels of gata3 were assessed via qPCR.  F. Cells from (E) were also restimulated in 
Th0 conditions for 18 hours and supernatant collected for analysis via ELISA.  Mean ±  
A. B. 
C. 
D. E. F. 
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SE; **p < 0.01 via t test. 
 
 
compared to +/+ after twenty four hours, however EM cells from the same mice, 
stimulated for the same amount of time, in the same manner, showed a further increase 
in IL-4 production (Figure 35 D).  However, when naïve cells were activated in Th0 
media for five days, followed by an overnight restimulation, IL-4 secretion from fl/fl cells 
was shown to be significantly reduced (Figure 35 C).  In the presence of Th2-skewing 
cytokines, neither GATA3 transcript, nor IL-4 production, was significantly changed.  
Therefore, while GL KO mice have typically shown an overwhelming skewing of Th cells 
toward a Th2 phenotype, here we do not see evidence of that skewing.  GATA3 
transcript levels are only marginally increased overall, depending on the stimulation 
method, and IL-4 is actually reduced, both in vivo and in vitro during longer-term 
cultures. 
 
The role of BCL6 in Th17 cells 
 
Previous work by our lab has shown BCL6 to have a role in promoting Th17 
differentiation through suppression of Th2 differentiation (97).  However, that work was 
done using a BCL6 GL KO model.  Here we are able to better understand the role of 
BCL6 in Th17 cells in the absence of inflammatory cytokines in vivo.  In our new model, 
BCL6-deficient CD4+ T cells show only marginal increases in rorc expression, the gene 
that encodes RORγt, both before and nine days after immunization (Figure 36 A-B).  At 
earlier time points in the immune response, CD4+ T cells from fl/fl mice show an increase 
in rorc transcription, and significantly so on day five after injection (Figure 36 C-top).  
However, when these T cells are stimulated ex vivo with antibodies for 24 hours, fl/fl Th 
cells drastically reduce their rorc expression compared to +/+ cells (Figure 36 C-bottom). 
 
Next, we evaluated the expression and secretion of IL-17A, the signature cytokine of 
Th17 cells.  Nine days after immunizing mice with SRBC, no differences were seen in IL-
17A secretion, either by ELISA (Figure 37 A) or by ICS (Figure 37 B-C).  Transcript 
levels of il17a assessed in total CD4+ T cells lysed directly ex vivo showed no difference 
in RNA levels either (Figure 37 D).  In a time course experiment, where mice were 
sacrificed one, three, five, and seven days after immunization, total CD4+ T cells 
stimulated with antibodies overnight showed significantly more IL-17A secretion by 
 74  
 
 
 
 
 
 
 
 
Figure 36.  RORγt RNA levels are marginally 
increased in the absence of BCL6 in vivo.  A. RNA 
expression of rorc (RORγt) in total CD4+ T cells from 
unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice.  
Total CD4+ T cells isolated via bead separation and 
lysed for RNA analysis directly ex vivo.  B. RNA 
expression of rorc in mice immunized i.p. with SRBC 
and sacrificed on day 9.  Total CD4+ T cells isolated via 
bead separation and lysed for RNA analysis directly ex 
vivo.  C. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were 
immunized i.p. with SRBC and sacrificed 1, 3, and 5 days after.  Total CD4+ T cells were 
isolated via bead separation.  RNA expression of rorc in cells lysed directly ex vivo (top) 
or after 24 stimulation with anti-CD3 and anti-CD28 antibodies (bottom) in Th0 media.  
Samples normalized to Day 1 +/+ (dotted line at 1.0).  Mean ± SE; *p < 0.05, **p < 0.01 
by t test. 
 
 
BCL6-deficient T cells only on day five; all other time points showed no difference in  
cytokine production (Figure 37 E).  Finally, aged mice were assessed for any T cell 
skewing associated with aging, and no difference was seen between +/+ and fl/fl Th 
cells, although BCL6fl/fl CreCD4 mice trended toward more IL-17A production (Figure 37 
F).  In in vitro cultures of naïve Th cells, levels of rorc and IL-17A depended on the 
media environment.  Naïve CD4+ T cells isolated from BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice activated with antibodies in Th0, ThN, or TFH media showed increases in 
rorc transcription only with the presence of TFH-skewing cytokines (Figure 38 A).  
Furthermore, naïve Th cells from fl/fl mice in Th0 media did not secrete more IL-17A; 
neither did EM cells, which have been previously activated in vivo, after 24 hours in Th0 
media (Figure 38 B).  When naïve cells were cultured in vitro in Th0 media for five days, 
IL-17A production was significantly reduced in BCL6-deficient mice (Figure 38 C).  In the 
limiting environment of ThN media, fl/fl naïve CD4+ T cells showed significantly reduced 
levels of rorc three days after activation (Figure 38).  By day five, however, no difference 
was seen between the two cell types, as +/+ Th cells had reduced their rorc levels to that 
of the fl/fl cells.  Conversely, in the presence of Th17-skewing cytokines, after three days  
A. B. C. 
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Figure 37.  IL-17A secretion is not altered in the absence of BCL6.  A. BCL6+/+ 
CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed on day 9.  
Total CD4+ T cells were isolated from spleen via bead separation and stimulated in vitro 
with anti-CD3 and anti-CD28 antibodies in Th0 media for 24 hours.  Supernatants were 
analyzed for IL-17A via ELISA.  B. Mice were immunized and sacrificed as in (A).  Total 
CD4+ T cells were isolated from spleen via bead separation and stimulated for 5 hours in 
vitro with PMA and ionomycin.  IL-17A levels were assessed via ICS.  Cells gated on 
CD3+ CD4+.  C. Representative flow plots of ICS in (B).  D. Mice were immunized, 
sacrificed, and CD4+ T cells isolated as in (A).  T cells were lysed directly ex vivo for 
RNA analysis.  IL-17A transcript levels assessed via qPCR; normalized to +/+.  E. 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed 
1, 3, 5, and 7 days afterward.  Total CD4+ T cells were isolated via bead separation and 
stimulated for 24 hours with anti-CD3 and anti-CD28 antibodies in Th0 media.  
Supernatants were assessed for IL-17A via ELISA.  F. BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice were aged to 13 months and sacrificed without immunization.  Total CD4+ T 
cells were isolated via bead separation and stimulated for 24 hours with anti-CD3 and 
anti-CD28 antibodies in Th0 media.  IL-17A levels in supernatants were measured via 
ELISA.  Mean ± SE; *p < 0.05 by t test. 
 
 
rorc was increased in BCL6-deficient T cells (Figure 38 E), while IL-17A production was 
only marginally increased (Figure 38 F).  
 
BCL6 influences Foxp3 expression in CD4+ T cells  
 
Work by our lab has shown BCL6 to play a role in Treg cells, wherein BCL6 suppresses  
GATA3 and Th2 cytokine secretion by the regulatory cells, thus facilitating their 
A. B. BCL6fl/fl CreCD4BCL6+/+ CreCD4 C. 
IL-17A 
D. E. F. 
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Figure 38.  RORγt expression is reliant on BCL6 and exogenous cytokines for 
sustained expression.  A.  Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 or 
BCL6fl/fl CreCD4 mice via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in 
Th0, ThN, or TFH culture conditions for approximately 20 hours.  RNA expression of rorc 
was assessed by microarray (Th0 and TFH) or qPCR (ThN) analysis.  B. Naïve and 
effector memory (EM) cells were isolated from unimmunized mice via FACS.  Cells were 
stimulated with anti-CD3 and anti-CD28 antibodies in Th0 culture conditions for 24 
hours.  IL-17A concentrations in supernatants measured via ELSA.  C. Total CD4+ T 
cells were isolated from unimmunized mice via bead separation and activated as in (B) 
in Th0 media for 5 days.  After a 6 hour restimulation with anti-CD3 and anti-CD28, 
supernatants were collected and tested for IL-17A secretion via ELISA.  D. Naïve CD4+ 
T cells were isolated via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in 
ThN culture conditions.  Cells were harvested and analyzed 1, 3, and 5 days after 
stimulation for rorc RNA expression via qPCR.  E. Naïve CD4+ T cells were isolated via 
FACS and activated with anti-CD3 and anti-CD28 antibodies under Th17 polarizing 
culture conditions for 3 days, then restimulated in Th0 conditions for 6 hours.  RNA 
levels of rorc were assessed via qPCR.  F. Cells from (E) were also restimulated in Th0 
conditions for 18 hours and supernatant collected for analysis via ELISA.  Mean ± SE; *p 
< 0.05, **p < 0.01 via t test. 
 
 
suppressive nature and not promoting further inflammation (108).  However, once again, 
these experiments were done using GL KO mice.  Also, recent work by others has 
identified a specific subset of Treg cells which can traffic into the GC and contribute an 
additional layer of regulation to the cell activity there (35, 36).  These studies show BCL6 
and Foxp3 being co-expressed in these cells, with BCL6 facilitating the migration of the 
Treg cells into the GC.  Therefore, it has been established that these two master  
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Figure 39.  Foxp3 transcript levels are significantly reduced in BCL6-deficient  
CD4+ T cells.  A. Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice via FACS.  Cells were activated with anti-CD3 and anti-CD28 antibodies in 
Th0 or TFH media for 20 hours before lysing for RNA.  Transcript levels of Foxp3 were 
assessed via microarray.  BCL6fl/fl CreCD4 transcript levels are shown relative to +/+ 
(dotted line at -1.0) in each culture condition.  Mean shown; **p < 0.01.  B. Mice were 
immunized i.p. with SRBC and sacrificed 1, 3, and 5 days after.  Total CD4+ T cells were 
isolated via bead separation.  RNA expression of foxp3 in cells lysed directly ex vivo 
(left) or after 24 stimulation with anti-CD3 and anti-CD28 antibodies (right) in Th0 media.  
Samples normalized to Day 1 +/+ (dotted line at 1.0).  Mean ± SE; *p < 0.05, **p < 0.01 
by t test. 
 
 
transcription factors can be co-expressed, but what effects BCL6 has specifically on 
Foxp3 expression has not been explored in a non-GL KO mouse model.   
 
As shown in Figure 23 D in Chapter 3 of this thesis, no differences in Foxp3+ CD4+ T 
cells in the spleen of unimmunized mice were found between BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice.  To investigate what role BCL6 may have on Foxp3 expression 
early after activation, naïve CD4+ T cells were isolated via FACS and activated with 
antibodies in Th0 or TFH media overnight.  Cells were then harvested and analyzed for 
RNA expression via microarray.  In both media conditions, significant reductions in foxp3 
RNA transcript were found in fl/fl T cells (Figure 39 A).  This was confirmed in an in vivo 
time course experiment.  When mice were sacrificed one, three, and five days after 
immunization with SRBC and cells lysed for RNA directly ex vivo, foxp3 was found to be 
significantly reduced both at the three and five day time points in fl/fl mice (Figure 39 B-
left).  Ex vivo stimulation with antibodies for 24 hours only exacerbated this difference 
(Figure 39-right).  Therefore, unlike the inconsistencies seen with other master 
transcription factors after in vitro stimulation, Foxp3 appears to be down-regulated in the 
absence of BCL6, regardless of stimulation method. 
 
A. B. 
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Blimp-1 is not increased in the absence of BCL6 
 
Many researchers have established a reciprocal expression model for Blimp-1 and BCL6 
(62).  However, this work has been primarily done with BCL6 GL KO mice and Blimp-1 
cKO mice.  Therefore, no one has examined the changes in Blimp-1 expression in the 
absence of BCL6 in a non-inflammatory prone model.  Using our new conditional mouse 
model we were able address this issue, and found the repression of prdm1, the gene for 
Blimp-1, by BCL6 is not as clear as previously thought. 
 
Total CD4+ T cells from fl/fl mice showed no increase in prdm1 expression either before 
(Figure 40 A) or nine days after immunization with SRBC (Figure 40 B).  In a time course 
experiment, in which mice were sacrificed one, three, and five days after immunization, 
cells assessed directly ex vivo showed a significant decrease in prdm1 expression in the 
absence of BCL6 early after immunization (Figure 40 C-top).  This was also seen when 
cells were stimulated with antibodies for 24 hours (Figure 40 C-bottom).  Interestingly, 
while cells analyzed ex vivo showed a decrease in prdm1 expression over time in +/+ 
cells, the gene seemed to increase on day five when those cells were stimulated with 
antibody.  However, that increase was never able to match the levels seen in ex vivo 
analyzed +/+ cells, even at their lowest levels (Figure 40 D). 
 
When naïve Th cells were isolated and activated in vitro under different culture 
conditions, Th0 media resulted in no differences between +/+ and fl/fl cells, ThN 
conditions seemed to facilitate reduced prdm1 transcript in fl/fl cells, while TFH- 
polarizing conditions were able to trigger a significant increase in prdm1 in the absence 
of BCL6 (Figure 40 E).  When cells were cultured for longer periods in ThN media, 
prdm1 remained low in fl/fl cells until day five, at which point they seemed to equal that 
of the unchanged levels in +/+ cells (Figure 40 F).  Together this data demonstrates 
while BCL6 may be up-regulated in the absence of Blimp-1, as has been reported, the 
opposite is not necessarily true.  In fact, Blimp-1 appears to be somewhat reliant on 
BCL6 for its own transcription, and is only able to overcome the absence of BCL6 in the 
presence of TFH-polarizing cytokines. 
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Figure 40.  Blimp-1 is decreased in CD4+ T cells lacking BCL6.  A. RNA expression 
of prdm1 (Blimp-1) in total CD4+ T cells from unimmunized BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice.  Total CD4+ T cells isolated via bead separation and lysed for RNA analysis 
directly ex vivo via qPCR.  B. RNA expression of prdm1 in mice immunized i.p. with 
SRBC and sacrificed on day 9.  Total CD4+ T cells isolated via bead separation and 
lysed for RNA analysis directly ex vivo via qPCR.  C. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 
mice were immunized i.p. with SRBC and sacrificed 1, 3, and 5 days after.  Total CD4+ T 
cells were isolated via bead separation.  RNA expression of prdm1 in cells lysed directly 
ex vivo (top) or after 24 stimulation with anti-CD3 and anti-CD28 antibodies (bottom) in 
Th0 media.  Samples normalized to Day 1 +/+ (dotted line at 1.0).  Mean ± SE; *p < 
0.05, **p < 0.01 by t test.  D. Samples from (C) together normalized to levels in +/+ Day 
1 ex vivo (dotted line at 1.0).  Mean ± SE; *p < 0.05, **p < 0.01, ***p < 0.001 by ANOVA; 
Tukey post hoc.  E. Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 or BCL6fl/fl 
CreCD4 mice via FACS and stimulated with anti-CD3 and anti-CD28 antibodies in Th0, 
ThN, or TFH culture conditions for approximately 20 hours.  RNA expression of gata3 
was assessed by microarray (Th0) or qPCR (ThN & TFH) analysis.  Mean ± SE; *p < 
0.05 by t test.  F. Naïve CD4+ T cells were isolated via FACS and stimulated with anti-
CD3 and anti-CD28 antibodies in ThN culture conditions.  Cells were harvested and 
analyzed 1, 3, and 5 days after stimulation for prdm1 RNA expression via qPCR.  Mean 
± SE 
A. B. C. 
D. 
E. F. 
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Figure 41.  IL-10 is increased, in an intrinsic manner, in BCL6fl/fl CreCD4 CD4+ T 
cells.  A. Unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were sacrificed and 
total CD4+ T cells isolated from spleen.  Cells were activated with anti-CD3 and anti- 
CD28 antibodies in Th0 media for 24 hours.  Supernatants were tested for IL-10 via 
ELISA.  B - F. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were immunized with SRBC and 
sacrificed 9 days later.  Total CD4+ T cells were isolated via bead separation.  B. Cells 
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were stimulated with anti-CD3 and anti-CD28 antibodies in Th0 media for 24 hours and 
supernatants assessed for IL-10 via ELISA.  C. Cells were stimulated as in (B) then 
lysed for RNA analysis.  Transcript levels of il10 were assessed via qPCR; levels 
normalized to +/+.  D. Isolated T cells were stimulated with PMA and ionomycin in Th0 
media for 5 hours then cytokines assessed via ICS.  IL-10+ cells are shown as percent of 
CD3+ CD4+.  E. Representative flow plots of cells in (B).  Gated on CD3+ CD4+.  F. MFI 
of IL-10+ cells in (D).  G. Percent of IFNγ+ cells that are IL-10+ cells.  Gated on CD3+ 
CD4+ IFNγ+.  H. Representative flow plots of cells in (G).  Gated on CD3+ CD4+.  I. 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were immunized with SRBC and sacrificed 1, 3, 
5, and 7 days after.  Total CD4+ T cells were isolated and stimulated as in (A).  IL-10 
levels in supernatant were measured via ELISA.  Mean ± SE; *p < 0.05, **p < 0.01, ***p 
< 0.001 via t test.  J. Mice were aged to 13 months and sacrificed without immunization.  
Total CD4+ T cells were isolated and stimulated as in (A).  IL-10 levels in supernatants 
were measured via ELISA.  Mean ± SE.  K. Spleen cells were isolated from 
unimmunized BCL6+/+ CreCD4, BCL6fl/fl CreCD4, BCL6∆ZF/ ∆ZF, and BCL6fl/fl CreLysM mice.  
Effector memory (EM) and central memory (CM) cells were isolated via FACS and 
stimulated 24 hours with anti-CD3 and anti-CD28 antibodies in Th0 media.  Total spleen 
cells were stimulated with LPS for 24 hours in Th0 media.  Supernatants were assessed 
for IL-10 via ELISA.  Mean ± SE; *p < 0.05, **p < 0.01 by ANOVA; Tukey post hoc. 
 
 
IL-10 is suppressed by BCL6 
 
During evaluation of our new mutant cKO mouse model, one cytokine, IL-10, which is 
not traditionally a signature cytokine of any of the Th subsets, was shown to be 
consistently increased in a variety of experimental conditions.  When total CD4+ T cells 
from unimmunized mice were isolated and stimulated overnight with antibodies, BCL6fl/fl 
CreCD4 cells showed a significant increase in IL-10 secretion (Figure 41 A).  Nine days 
after immunization with SRBC, both protein and transcript levels of IL-10 were 
significantly increased in BCL6-deficient CD4+ T cells (Figure 41 B-C).  When IL-10 
production was assessed in immunized mice via ICS, no difference in the percentage of 
IL-10+ CD4+ T cells was found between the two mouse strains (Figure 41 D-E).  
However, the MFI of IL-10 in fl/fl T cells was significantly higher than +/+ cells (Figure 41 
F).  Therefore, although the same percentage of cells are making IL-10, those lacking 
BCL6 make more.  
 
We next wished to determine if the cytokine secretion profile of the CD4 T cells in fl/fl 
mice was altered.  Using ICS of CD4+ T cells from immunized mice, we saw no 
differences in IL-4/IL-10 dual positive cells, nor were there differences in IL-17A 
producing cells which also made IL-10 (data not shown).  However, we did find an 
interesting result when analyzing IFNγ producing cells.  As shown in Figure 30 C, no 
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differences in percent of IFNγ+ Th cells were found between BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice.  However, the percent of IFNγ+ cells which also produce IL-10 was 
significantly higher in the fl/fl CD4+ T cells (Figure 41 G-H), suggesting in the absence of 
BCL6, more Th cells which make IFNγ are also producing IL-10. 
 
Using a time course experiment, CD4+ T cells from fl/fl mice were shown to secrete more 
IL-10 at all time points checked after immunization, peaking on day five (Figure 41 I).  
Even the CD4+ T cells from mice aged to thirteen months trended toward secreting more 
IL-10 in the absence of BCL6 (Figure 41 J).   
 
However, the IL-10 produced by fl/fl Th cells was not as high as the level seen in GL KO 
mice.  Using FACS, we sorted effector memory (EM) and central memory (EM) cells 
from BCL6+/+ CreCD4, BCL6fl/fl CreCD4 and BCL6∆ZF/∆ZF mice and stimulated those cells, 
along with total spleen cells, overnight in Th0 media.  While cells from +/+ mice 
produced very little IL-10, EM cells from fl/fl and ∆ZF/∆ZF mice produced significantly 
more IL-10, although fl/fl cells did not produce as much IL-10 as ∆ZF/∆ZF cells.  When 
CM supernatants were evaluated, ∆ZF/∆ZF cells were the only group to secrete 
measurable amounts of the cytokine.  Finally, while total spleen cells from all three mice 
were able to produce IL-10 after stimulation with LPS, the levels appeared in a step-wise 
fashion, with +/+ making the least, fl/fl cells producing intermediate amounts, and 
∆ZF/∆ZF Th cells secreting the most.    
 
To demonstrate that the propensity to secrete more IL-10 is due to Th cell intrinsic 
factors in BCL6fl/fl CreCD4 mice, EM and CM cells were also sorted from BCL6fl/fl CreLysM 
mice.  These LysM mice express the cre recombinase enzyme specifically in myeloid 
cells, thus inducing the inflammatory nature of myeloid cells seen in GL KO mice.  T 
cells sorted from these mice, as well as total spleen cells, produced levels of IL-10 
similar to that seen in BCL6+/+ CreCD4 mice.  Therefore, increased IL-10 production of 
BCL6-deficient CD4+ T cells is due to loss of BCL6 specifically in CD4+ T cells and not to 
extrinsic stimulating factors.  
 
Finally, we evaluated the expression and secretion of IL-10 in several in vitro culture 
conditions (Figure 42).  Naïve CD4+ T cells were isolated from BCL6+/+ CreCD4 and 
BCL6fl/fl CreCD4 mice and activated in different polarizing media conditions with  
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Figure 42.  IL-10 is increased in different skewing culture conditions.  A. Naïve 
CD4+ T cells were isolated from BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice via FACS and 
activated with anti-CD3 and anti-CD28 antibodies in Th0, ThN, or TFH media.  After 24 
hours, cells were lysed for RNA analysis.  IL-10 transcript levels in Th0 and TFH cultures 
analyzed via microarray; ThN cultured cells analyzed via qPCR.  B. Naïve CD4+ cells 
were isolated from spleen via FACS and activated with anti-CD3 and anti-CD28 
antibodies in Th1, Th2, and Th17 polarizing media for 3 days.  After a 6 hour 
restimulation with the same antibodies, cells were lysed for RNA analysis via qPCR.  
Samples normalized to +/+ for each culture condition (dotted line at 1).  C. Cells in (B) 
were restimulated for 24 hours with antibodies and supernatants assessed for IL-10 via 
ELISA.  D. Same samples as in (B) except all are normalized to Th1 +/+ cells (dotted 
line at 1).  Mean ± SE; *p < 0.05 by t test. 
 
 
antibodies.  When naïve cells were activated overnight in Th0, ThN, and TFH culture 
conditions, il10 transcript levels were increased in Th0 culture conditions and 
significantly increased in TFH conditions (Figure 42 A).  Blocking IFNγ and IL-4 in ThN 
conditions led to a drop in il10 RNA.  When naïve cells were activated under Th1, Th2, 
and Th17 polarizing conditions for three days, il10 transcript levels were elevated in fl/fl 
Th cells, and significantly so under Th17 conditions (Figure 42 B).  This increase in RNA, 
however, did not necessarily translate to increases in cytokine secretion.  Under Th1-
polarizing culture conditions, fl/fl Th cells seemed to secrete more IL-10; however the 
sample size was too small to determine statistical significance (Figure 42 C).  Th2-
polarized cells showed no difference in IL-10 production between the two cell types.  
Finally, while Th17-polarizing conditions yielded the highest fold increase of il10 
transcript over +/+, these cells secreted the least IL-10 of all culture conditions.  When 
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transcript levels were reanalyzed and all samples normalized to Th1 +/+ samples (Figure 
42 D), the il10 transcript profile seemed to match the IL-10 secretion by these cells.  
Therefore, while Th2 culture conditions facilitated the most IL-10 secretion of the three 
Th cell polarizing conditions, no difference in IL-10 was seen in BCL6-deficient cells.  
Therefore, the cytokine conditioning of the media must be abrogating any effects loss of  
BCL6 may have on the production of IL-10 by these cells. 
 
BCL6 limits the proliferation of activated Th cells 
 
As demonstrated in Chapter 3 of this thesis, BCL6fl/fl CreCD4 mice appear to have a 
defect in Th cell activation.  However there are effector Th cells in these mice.  
Therefore, we wished to analyze whether the proliferation of Th cells is affected by the 
absence of BCL6, once the cells are activated. 
 
As was done previously, a time course experiment was performed, wherein mice were 
immunized i.p. with SRBC and sacrificed one, three, and five days after.  Total spleen 
cells were assessed for Ki67, a proliferation marker, via flow cytometry.  As shown in 
Figure 43 A, total CD4+ T cells from BCL6fl/fl CreCD4 mice had decreased Ki67 staining 
compared to BCL6+/+ CreCD4 mice.  However, this could likely be due to fewer activated 
cells, as seen in Chapter 3.  Therefore, cells were further gated on CXCR5, a surface 
marker which is up-regulated on many Th cells soon after activation.  One day after 
immunization, BCL6fl/fl CreCD4 mice showed a decrease in Ki67 in this population, 
however by days three and five, there were no differences between the two mouse 
strains (Figure 43 B).  Th cells were also gated on an effector cell phenotype, which 
should include most activated cells.  When this was done, no difference was seen 
between BCL6-deficient and WT Th cells one and three days after immunization.  
Furthermore, BCL6-deficient Th cells had significantly more Ki67 staining five days after 
immunization (Figure 43 C), suggesting BCL6 may actually be repressing proliferation 
starting at intermediate time points after immunization.   
 
When mice were analyzed nine days after immunization, significantly more effector Th 
cells from fl/fl mice were expressing CD25, an activation marker, as compared to +/+ 
mice (Figure 43 D-left).  Also, the amount of CD25 expressed on CD25+ cells trended 
toward being higher in fl/fl cells, although the MFI levels were not statistically significant 
 85  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43.  BCL6 limits proliferation of activated CD4+ T cells.  A – C. BCL6+/+ 
CreCD4 and BCL6fl/fl CreCD4 mice were immunized i.p. with SRBC and sacrificed 1, 3, and 
5 days after.  Total spleen cells were stained for CD3, CD4, and assessed for Ki67 
expression via flow cytometry.  A. Ki67+ cells in total Th cell population.  B. Ki67+ cells 
that are CD3+ CD4+ CXCR5+.  C. Ki67+ cells that are CD3+ CD4+ CD44hi.  D. Mice were 
immunized i.p. with SRBC and sacrificed on day 9.  Total spleen cells stained for CD3+ 
CD4+ CD44hi CD25+.  Percent of CD25+ cells in CD44hi Th cell population (left).  MFI of 
CD25 in CD25+ population shown at left.  E. Naïve CD4+ T cells were isolated via FACS 
and activated in vitro with different concentrations of anti-CD3 and anti-CD28 antibodies 
in Th0 media for 48 hours.  Cells were then pulsed with tritiated thymidine for 18 hours.  
Incorporation shown as corrected counts per minute (CCPM). Mean ± SE; *p < 0.05, **p 
< 0.01 by t test. 
 
 
(Figure 43 D-right).  Therefore, it appears BCL6 limits the expression of activation 
markers on already activated Th cells.  
 
To investigate the difference in cell activation markers in vitro, naïve Th cells were 
isolated via FACS and activated in vitro with different concentrations of anti-CD3 and 
anti-CD28 antibodies.  After 48 hours in Th0 media, cells were pulsed with tritiated 
thymidine (3H) for 18 hours.  Scintillation counting of the incorporated thymidine revealed 
no differences in baseline proliferation (cultured without antibodies) (0x0) or at lower 
levels of activating antibodies (1 ug/mL anti-CD3 + 2 ug/mL anti-CD28 (1x2) and 5 
ug/mL anti-CD3 + 2 ug/mL anti-CD28 (5x2)) (Figure 43 E).  However, at the highest 
A. B. 
C. 
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concentrations of antibodies (10 ug/mL anti-CD3 and anti-CD28 (10x10)), which would 
activate the most Th cells and do so with strong stimulation, cells from fl/fl mice showed 
significantly more thymidine incorporation.  This demonstrates a higher proliferative 
capability for Th cells lacking BCL6 in the presence of strong stimulation.  
  
DISCUSSION 
 
Overall, there appeared to be no overwhelming effects on Th subset cell differentiation in 
the absence of BCL6, contrary to what has been seen previously with GL KO mouse 
models.  However, the mode of cellular activation (in vitro vs. in vivo) and the cell culture 
environment seemed to greatly affect the regulation of master transcription factors and 
cytokine secretion.  In the case of Th1 cells, IFNγ production did not seem to be altered 
in the absence of BCL6 in vivo.  However, when naïve fl/fl cells were activated in vitro for 
several days in Th0 media, which contains no skewing agents of any kind, the signature 
cytokine was reduced, as compared to +/+ cells.  This would suggest that IFNγ 
production is at least somewhat facilitated by BCL6.  These findings seem to contradict 
the findings of recent research in which BCL6 is necessary to limit excessive IFNγ 
production which is initiated by Tbet (39, 95).  This finding is especially perplexing since 
Tbet protein levels were significantly elevated in vivo in the absence of BCL6.  Our data 
demonstrates a role for BCL6 regulating Tbet at the post-transcriptional level in an in 
vivo immunization model.  When fl/fl naïve cells were activated in vitro, we saw 
significant increases in tbx21 transcript after 24 hours in Th0 media and after 3 days in 
ThN media.  However, when cells were cultured in TFH-skewing conditions, tbx21 
mRNA was significantly reduced in the absence of BCL6.  Therefore, it seems that BCL6 
can limit tbx21 transcription when no additional cytokines are present or when they are 
blocked, but in the presence of a cytokine rich environment, such as is found in vivo or in 
TFH in vitro conditions, tbx21 transcription is abrogated.  At the post-transcriptional level, 
though, it seems that BCL6 will limit Tbet production in vivo.  However, most of these 
findings are quite nuanced and IFNγ production was not significantly altered in our cKO 
mice.  Therefore, it appears that loss of BCL6 has very little effect on Th1 cell 
differentiation.  
 
The one subset we expected to see overwhelming increases in in the BCL6fl/fl CreCD4 
mice was Th2 cells.  This, however, did not prove to be true.  In fact, we saw significant 
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reductions in IL-4 secretion and transcription, both in vitro and in vivo.  Therefore, BCL6 
clearly plays a role in the production of this cytokine.  Overall, we saw few differences in 
gata3 transcription in the absence of BCL6.  Th cells activated in vivo had no difference 
in GATA3 mRNA without BCL6, while naïve cells activated in vitro showed increases in 
transcription in certain circumstances, particularly very early after activation (i.e. within 
24 hours).  Therefore, unlike the published findings using the BCL6 GL KO mouse 
model, we do not have evidence for increased Th2 differentiation in our cKO mice, and 
in fact, they appear to have a defect in IL-4 production. 
 
Like Th1 and Th2 cell analysis, the differentiation of Th17 cells did not appear to be 
consistently affected by loss of BCL6.  However, upon closer inspection, we detected a 
phenotype which adds further support for our model of graded expression, as set forth in 
Chapter 2.  In that model, Th17 cells require low levels of BCL6 for differentiation.  We 
can see evidence for this in the data presented in Figure 37.  When +/+ cells were 
assessed ex vivo for rorc mRNA, levels did not change much over the first five days of 
the immune response (Figure 36 C-top).  However, when WT total CD4+ T cells were 
stimulated with antibodies overnight, the levels of rorc increased.  Most interestingly, if 
you consider the transcript levels of BCL6 after in vitro stimulation (Figure 29 B), with 
day five having the lowest levels, we can see an inverse correlation between rorc 
transcripts and BCL6 RNA in WT mice.  Furthermore, when WT naïve cells are activated 
in vitro for several days, we saw a time-dependent decrease in rorc transcript levels 
(Figure 38 D).  However, that decrease was much slower than what was seen in fl/fl 
cells.  BCL6 is up-regulated upon initial activation of naive Th cells (22, 23), thus, it 
appears that the low levels of BCL6 in recently activated cells reinforces the expression 
of RORγt for a few days, longer than when BCL6 is completely absent.  Together, this 
analysis of BCL6 and RORγt in WT cells suggests that low levels of BCL6 are necessary 
for continued expression of RORγt.    
 
Analysis of our fl/fl mice provides evidence that an enhanced cytokine environment can 
overcome any necessity for BCL6 in RORγt expression, and, in some cases, facilitate 
even higher expression.  For example, cells assessed ex vivo show increases in rorc 
transcript levels one, three, and five days after immunization in the absence of BCL6.  
Therefore, when subjected to an in vivo environment, likely to be rich in cytokines, BCL6 
appears to inhibit RORγt expression.  In vitro, when naïve cells are activated in TFH 
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media, rorc mRNA is significantly increased in the absence of BCL6, while it is 
marginally increased in Th17-skewing media.  When the contents of these two media 
types are compared, it appears that IL-6 may be facilitating the increase in RORγt 
expression.   
 
To summarize our findings for Th17 cells, we propose that low levels of BCL6 are 
necessary to sustain RORγt expression, both in vitro and in vivo.  However, BCL6 
appears to limit RORγt expression, particularly in an environment that is rich in IL-6, 
such as the case in vivo, and in Th17 and TFH cultures in vitro.  Without BCL6 or IL-6, 
rorc transcription is not sustained.  Therefore, a careful balance between BCL6 
expression levels and IL-6 stimulation from the surrounding environment is necessary to 
regulate Th17 differentiation (Figure 44).   
 
While recent research has shown BCL6 and Foxp3 to be dually expressed in TFR cells, 
little work has been done to investigate the specific effect BCL6 may have on Foxp3 
expression.  Using our new cKO mouse model, we were able to establish that BCL6 
contributes to foxp3 expression, both in vitro and in vivo.  While TFR cells do express 
both transcription factors, they are thought to be derived from Treg cells and not TFH 
cells (35, 36).  Therefore these cells would express Foxp3 first, before up-regulating 
BCL6.  However, it is possible that even low levels of BCL6 are necessary for Th cells to 
express Foxp3.  What this means for nTreg cell development in the thymus cannot be 
determined here.  However, our data does suggest that low levels of BCL6 would be 
necessary for iTreg development in vivo. 
 
The balance between BCL6 expression and Blimp-1 is one which has been extensively 
studied, particularly in B cells and CD8+ T cells.  Current dogma states, in the absence 
of Blimp-1, BCL6 is up-regulated, and vice versa.  However, work recently published by 
our lab shows prdm1 transcript to only be significantly increased in the absence of BCL6 
in TFH media conditions (110).  Here, we present a more in-depth analysis of the 
expression of Blimp-1 in BCL6-deficient Th cells.    
 
When mice are immunized with SRBC, a strong GC reaction is induced, and, thus, many 
Th cells will be expressing high levels of BCL6 in +/+ mice.  It should follow then, that 
Blimp-1 levels would be particularly low in Th cells in this type of immune response.  
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Therefore, when transcript levels of prdm1 are assessed in cKO mice and normalized to 
+/+ levels, any increases in the absence of BCL6 should be strongly evident, due to the 
assumed low levels in WT mice.  However, when this was done, no differences in prdm1 
expression were found between the two types of cells.  When WT cells were analyzed 
for prdm1 transcript early after immunization, levels decreased over time, as expected.  
However, mRNA from fl/fl Th cells was low one day after immunization and remained 
low thereafter.  This experiment showed that in WT Th cells, Blimp-1 levels increase just 
after immunization, but decrease over time, down to the levels seen in cKO Th cells by 
day nine.  Interestingly, when those same Th cells are stimulated overnight with 
antibodies, the levels of prdm1 transcript does increase, however, not to the levels seen 
in WT mice assessed ex vivo.  Therefore, like BCL6, Blimp-1 transcription is severely 
abrogated with in vitro stimulation. 
 
As we have previously published (110), when naïve cells are activated for 24 hours in 
different media conditions, Blimp-1 was increased only in the TFH culture.  Furthermore, 
when naïve cells were cultured for several days in ThN media, Blimp-1 was severely 
decreased in the absence of BCL6 twenty four hours after activation.  However over 
time, those cells were able to transcribe prdm1 to the levels of +/+ cells.  This would 
suggest BCL6 restricts Blimp-1 expression in TFH conditions, but facilitates its 
transcription in the limiting environment of ThN culture conditions. 
 
Taken together, the data presented here demonstrate a much more complicated 
relationship between BCL6 and Blimp-1 than previously thought.  While it seems clear 
that BCL6 is up-regulated in Blimp-1 KO cells, the converse is not necessarily true.  Only 
in particular stimulatory and cytokine conditions is Blimp-1 increased in the absence of 
BCL6.  In fact, it seems more probable from this data that BCL6 is necessary for Blimp-1 
expression, particularly in vivo.  Clearly more work needs to be done to fully analyze the 
effects of BCL6 loss on Blimp-1 expression, but the data presented here should at least 
trigger a reassessment of the current understanding of the relationship between these 
two transcriptional repressors.  
 
The one cytokine in our extensive analysis of BCL6fl/fl CreCD4 mice which was 
consistently increased in the absence of BCL6 was IL-10.  We saw statistically 
significant increases in this cytokine at the transcriptional and protein levels in BCL6-
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deficient CD4+ cells from unimmunized mice, at various time points after immunization, 
and in aged mice.  Because IL-10 is a suppressive cytokine, this would suggest that the 
immune response is trying to function in a limiting environment in cKO mice.  It is 
possible that secretion of IL-10 by activated Th cells in BCL6fl/fl CreCD4 mice is 
contributing to the decreased activation seen in these mice, as discussed in Chapter 3.  
However, BCL6 GL KO mice are known to have large proportions of activated Th cells 
that secrete IL-10 (61), yet there appears to be no activation defect in these mice.  In 
fact, GL KO mice typically have increases in activated Th cells and decreases in naive 
Th cells.  The role IL-10 is playing in BCL6fl/fl CreCD4 mice cannot be determined from the 
data presented.  However, it is clear that BCL6 works to repress IL-10 in WT Th cells.  
 
We can also deduce from our data that IFNγ may be playing a role in the increased 
secretion of IL-10 by BCL6-deficient cells.  Firstly, using ICS, we determined that only 
IFNγ+ cells from immunized mice, and not IL-4+ or IL-17A+ cells, had a larger percentage 
of cells also producing IL-10.  Secondly, analyses using in vitro assays showed a 
reduction in IL-10 secretion in a ThN environment, which blocks IFNγ and IL-4.  This 
suggests that IFNγ or IL-4 may be facilitating IL-10 secretion.  When cells were cultured 
in Th1- and Th2-skewing environments, IL-10 production was only increased in the 
presence of IFNγ, and not IL-4.  This would suggest that IFNγ facilitates increased IL-10 
production by Th cells in the absence of BCL6. 
 
Finally, we utilized our new cKO mouse model to determine if BCL6 has any role in the 
proliferation of already activated cells.  Analysis using Ki67 staining and tritiated 
thymidine incorporation provided data which suggests BCL6 limits the proliferation of 
activated cells.  Therefore, while BCL6 is necessary for proper Th cell activation, as was 
presented in Chapter 3, here we show that once activated, the transcriptional repressor 
will actually limit cellular proliferative capabilities.  
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Figure 44.  Th17 differentiation and BCL6.  In the presence of high BCL6 and high IL-
6 expression, TFH cells will differentiate.  Proper differentiation of Th17 cells is 
dependent on moderate levels of IL-6 and low levels of BCL6.  When BCL6 is absent 
and IL-6 is present at high levels, excessive Th17 skewing occurs.  In the absence of 
both BCL6 and IL-6 no Th17 differentiation will occur. 
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CHAPTER 5 – ROLE OF BCL6 IN TFH CELL SURFACE MARKER EXPRESSION 
 
 
INTRODUCTION 
 
Follicular T helper (TFH) cells are an important CD4+ T cell subset responsible for 
facilitating the production of high affinity antibodies from B cells (24).  Historically, this 
task was associated with Th2 cells, and only recently have TFH cells emerged as the 
primary T cell responsible for assisting B cells (26).  While TFH cells have been shown 
to migrate into the B cell follicle for some time, only in the last five years has their master 
transcription factor, BCL6, been identified (37-39, 62).  Under the control of this 
transcriptional repressor, TFH cells up-regulate CXCR5, ICOS, PD-1, and several other 
surface markers.  However, the majority of studies focus on CXCR5, ICOS, and PD-1 
when identifying these cells (24).  While expression of these markers is not exclusive to 
TFH cells, their combination and high level expression is.    
 
Upon activation of naïve CD4+ T cells, BCL6 becomes up-regulated at low levels (22, 
23).  During this time, the chemokine receptor CXCR5 also becomes up-regulated, 
although this increase in surface expression has been shown to be independent of BCL6 
(81).  Expression of CXCR5 enables CD4+ T cells to follow a CXCL13 chemokine 
gradient toward the B cell follicle.  Once these cells reach the T/B cell border region, 
interactions with B cells will determine whether they will become TFH cells or not (24, 
26).  During the peak of the immune response, the vast majority of CXCR5+ Th cells are 
TFH cells (26).  Furthermore, prolonged expression of this surface marker has been 
shown to be dependent on BCL6 expression (81).  CXCR5 is widely used to identify TFH 
cells, however, how BCL6 controls its expression has yet to be fully understood.   
 
ICOS is a CD28-like costimulatory molecule which is expressed on several Th subsets, 
but is particularly highly expressed on TFH cells (111, 112).  Its up-regulation occurs 
early after cell activation and is crucial for sustaining cell-cell contact with B cells (26).  
Furthermore, it has been shown that ICOS signaling can program Th cells to become 
TFH very early in the immune response (113).  Continued ICOS-ICOSL interactions 
between TFH and APCs, has been shown to be vital for continued TFH differentiation 
(113).  
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Programmed death-1, or PD-1, is encoded by the gene pdcd1 and plays a crucial role in 
controlling T cell proliferation (114, 115).  While expressed on many different T cell 
subsets, including CD8+ T cells, this inhibitory marker is highly expressed on TFH cells 
(116).  PD-1 has been shown to block TCR activation signals through the recruitment of 
two phosphatases: Src homology region 2 domain-containing phosphatase-1 (SHP-1) 
and SHP-2 (114, 117-119).  These phosphatases can then, in turn, abrogate 
downstream activity of PI3K, which is necessary for Th cell activation and cytokine 
secretion (117, 120).  Furthermore, PD-1 signaling can inhibit TCR signals facilitating 
ongoing interactions with APCs (121).  An additional study demonstrated a role for PD-1 
signaling in blocking CD4+ T cell entry into S phase of the cell cycle (122).   It is believed 
that high expression of PD-1 on TFH cells limits the proliferation of these cells (24, 114), 
and blockade of PD-1 signaling leads to increased TFH populations (123).   
 
Like the above mentioned TFH markers, PD-1 has been shown to be up-regulated soon 
after cell activation (114, 117).  Recent publications have demonstrated a role for 
epigenetics in the regulation of PD-1 expression in CD8+ T cells.  One study in particular 
demonstrated a loss of methylation at the PD-1 promoter upon T cell activation, while 
remethylation of the region allowed cells to become long-lived memory cells (124).  
Additionally, exhausted CD8+ T cells had complete demethylation of the PD-1 promoter.  
While epigenetic modifications to the PD-1 promoter have been well studied, what 
controls those epigenetic changes has not been identified.  Furthermore, although it has 
been suggested that PD-1 signaling controls TFH cell proliferation, by what means this is 
done has not yet been discussed.  Here, we present data which attempts to elucidate 
these issues.   
 
The fact that PD-1 expression has been shown to be controlled, to some extent, by 
methylation is important, as DNA methylation is one of the only epigenetic modifications 
which can be passed on to daughter cells efficiently (125).  Methylating DNA, typically 
cytosines at CpG dinucleotides, is one way of remodeling chromatin into a less 
accessible state, leading to silencing of genes (125, 126).  This activity is carried out by 
DNA-methyltransferases (Dnmt).  Initial methylation patterns, or de novo methylation, in 
unactivated cells, is thought to be carried out by Dnmt3a and Dnmt3b, while maintaining 
the established methylation pattern of DNA during cell division is the job of Dnmt1 (126-
128).  When a cell divides, the daughter DNA is hemi-methylated, and Dnmt1 recognizes 
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and targets this pattern for full methylation to maintain the epigenetic modifications 
(127).  Conversely, the Ten-Eleven-Translocation, or TET, proteins can also recognize 
these hemi-methylated regions and further reduce the methyl groups at those sites (127, 
129).  This makes it less likely Dnmt1 will recognize the region and target it for templated 
methylation.  Therefore, TET proteins play a critical role in the demethylation of gene 
promoters over successive cell differentiations (127, 129).  
  
How de novo methylation patterns are established has not been well studied in vivo, 
however, cell line experiments have provided several hypothesizes.  Two potential ways 
in which Dnmt3a and Dnmt3b are targeted to genes for silencing are 1) by recognition of 
specific domains directly by the Dnmts, or 2) via recruitment to gene regions by 
transcriptional repressors (128).  Once localized to a promoter region, Dnmts can block 
transcription either by physically interfering with the binding of transcriptional machinery 
or through methylation modifications to the chromatin structure.  Furthermore, Dnmts 
can also associate with histone deacetylases (HDACs), and this association, combined 
with targeting to a specific gene, will lead to remodeling of the chromatin and silencing of 
gene transcription (128).   
 
At this time, no data has shown that BCL6 can activate genes directly.  Therefore, in 
order to activate genes that define the TFH phenotype, BCL6 must activate transcription 
indirectly, such as by repressing other transcriptional repressors or by binding these 
suppressors and sequestering them away from their targets (46, 50).  The exact 
mechanisms by which this is accomplished are not known at this time.  Multiple models 
for how TFH cells differentiate have been proposed (17, 24, 99).  One model postulates 
that activated Th cells differentiate into another subset first, before up-regulating BCL6 
and becoming a TFH cell (94, 130).  The thought behind this model is that by down-
regulating the master transcription factors of other Th subsets, any repression these 
factors held over TFH genes will be consequently lifted, thus allowing activation of TFH-
related genes.  Research using GL KO mice has shown that BCL6 can directly repress 
GATA3 and RORγt, the master transcription factors for Th2 and Th17 cells respectively 
(61, 97).   
 
A second theory for how TFH cells develop is by directly differentiating from activated 
naïve Th cells (131).  Multiple studies have shown this, using both in vivo and in vitro 
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methods (24).  The interplay between BCL6 and other Th subsets proved even more 
complex when several groups published data showing a subset of Treg cells which were 
able to acquire TFH-like characteristics, such as up-regulated BCL6 and CXCR5 
expression, and traffic into the GC, where they helped to regulate the GC reaction (35, 
36).  Therefore, the role BCL6 plays in Th cells is complicated and not well understood.  
However, here we provide evidence for how BCL6 may be regulating the expression of 
some TFH cell markers and what role this master transcription factor plays in TFH cell 
survival. 
 
 
METHODS AND MATERIALS 
 
Mice and immunizations 
 
Bcl6fl/fl mice were mated to CD4-cre mice (82) to generate Bcl6fl/fl CreCD4 mice.  Mice with 
the wild type BCL6 allele were bred to CD4-Cre mice for use as controls (BCL6+/+ 
CreCD4).  C57BL/6 mice were obtained from Jackson Laboratories.  
The floxed allele was genotyped by PCR using the following primers:  
5’ loxP forward (5’ – TGAAGACGTGAAATCTAGATAGGC – 3’)  
5’ loxP reverse (5’ – ACCCATAGAAACACACTATACATC – 3’)  
3’ loxP forward (5’ –TCACCA ATCCCAGGTCTCAGTGTG–3’)  
3’ loxP reverse (5’ – CTTTGTCATATTTCTCTGGTTGCT–3’) 
 
Cre-CD4 transgene was genotyped using the following primers: 
Forward (5’ –ATCGCCATCTTCCAGCAGGCGCACT– 3’) 
Reverse (5’ –ATTTCCGTCTCTGGTGTAGCTGAT– 3’) 
 
Mice were immunized i.p. with 1 x 109 sheep red blood cells (SRBC; Rockland 
Immunochemicals Inc., Gilbertsville, PA) in PBS. 
 
Serum antibody analysis 
 
Blood was collected from sacrificed mice.  After clotting, blood was centrifuged for 10 
minutes at 10,000 RPM and serum collected.  For total IgG, capture antibody was anti-
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mouse kappa chain antibody (Sigma Cat. # SAB3701212) and an anti-mouse IgG-
Peroxidase detection antibody used was used (Sigma Cat. # A9044).  SRBC-specific Ig 
was measured as previously described (132).  Briefly, wells were coated with SRBC 
membrane extract (prepared as described (132)) overnight at 4˚C.  Wells were blocked 
with 10% FCS and diluted serum was incubated in wells for 2 hours at RT.  A peroxidase 
labeled Fc-specific anti-mouse Ig detection antibody was used for each isotype (Sigma).  
Titration method was used to determine concentration.  For total IgM, IgG1, IgG2b, 
IgG3, and IgA, capture antibodies were isotype-specific (Sigma Cat. # ISO2) and an 
anti-mouse Ig-Peroxidase detection antibody was used.  Concentrations determined 
according to a standard curve.  Standards were purchased from Southern Biotech (IgM 
Cat. # 0101-01; IgG1 Cat. # 0102-01; IgG2b Cat. # 0104-01; IgG3 Cat. # 0105-01; IgA 
Cat. # 0106-01).  
 
Flow cytometry 
 
Total spleen or thymus cells were incubated with anti-mouse CD16/CD32 (Fcγ receptor) 
for 20 minutes, followed by surface staining for the indicated markers.  A fixable viability 
dye (eFluor 780, eBioscience) was used for all samples.  The following antibodies were 
used for staining GC B cells: α-mCD19 Alexa Fluor 700, clone eBio1D3 (eBioscience); 
α-mB220 PE, clone RA3-682 (BD Bioscience); α-mFas Biotin, cat. # 554256 (BD 
Bioscience); Streptavidin-PECy7 (Biolegend); α-mGL7 APC, clone GL7 (BD Bioscience); 
PNA FITC (Vector Laboratories Inc.).  The following antibodies were used to stain TFH 
cells: α-mCD3 Alexa Fluor 700, clone 500A2 (BD Bioscience); α-mCD4 PECy7, clone 
RM4-5 (BD Bioscience); α-mCXCR5 PerCP-efluor 710, clone SPRCL5 (eBioscience); α-
mPD-1 APC, clone 29F.1A12 (Biolegend); α-mICOS FITC, clone C398.4A 
(eBioscience).  Samples were run on a BD LSR II flow cytometer using FACSDiva 
software.  Data was analyzed using FlowJo software. 
 
Cell isolation 
 
Total CD4+ T cells were isolated via magnetic bead separation (Miltenyi Biotec); naïve 
CD4+ T cells were isolated via FACS and gated on CD3+ CD4+ CD44− CD62L+.  
Propidium iodide was used as a viability gate. 
 
 97  
 
Gene expression analysis 
 
Total RNA was prepared using a kit (Qiagen) after lysis of the cells via Trizol (Life 
Technologies); cDNA was prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Quantitative PCR (qPCR) reactions were run by assaying each sample in 
triplicates using the Fast Start Universal SYBR Green Mix (Roche Applied Science) with 
custom primers or specific Taqman assays (ABI).  Assays were run with a Stratagene 
Mx3000P Real-Time QPCR machine.  Levels of mRNA expression were normalized to 
beta-tubulin mRNA levels, and differences between samples analyzed using the ∆∆CT 
method.  Primers for SYBR Green assays were previously described (14, 19). 
 
Microarrays 
 
Naïve CD4+ T cells were isolated via FACS using the following surface markers: CD3+ 
CD4+ CD62L+ CD44−.  A cell viability gate was also used.  Cells were activated in vitro 
with anti-CD3 and anti-CD28 antibodies, as described above, in Th0 or TFH media 
conditions.  TFH conditions contain IL-6 and IL-21 [10 ng/ml each (R&D Systems)], plus 
anti-IFNγ (10 μg/mL), anti-IL-4 (10 μg/mL), and anti–TGF-β (20 µg/mL) antibodies.  Cells 
were cultured for 20 hours.  Cells were lysed, RNA prepared using an RNeasy kit 
(Qiagen), and cDNA prepared with the Transcriptor First Strand cDNA synthesis kit 
(Roche).  Affymetrix gene expression microarrays were carried out by Center for Medical 
Genomics at the Indiana University School of Medicine. 
  
Chromatin immunoprecipitation assay  
 
BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were sacrificed either unimmunized or five days 
after immunization with SRBC.  Total CD4+ T cells were isolated from spleen via bead 
separation (Miltenyi Biotech).  ChIP assay was performed as previously described (133).  
Briefly, cells were cross-linked for 10 min with 1% formaldehyde and lysed by sonication.  
After pre-clearing with salmon sperm DNA, bovine serum albumin, and protein agarose 
bead slurry (50%), cell extracts were incubated with either Dnmt3a antibody (IMG-268A; 
IMGENEX), Dnmt3b antibody (804-233-c100; Alexis), H3ac antibody (Millipore), H4ac 
antibody (06-866; Millipore), or normal rabbit IgG (Millipore) overnight at 4 °C.  The 
immunocomplexes were precipitated with protein agarose beads at 4 °C for 2 h, washed, 
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eluted, and cross-links were reversed at 65 °C overnight.  DNA was purified, 
resuspended in H2O, and analyzed by quantitative PCR with SYBR primers as 
described previously (134).  Additional primers were as follows:  
 
PD-1 CRB forward (5’ –CTCTGACTAGCTGTCCTTGCCTC– 3’) 
PD-1 CRB reverse (5’ –CTCGACACCCACCCTCCAAAG– 3’) 
PD-1 CRC forward (5’ –CCTCACCTCCTGCTTGTCTCTC– 3’) 
PD-1 CRC reverse (5’ –GTGAGACCCACACATCTCATTGC– 3’) 
CXCR5 forward (5’ –CAGTGCTTCGTCAGCTCCAGAC– 3’) 
CXCR5 reverse (5’ –CTCAGGTAGTCATGTTTGATGGC– 3’) 
 
Statistical analysis 
 
Statistical analysis was done using IBM SPSS Statistics 21 software.  Statistics for 
microarray data was done using GraphPad Prism software. In all figures, *p < 0.05, **p < 
0.01, ***p < 0.001. 
 
 
RESULTS 
 
Germinal center cells fail to develop at any time after immunization in BCL6fl/fl 
CreCD4 mice 
 
Using our new cKO mice, we wanted to verify that GCs fail to develop in the absence of 
BCL6 in Th cells.  Nine days after immunization with SRBC, BCL6fl/fl CreCD4 mice failed 
to generate GC B cells or TFH cells, while BCL6+/+ CreCD4 mice had robust populations 
of these cells (Figure 45 A-B).  Next, we wondered whether these cell populations are 
able to differentiate early in the immune response, but are not sustained when Th cells 
are BCL6-deficient.  When mice were sacrificed one, three, and five days after 
immunization and analyzed for GC cell populations, we found no evidence of TFH cell 
development in fl/fl mice (Figure 45 C-D).  This experiment also demonstrated the 
exponential expansion of GC B cells and TFH cells in +/+ mice between days three and 
five.  
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Figure 45.  BCL6fl/fl CreCD4 mice fail to generate germinal centers.  A – B. Mice were 
immunized i.p. with SRBC and sacrificed on day 9.  Spleen cells were analyzed via flow 
cytometry.  A. GC B cells, shown as percent of total spleen, with representative flow 
plots.  Cells gated on B220+ CD19+ Fas+ PNA+ GL7+.  B. TFH cells, shown as percent of 
total spleen, with representative flow plots.  Cells gated on CD3+ CD4+ CXCR5+ ICOS+ 
PD-1hi.  C – D. Mice were immunized i.p. with SRBC and sacrificed 1, 3, and 5 days 
after.  Spleen cells were analyzed via flow cytometry.  C. GC B cells, gated as in (A).  D. 
TFH cells, gated as in (B).  Mean ± SE; *p < 0.05, **p < 0.01, ***p < 0.001 by t test. 
 
 
To determine the functional effects of loss of GCs in fl/fl mice, serum from unimmunized 
mice and mice sacrificed nine days after immunizing with SRBC was analyzed for 
antibody concentrations.  When total IgG was assessed, we found the titer in both +/+ 
and fl/fl to increase with immunization and no significant difference in titer levels were 
found between the two mouse strains either before or after immunization (Figure 46 A).   
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Figure 46.  Antibody titers in BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice.  Mice were 
immunized with either SRBC or PBS (control) and sacrificed on day 9, when serum was 
harvested.  Antibody titers assessed via ELISA.  A. Total IgG (top) and SRBC-specific 
IgG (bottom) determined using titration method.  B. Total IgM (top) determined using 
standard curve and SRBC-specific IgM (bottom) determined via titration method.  *p < 
0.05 via t test.  C. Total IgG1 (top) and SRBC-specific IgG1 (bottom) determined as in 
(B).  D. Total IgG2b (top) and SRBC-specific IgG2b (bottom) determined as in (B).  E. 
Total IgG3 (top) and SRBC-specific IgG3 (bottom) determined as in (B).  F. Total IgA 
determined as in (B).  Mean ± SE.  For all analysis except (B): *p < 0.05, **p < 0.01, ***p 
< 0.01 by two-way ANOVA; Tukey post hoc analysis. 
A. B. C. 
D. E. F. 
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However, when antigen-specific IgG was measured, fl/fl mice were found to have a 
significant reduction in these antibodies, compared to serum from +/+ mice.  Total IgM, 
while increasing with immunization, was not found to be different between the two types 
of mice, but again, SRBC-specific IgM was reduced, approximately three-fold, in fl/fl 
mice (Figure 46 B).  When total IgG1 and IgG2b were analyzed, +/+ mice were found to 
have significantly higher levels after immunization (Figure 46 C-D).  Also, fl/fl mice were 
shown to have almost no production of antigen-specific antibodies of these isotypes 
(Figure 46 C-D).  Finally, while no differences in total IgG3 and IgA were found, after 
immunization, +/+ mice had a slightly higher SRBC-specific IgG3 titer compared to fl/fl 
mice, although it was not significant (Figure 46 E-F). 
 
TFH surface marker expression in BCL6-deficient Th cells 
 
Because TFH cells are so often identified by their surface marker expression via flow 
cytometry, we did further analysis on the expression of frequently used TFH markers to 
determine what effects loss of BCL6 has on their expression.  First, the canonical marker 
for TFH, CXCR5, was found to be expressed at fairly similar levels between +/+ and fl/fl 
mice before immunization, however, nine days after immunization, the percentage of 
CD4+ T cells expressing CXCR5 significantly increased in +/+ mice, but remained fairly 
stagnant in fl/fl mice (Figure 47 A).  While significantly more Th cells in +/+ mice were 
expressing the surface marker after immunization, the relative surface expression per 
CXCR5+ cell remained unchanged between WT and BCL6-deficient Th cells (Figure 47 
A).  To assess how early the difference in CXCR5+ cell percentages takes place, mice 
were immunized with SRBC and sacrificed one, three, and five days later.  When total 
spleen cells were analyzed for CXCR5+ Th cells, no significant differences in 
percentages were seen until day five, when the +/+ cells had more (Figure 47 B).  This 
increase also correlated with mRNA analysis of cxcr5 transcript in ex vivo Th cells 
(Figure 47 C).  But again, while the percentage of CXCR5+ cells significantly increased 
in +/+ mice, compared to fl/fl mice, no differences in the relative expression of CXCR5 
per cell were found (Figure 47 B).  Therefore, while BCL6fl/fl CreCD4 mice appear to have 
significantly fewer Th cells expressing CXCR5 by day five, the amount of CXCR5 on 
each cell is not changed compared to BCL6+/+ CreCD4 mice.   
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Figure 47.  CXCR5 expression in BCL6-deficient CD4+ T cells.  A. CXCR5 surface 
expression on Th cells from spleen was evaluated in unimmunized (+PBS) mice and 
mice immunized with SRBC and sacrificed on day 9 via flow cytometry.  The percent of 
CXCR5+ cells is shown as a percentage of CD4+ cells (top) and the MFI of CXCR5 in the 
CXCR5+ population is shown (bottom).  Cells gated on CD3+ CD4+ CXCR5+.  Mean ± 
SE.  *p < 0.05 by two-way ANOVA; Tukey post hoc.  B. Mice were immunized with 
SRBC and sacrificed 1, 3, and 5 days after.  Spleen cells were assessed for CXCR5 
expression as in (A).  Mean ± SE. **p < 0.01 by t test.  C. Total CD4+ T cells were 
isolated via bead separation from spleen of mice immunized in (B) and lysed for RNA 
analysis.  Transcript levels of cxcr5 were assessed and normalized to Day 1 +/+ 
samples (dotted line at 1).  Mean ± SE. *p < 0.05, **p < 0.01 by t test. 
 
 
The next marker we analyzed was ICOS.  By first gating cells on CXCR5 expression, we 
were able to evaluate the potential for ICOS expression on TFH and non-TFH cells in 
+/+ mice.  Because fl/fl mice are unable to produce TFH cells, in this way we can 
equalize any bias in ICOS expression on TFH cells in +/+ mice.  First, when ICOS+ cells 
were evaluated in CXCR5+ cells, those which are poised to become TFH cells, we saw a 
significant increase in ICOS+ cells after immunization in +/+ mice, which was expected 
as these mice have TFH cells (Figure 48 A).  Like CXCR5, we saw no significant 
difference in ICOS MFI on ICOS+ cells within this CXCR5+ gate (Figure 48 A).  Next, we 
evaluated ICOS expression on CXCR5− Th cells.  While the percentage of ICOS+ cells 
significantly increased in both BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice after 
immunization, +/+ Th cells still had a significantly larger proportion expressing the 
surface marker (Figure 48 B).  However, once again, there was no difference in the 
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Figure 48.  ICOS expression in BCL6-deficient 
CD4+ T cells.  A. ICOS surface expression on Th 
cells from spleen was evaluated in unimmunized 
(+PBS) mice and mice immunized with SRBC and 
sacrificed on day 9 via flow cytometry.  The percent 
of CXCR5+ ICOS+ cells is shown as a percentage of 
CXCR5+ cells (top) and the MFI of ICOS in the 
ICOS+ CXCR5+ population is shown (bottom).  Cells 
gated on CD3+ CD4+ CXCR5+ ICOS+.  Mean ± SE.  
**p < 0.01, ***p < 0.001 by two-way ANOVA; Tukey 
post hoc.  B. Cells assessed as in (A) but for CXCR5− 
ICOS+ cells.  Cells gated on CD3+ CD4+ CXCR5− 
ICOS+.  Mean ± SE.  **p < 0.01, ***p < 0.001 by two-
way ANOVA; Tukey post hoc.  C. Mice were 
immunized with SRBC and sacrificed 1, 3, and 5 days 
after.  Spleen cells assessed and gated as in (A).  
Mean ± SE.  **p < 0.01 by t test.  D. Mice were 
immunized as in (C) and cells assessed and gated as 
in (B).  Mean ± SE.  *p < 0.05, ***p < 0.001 by t test.   
 
 
amount of ICOS expressed per cell when comparing +/+ and fl/fl Th cells (Figure 48 B).    
 
To evaluate any differences early in the immune response, the same time course 
experiment was done and ICOS was evaluated on CXCR5+ and CXCR5− cells one, 
three, and five days after immunization.  Th cells from fl/fl mice had significantly fewer 
CXCR5+ cells expressing ICOS five days after immunization (Figure 48 C).  Like CXCR5 
expression, this was expected, as +/+ mice have TFH cells which significantly increased 
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Figure 49.  PD-1 expression is altered in the absence of BCL6.  A. PD-1 surface 
expression on Th cells from spleen was evaluated in unimmunized (+PBS) mice and 
mice immunized with SRBC and sacrificed on day 9 via flow cytometry.  The percent of 
CXCR5+ PD-1+ cells is shown as a percentage of CXCR5+ cells (top) and the MFI of PD-
1 in the PD-1+ CXCR5+ population is shown (bottom).  Cells gated on CD3+ CD4+ 
CXCR5+ PD-1+.  Mean ± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA; 
Tukey post hoc.  B. Cells assessed as in (A) but for CXCR5− PD-1+ cells. Cells gated on 
CD3+ CD4+ CXCR5− PD-1+.  Mean ± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 by two-way 
ANOVA; Tukey post hoc.  C. Mice were immunized with SRBC and sacrificed 1, 3, and 5 
days after.  Total CD4+ T cells were assessed for PD-1 expression.  Cells gated on CD3+ 
A. B. C. 
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CD4+ PD-1+; shown as percent of CD4+ (top) and MFI of PD-1 in total CD4+ T cells 
shown (bottom).  Mean ± SE.  **p < 0.01, ***p < 0.001 by t test.  D. PD-1 MFI of PD-1+ 
cells in (C).  Mean ± SE.  **p < 0.01, ***p < 0.001 by t test.  E. Total CD4+ T cells were 
isolated from mice in (B) and lysed for RNA analysis.  Transcript levels of pdcd1 (PD-1) 
were normalized to Day 1 +/+ samples.  Mean ± SE.  ***p < 0.001 by t test.  F. Cells 
from (C) were further gated on CXCR5+ cells, then assessed for PD-1 expression.  Cells 
gated on CD3+ CD4+ CXCR5+ PD-1+; shown as percent of CXCR5+ (top) and MFI of PD-
1 in CXCR5+ PD-1+ population (bottom).  Mean ± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 
by t test.  G. Cells assessed the same as in (F) except in the CXCR5− population.  Mean 
± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 by t test.  
 
 
on day five (Figure 45 D).  However, ICOS MFI was not changed between +/+ and fl/fl 
mice in this CXCR5+ gate (Figure 48 C).  When ICOS expression was evaluated on non-
TFH, or CXCR5− cells, fl/fl mice had significantly fewer Th cells expressing the marker 
one and five days after immunization (Figure 48 D).  Interestingly, while the MFI of ICOS 
on those days was unchanged between the two types on mice, on day three, when the 
percentages of ICOS+ cells were equivalent, fl/fl ICOS+ cells had a higher MFI (Figure 48 
D).  These data demonstrate that while fewer Th cells in BCL6fl/fl CreCD4 mice are 
expressing ICOS on their surface, their potential to do so is not changed, as is indicated 
by ICOS MFI levels.   
 
PD-1 expression is altered in BCL6-deficient Th cells  
 
When PD-1, another key marker for TFH cells, was assessed in unimmunized mice, 
irrespective of CXCR5 expression, the percentage of PD-1-expressing Th cells was 
reduced, significantly so in CXCR5− cells (Figure 49 A-B).  Nine days after immunization, 
the difference in PD-1+ cells between +/+ and fl/fl mice was even more significant, 
regardless of the CXCR5 expression status of the cells (Figure 49 A-B).  What was most 
interesting, though, was, unlike CXCR5 and ICOS expression, the MFI of PD-1 was 
significantly reduced, both before and after immunization, and on both CXCR5+ and 
CXCR5− cell subsets (Figure 49 A-B).  In fact, the amount of PD-1 expressed on fl/fl PD-
1+ cells after immunization was still significantly less than the amount of PD-1 seen on 
+/+ cells from unimmunized mice. 
 
Using our time course experiment, we saw that the percent of PD-1+ cells in total CD4+ T 
cells was significantly reduced on day one after immunization and the difference is only 
exacerbated over time (Figure 49 C).  This is not surprising, as +/+ mice are generating  
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Figure 50.  BCL6 limits apoptosis of 
PD-1high TFH cells.  Mice were 
immunized with SRBC and sacrificed on 
day 10.  Spleen cells were analyzed.  A. 
Representative flow plots of gating 
strategy.  Gated on CD3+ CD4+ 
CXCR5+.  Gates for different levels of 
PD-1 expression are shown.  B. 
Percentage of Caspase-3+ cells in 
different populations of PD-1 subsets 
are shown.  “Non TFH” cells are gated 
on CD3+ CD4+ CXCR5− ICOS− PD-1−.  
C. Percentage of Annexin V+ cells in different populations of PD-1 subsets.  Same gating 
as in (B).  Mean ± SE. * p < 0.05, *** p < 0.001 by t test.  
 
 
TFH cells, and they are likely contributing to the overall increase in PD-1+ cells in +/+ 
mice.  The MFI of PD-1 in total Th cells also mirrored these differences (Figure 49 C), as 
did the mRNA levels of PD-1 (as expressed by the gene pdcd1) in total Th cells (Figure 
49 E).  When PD-1 expression in PD-1+ cells was assessed over time, saw see 
significantly lower levels of PD-1 surface expression in fl/fl mice (Figure 49 D).  Since 
these assessments are likely skewed by the development of TFH cells in +/+ mice, we 
further gated Th cells on CXCR5+ (TFH) and CXCR5− (non-TFH) cells.  In the TFH gate, 
+/+ mice had significantly more cells expressing PD-1 one and five days after 
immunization (Figure 49 F).  However, the amount of PD-1 on the surface of these PD-
1+ cells was significantly reduced in fl/fl cells at all time points (Figure 49 F).  When non-
TFH cells were assessed, significantly fewer fl/fl Th cells were expressing PD-1 at all 
time points, and the MFI of PD-1 on PD-1+ cells was also significantly reduced (Figure 
49 G).  Therefore, taken together, this data demonstrates not only a lowered potential for 
Th cells from fl/fl mice to express PD-1, but those cells expressing this marker, unlike 
CXCR5 and ICOS, do so at significantly lower levels than +/+ Th cells.  This would  
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suggest a role for BCL6 in promoting the elevated expression of PD-1 in CD4+ T cells.  
 
BCL6 limits apoptosis in PD-1high Th cells  
 
Because PD-1 has been shown to limit T cell proliferation, and, in some cases, facilitate 
apoptosis, we wanted to evaluate the fate of Th cells expressing high levels of PD-1 in 
the absence of BCL6.  To do this, we immunized mice and sacrificed them ten days 
later.  Spleen cells were assessed for PD-1 expression on Th cells via flow cytometry.  
CD4+ T cells were subdivided into “non TFH” cells (CD4+ CXCR5− ICOS− PD-1−), PD-1 
negative (“neg”: CD4+ CXCR5+ ICOS− PD-1−), PD-1 low-expressing (“low”: CD4+ 
CXCR5+ ICOS+/− PD-1low), PD-1 mid-level-expressing (“mid”: CD4+ CXCR5+ ICOS+/− PD-
1mid), and TFH, or PD-1 high-expressing (“TFH”: CD4+ CXCR5+ ICOS+ PD-1hi) cells.  An 
example of these gates for both +/+ and fl/fl mice is shown in Figure 50 A.  Cells within 
each gate were then assessed for active Caspase-3 staining (Figure 50 B) or Annexin V 
staining (Figure 50 C).  Our results show a striking correlation between PD-1 expression 
and positive staining for apoptosis markers.  In both +/+ and fl/l mice, as PD-1 MFI 
increased, so did the percentage of cells which were Caspase-3+ or Annexin V+.  
Interestingly, at lower levels of PD-1 expression, BCL6-deficient cells had less Annexin 
V staining than +/+ cells (Figure 50 C).  At higher levels of PD-1 though (PD-1 mid and  
TFH), +/+ cells seemed to be protected from apoptosis, while almost 100 percent of the 
few BCL6-deficient cells to be included in the TFH gate were Annexin V+, and, to a 
lesser extent, Caspase-3+.  This data suggests that at low levels of PD-1 surface 
expression, BCL6 seems to facilitate apoptosis, while at the highest levels of PD-1, 
BCL6 limits apoptosis of TFH cells. 
 
Methylation and deacetylation machinery is increased in the absence of BCL6  
 
To investigate what may be restricting the expression of PD-1 in our BCL6-deficient Th 
cells, we revisited the data produced from our microarray experiment (See Table 1 in 
Chapter 3).  Upon closer inspection, we observed significant increases in the chromatin 
remodeling enzymes responsible for adopting a more closed conformation.  In the case 
of our results, Dnmt1, which is responsible for maintaining the methylation profile of 
replicated DNA, was not changed in fl/fl mice (Figure 51 A).  However, one Dnmt which 
is responsible for de novo methylation of DNA, Dnmt3b, was significantly increased in  
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           Figure 51.  Expression of methylation and 
deacetylation enzymes is increased in absence 
of BCL6.  A. Naïve CD4+ T cells were isolated via 
FACS and activated in vitro with anti-CD3 and anti-
CD28 antibodies in Th0 or TFH media for 20 hours 
before cells were lysed for RNA analysis via 
microarray.  Values shown for fl/fl T cells and are 
normalized to +/+ values (-1 and 1).  Dnmt1 is 
responsible for maintenance methylation; Dnmt3a 
and Dnmt3b are responsible for de novo 
methylation.  HDAC1 and HDAC2 are responsible 
for deacetylation of histones.  Naïve cells gated on  
CD3+ CD4+ CD44− CD62L+.  B-D.  Mice were immunized with SRBC and sacrificed 1, 3, 
and 5 days after.  Total CD4+ T cells were isolated from spleen via bead separation and 
lysed ex vivo for RNA analysis via qPCR.  Transcript levels for B. dnmt3b, C. hdac1, and 
D. hdac2 are normalized to Day 1 +/+ (dotted line at 1.0).  Mean ± SE.  *p < 0.05, **p < 
0.01, ***p < 0.001 by t test. 
 
 
both culture conditions.  Furthermore, the HDAC which Dnmt3b has been shown to 
associate with, HDAC1, was significantly increased in a similar fashion (Figure 51 A).  
 
To verify these changes, we tested the RNA from our time course experiment (Figure 45 
C) for expression of these enzymes.  Transcript levels of dnmt3b were increased in the 
Th cells from fl/fl mice at all time points after immunization (Figure 51 B).  Unlike the 
microarray data, hdac1 expression was not increased in an in vivo model (Figure 51 C), 
however hdac2 was (Figure 51 D).  It is important to note, though, that this RNA analysis 
was done on Th cells with mixed statuses of activation, while the microarray was used to 
analyze naïve Th cells which were all, presumably, activated in the in vitro culture.  
Therefore, taken together, these data show that Dnmt3b is significantly increased in all 
Th cells, regardless of activation status, while expression of HDAC enzymes may be 
affected more by the in vitro culture conditions and level of cellular activation.  But 
overall, these data provide evidence that epigenetically, the DNA structure of Th cells in 
A. B. C. 
D. 
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fl/fl mice may be altered and in a more closed confirmation, thus blocking access to 
transcriptional machinery. 
 
The promoter region of PD-1 has increased binding of DNA-methyltransferases  
 
To test if PD-1 is being repressed by epigenetic modifications to the gene in vivo, we 
performed a chromatin immunoprecipitation (ChIP) assay.  First, total CD4+ T cells were 
isolated from unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice, or from mice 
immunized with SRBC and sacrificed on day five.  We chose to evaluate T cells from five 
day immunized mice because this is the time point at which we saw the most significant 
differences in PD-1 and Dnmt3b expression.  For ChIP analysis, isolated chromatin was 
immunoprecipitated (IP) for Dnmt3a (as a control) or Dnmt3b.  The DNA pulled down 
with these proteins was then assessed for the presence of the PD-1 (pdcd1) promoter 
region.  Before immunization (Day 0), no differences in Dnmt3a binding to either of the 
two PD-1 promoter sites checked were found between +/+ and fl/fl cells (Figure 52 A-B).  
Five days after immunization, fl/fl samples were shown to have significantly more 
Dnmt3a present at one region of the PD-1 promoter (Figure 52 A).  When cells were IP 
for Dnmt3b, fl/fl samples had more of the methyltransferase present at the PD-1 
promoter, both before and after immunization (Figure 52 C-D).  Interestingly, +/+ cells 
had no detectable presence of Dnmt3b at the PD-1 promoter before immunization 
(Figure 52 C-D). 
 
Next, using a ChIP assay, we investigated the acetylation status of the PD-1 promoter.  
When samples were IP for acetylated histone 3 (H3AC), then assessed for the presence 
of the PD-1 promoter, +/+ cells were found to have more acetylated histone at both 
regions of the PD-1 promoter checked (Figure 53 A-B).  The same was found when 
samples were IP for H4AC (Figure 53 C-D).  These data show fl/fl Th cells have less 
acetylation of their H3 and H4 histones at the PD-1 promoter.  Therefore, it is likely the 
PD-1 promoter in fl/fl Th cells has a less open conformation than the PD-1 promoter 
region in +/+ Th cells. 
 
Another crucial TFH marker, CXCR5, has been shown to be dependent on BCL6 
expression later in the immune response.  As shown in Figure 47, expression of CXCR5  
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Figure 52.  Dnmt3a and Dnmt3b bind to the pdcd1 
promoter region.  Total CD4+ T cells were isolated from 
the spleen of unimmunized BCL6+/+ CreCD4 and BCL6fl/fl 
CreCD4 mice or from mice immunized with SRBC and 
sacrificed on day 5.  A ChIP assay was done on isolated 
chromatin.  A-B.  Samples were IP for Dnmt3a and 
assessed for binding to two places in the pdcd1 
promoter; either A. the CRB region or B. the CRC 
region.  C-D.  Samples were IP for Dnmt3b and 
assessed for binding to two places in the pdcd1 
promoter; either C. the CRB region or D. the CRC region.  Shown as percent of input.  
ND = none detected. Mean ± SE.  *p < 0.05 by t test. Done in collaboration with Dr. Duy 
Pham. 
 
 
 
 
 
 
 
 
 
 
 
Figure 53.  The promoter region of pdcd1 in BCL6fl/fl 
CreCD4 mice is less acetylated than in BCL6+/+ CreCD4 
mice.  Total CD4+ T cells were isolated as in Figure G 
and ChIP analysis done.  A-B.  Samples were IP for 
H3AC and assessed for the presence of two regions of 
the pdcd1 promoter; either A. the CRB region or B. the 
CRC region.  C-D.  Samples were IP for H4AC and 
assessed for the presence of two regions of the pdcd1 
promoter; either C. the CRB region or D. the CRC 
region.  Shown as percent of input.  Mean ± SE.  *p < 
0.05 by t test.  Done in collaboration with Dr. Duy Pham. 
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was significantly decreased on fl/fl cells beginning five days after immunization.  When 
the promoter region of CXCR5 was assessed for the presence of Dnmt3a and Dnm3b 
binding via ChIP analysis, we saw no differences between +/+ and fl/fl samples either 
before or five days after immunization (Figure 54 A-B).  However, the acetylation status 
of the H3 and H4 histones was significantly altered.  While there was significantly less 
acetylated H3 histone at the cxcr5 promoter of fl/fl cells after immunization (Figure 54 C), 
H4 was significantly less acetylated both before and after immunization (Figure 54 D).  
Because the CXCR5 promoter in fl/fl mice did not have altered Dnmt binding, but did 
have decreased acetylation, it would appear that increased methylation via Dnmt3b is a 
mechanism for repression of PD-1 in fl/fl Th cells, while this method does not repress 
CXCR5. 
 
Blocking methylation increases PD-1 expression, but not CXCR5 expression  
 
To test the hypothesis that PD-1 expression is controlled by the methylation status of its 
promoter, we carried out in vitro experiments in which we block methylation.  Total CD4+ 
T cells were isolated from C57BL/6 mice and activated in vitro with anti-CD3 and anti- 
 
 
 
 
 
 
 
 
 
 
Figure 54.  The promoter region of cxcr5 in BCL6fl/fl 
CreCD4 mice is less acetylated than in BCL6+/+ CreCD4 
mice.  Total CD4+ T cells were isolated as in Figure G and 
ChIP analysis done.  A. Samples were IP for Dnmt3a and 
assessed for binding to the cxcr5 promoter.  B. Samples 
were IP for Dnmt3b and assessed for binding to the cxcr5 
promoter.  C. Samples were IP for H3AC and assessed 
for the presence of the cxcr5 promoter.  D. Samples were 
IP for H4AC and assessed for the presence of the cxcr5 
promoter.  ND = none detected.  Mean ± SE.  *p < 0.05, 
**p < 0.01 by t test.  Done in collaboration with Dr. Duy Pham. 
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Figure 55.  Blocking methylation increases PD-1 expression, but not CXCR5 
expression.  A. Total CD4+ T cells were isolated from C57BL/6 mice via bead 
separation.  Cells were activated in vitro with anti-CD3 and anti-CD28 antibodies in Th0 
media.  On day 0, cells were checked for surface expression of PD-1 via flow cytometry. 
On day 3, cells were again assessed for PD-1 expression, and half of the remaining cells 
were treated with 5-Aza-2′-deoxycytidine (+AZA-D3).  On day 5, all cells were assessed 
for PD-1 expression.  Half of the remaining untreated cells (media only) then had 5-Aza-
2′-deoxycytidine added to their media (+AZA-D5).  On day 8, all cells were harvested 
and assessed for PD-1 expression.  Shown as percent of total cells.  Gated on CD4+. 
Mean ± SE; n = 4.  *p < 0.05, ***p < 0.001 by ANOVA, Tukey post hoc.  B-C.  Total 
CD4+ T cells were isolated from unimmunized BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice 
via bead separation and activated in vitro with anit-CD3 and anti-CD28 antibodies in Th0 
media.  On day 5 of the culture, cells were checked for surface marker expression via 
flow cytometry.  Also, half of the cells were treated with 5-Aza-2′-deoxycytidine.  On day 
8, all cells were harvested and checked for surface marker expression via flow 
cytometry.  B. Surface expression of PD-1.  C. Surface expression of CXCR5.  
 
 
CD28 antibodies in Th0 media.  Three days later, samples were assessed for PD-1 
expression.  At this time, approximately 85% of cells were PD-1+ (Figure 55 A).  The 
remaining cells were then split; half continued to be culture in media and half were 
treated with 5-Aza-2′-deoxycytidine (Azacytidine), a methylation inhibitor.  On day five, 
all cells were assessed for PD-1 expression.  Cells which received Azacytidine on day 
three (+Aza–D3) had significantly more cells expressing PD-1 on the surface compared 
to untreated cells (Figure 55 A).  The remaining untreated cells were again split in half, 
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leaving one group in media only and the other group treated with Azacytidine (+Aza–
D5).  Eight days after the initial activation, all cells were harvested and assessed for PD-
1 expression via flow cytometry.  As shown in Figure 55 A, cells treated with Azacytidine 
on day three (+Aza–D3) were significantly increased in the percentage of cells 
expressing PD-1 on the surface compared to untreated cells.  While treatment with 
Azacytidine on day 5 did increase the percent of cells expressing PD-1, it was not 
significantly more than what untreated cells expressed (Figure 55 A). 
 
Using this approach, we next wanted to test if treatment with Azacytidine could restore 
PD-1 surface expression levels on fl/fl cells to those seen on +/+ cells.  As before, total 
CD4+ T cells from mice were isolated and activated in vitro.  Five days later, cells were 
treated with Azacytidine.  At this time point, untreated cells from +/+ and fl/fl mice had 
fairly low percentages of PD-1+ cells, although +/+ mice had more (Figure 55 B).  On day 
eight, when all samples were checked, treatment of +/+ Th cells with Azacytidine 
increased the percent of PD-1+ cells above what was seen on day five (Figure 55 B).  
While treatment of fl/fl Th cells was able to increase the percent of cells expressing PD-
1, it was only able to raise the level to that of untreated +/+ cells (Figure 55 B).  To verify 
that the increases seen with Azacytidine treatment were specific to PD-1 and not a 
genome-wide increase in expression, cells were also assessed for CXCR5 surface 
expression.  As shown in Figure 55, Azacytidine treatment did not increase the percent 
of CXCR5+ cells for either mouse group (Figure 55 C).  Therefore, it appears that PD-1, 
to some extent, is controlled by methylation of its promoter.  
 
 
DISCUSSION 
 
Using our new mouse model, we were able to verify the necessity of BCL6 in Th cells for 
the development of TFH cells and GCs.  Without this transcription factor, mice were 
unable to establish GCs at any time after immunization.  The functional effects of GC 
loss were observed by sharp reductions in antigen-specific antibody production, and, in 
some cases, decreases in total isotype production.  Therefore, these results 
demonstrate an inherent necessity for BCL6 expression in Th cells for not only the 
development of GCs, but also for high titers of antigen-specific antibodies.   
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These findings can be applied to human therapeutics in two distinct ways.  First, patients 
suffering from autoimmune disorders associated with increased TFH differentiation could 
benefit from protein inhibitors which target BCL6 in T cells.  As demonstrated in Chapter 
4, deletion of BCL6 in CD4+ T cells has little effect on the differentiation of other Th cell 
subsets.  Additionally, the antibody data presented here suggests that by inhibiting the 
development of TFH cells, antigen-specific antibody titers can be drastically reduced as 
well.  Therefore, a BCL6 protein inhibitor could provide a therapeutic alternative to those 
immune modulating drugs already on the market for autoimmune disease patients.   
 
Secondly, because the ultimate goal of vaccines is to trigger the development of B cells 
which secrete high affinity, antigen-specific antibodies, and survive long term, if said 
vaccines could be programmed to facilitate increased TFH differentiation upon 
immunization, more robust GCs could develop, and, theoretically, higher affinity 
antibodies would result.  Data presented in Chapter 6 concerning a prime/boost vaccine 
scheme would suggest that increased GCs may actually limit antibody quality in that 
type of approach.  However, whether increased GC development is beneficial when only 
one immunization is necessary has yet to be investigated.    
 
When evaluating TFH surface marker expression, we found evidence that CXCR5 can, 
in fact, be expressed in a BCL6-independent fashion, up to five days post-immunization.  
After that time point, it appears the BCL6-deficient Th cells cannot sustain surface 
expression and decrease the amount of CXCR5 expressed, as demonstrated by qPCR 
and flow cytometry analysis.  Furthermore, by day five, while BCL6fl/fl CreCD4 Th cells are 
still expressing CXCR5 above background levels, they cannot up-regulate the 
chemokine receptor to the levels seen in +/+ mice.  Evaluation of ICOS showed a similar 
trend, wherein Th cells from fl/fl mice can in fact up-regulate the marker in both TFH-like 
and non-TFH cells (CXCR5+ and CXCR5− subsets, respectively), but not as many cells 
are able to do so by day five.  However, in the case of both CXCR5 and ICOS, those 
cells which do express the markers in fl/fl mice are able to do so with the same potential 
as +/+ mice, as evidenced by similar MFI levels of CXCR5+ and ICOS+ cells.  
 
When PD-1 was assessed for surface expression, we found that while the percentage of 
PD-1+ cells was significantly reduced in fl/fl mice, unlike ICOS and CXCR5, the MFI of 
this TFH marker was also significantly reduced in BCL6-deficient Th cells.  This 
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difference was seen irrespective of whether a Th cell was CXCR5+ (TFH-like) or 
CXCR5− (non-TFH).  Therefore, the expression of PD-1 on Th cells is affected by loss of 
BCL6 even in non-TFH cells.  Also of interest was the observation that CXCR5 and 
ICOS deficiencies in fl/fl mice were only really seen as of day five after immunization.  
However, with PD-1 expression, a truly significant loss of positive cells and the amount 
of PD-1 expressed by those cells was seen in unimmunized mice.  After immunization, 
the difference in PD-1 expression was significantly lower in fl/fl mice and this difference 
only exacerbated over time.  It appears, though, that these differences are mainly due to 
the increased expression by +/+ Th cells, while CD4+ T cells in fl/fl mice fail to increase 
the percentage of PD-1+ cells and the existing PD-1+ cells are unable to increase their 
surface expression, as shown by decreases in MFI.  Therefore, the mechanism 
controlling PD-1 expression in TFH and non-TFH cells is affected even before 
immunization in BCL6-deficient Th cells and cannot be overcome with immunization. 
 
Data provided by our microarray analysis demonstrate a potential role for chromatin 
remodeling enzymes in the repression of PD-1 in the Th cells of BCL6fl/fl CreCD4 mice.  
After identifying Dnmt3b as a potential inhibitor of PD-1 expression, ChIP analysis 
confirmed that this DNA-methyltransferase does in fact bind to the promoter region of 
PD-1 in fl/fl Th cells before immunization, while it is not present in +/+ cells.  Because 
Dnmt3b is responsible for de novo methylation of DNA, this data would suggest that 
Dnmt3b is actively methylating the PD-1 promoter of unactivated Th cells in the absence 
of BCL6.  After immunization, significantly more Dnmt3a was found at one PD-1 
promoter site in fl/fl cells.  Because both Dnmt3a and 3b can silence genes by physically 
binding to the promoter and blocking the transcriptional machinery, this may be an 
additional way in which Dnmt activity is limiting PD-1 expression in fl/fl Th cells.  
Therefore, not only is it probable that the promoter region of PD-1 is hyper-methylated 
before cell activation, after immunization, binding of Dnmt3a to the promoter is likely 
inhibiting access of RNA polymerase to the region.  Furthermore, the consistent and 
significant decrease in acetylation of the H3 and H4 histones at the PD-1 promoter 
regions suggests an even more closed conformation of this gene.   
 
To verify that this activity is unique to PD-1, we assessed the presence of these 
enzymes at a promoter site of CXCR5.  We found no evidence of differential Dnmt3a or 
Dnmt3b binding at the CXCR5 promoter in +/+ and fl/fl mice.  However, when the 
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acetylation levels of H3 and H4 were examined, it was found that the CXCR5 promoter 
in fl/fl Th cells has significantly less acetylation, both before and after immunization.  
Therefore, expression of CXCR5 may be somewhat controlled by acetylation of its 
promoter, but Dnmts do not appear to be affecting its expression exclusively in BCL6-
deficient mice.   
 
Finally, to further investigate a potential role for methylation in PD-1 repression, 
activated CD4+ T cells were treated with 5-Aza-2′-deoxycytidine (Azacytidine).  This 
methylation inhibitor was able to increase PD-1 levels in C57BL/6 and BCL6+/+ CreCD4 
cells.  However, while the percent of PD-1+ cells did increase when BCL6fl/fl CreCD4 cells 
were treated, the levels were only increased to that of untreated +/+ cells.  Therefore, 
blocking methylation is able to partially overcome the decrease in PD-1 expression in the 
absence of BCL6.  Whether prolonged exposure to Azacytidine can further increase the 
levels seen in fl/fl Th cells needs to be investigated.   
 
In addition to describing how BCL6 may control PD-1 expression, we also found that 
BCL6 may be limiting the intracellular signals of PD-1 in TFH cells.  When CD4+ T cells 
were subdivided by PD-1 expression levels, we found that in the absence of BCL6, more 
PD-1-high Th cells were marked for apoptosis than their WT counterparts.  Because 
high levels of PD-1 are typically associated with exhausted T cells, researchers have 
wondered how TFH cells are able to remain functionally active while expressing this 
marker.  Here we demonstrate that the high expression levels of BCL6 found in TFH 
cells may be somehow limiting the quiescence or death signals coming from PD-1 
engagement, thus allowing for continued activity by these cells.   
 
Data presented in this chapter has established a new method for how BCL6 can activate 
gene expression: by repressing methylation.  Previous data (Chapter 2, Figure 9 A) has 
demonstrated a correlation between BCL6 and PD-1 expression.  Therefore, when we 
observed not only a reduction in the percent of Th cells expressing PD-1 in fl/fl mice, but 
a drop in the MFI of PD-1+ cells as well, we hypothesized that BCL6 controls PD-1 
expression through an as-yet identified mechanism.  Microarray and ChIP analysis 
enabled us to identify epigenetic modifiers which were increased in the absence of 
BCL6, and they were found to bind specifically to the PD-1 promoter, and not to other 
TFH markers, like CXCR5.  Identification of Dnmt3b as a BCL6 target is a unique finding 
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and the first of its kind as a way to describe how BCL6 controls TFH gene expression.  
Further work needs to be done to verify the specific nature of the relationship between 
BCL6 and Dnmt3b, but we are confident that we have, for the first time, described a 
method for BCL6-mediated gene activation. 
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CHAPTER 6 – GERMINAL CENTER DYNAMICS IN AN HIV-1-gp120 DNA 
PRIME/PROTEIN BOOST VACCINE SCHEME 
 
 
INTRODUCTION 
 
The Human Immunodeficiency Virus-1 (HIV-1) has affected hundreds of millions of 
people worldwide since its discovery in the early 1980s (135).  In 1996, hope was given 
to millions of infected patients with the release of the Highly Active Anti-Retroviral 
Therapy, or HAART (136).  This combination drug therapy meant people with HIV were 
no longer sentenced to die, but instead could manage their infection and extend their 
life.  The quality of that life, however, was not as high as their pre-infection standards.  
Side effects, including, but not limited to, nausea, vomiting, mental health issues, renal 
and liver failure, and heart attacks were common (136, 137).  Furthermore, the cost of 
these treatments meant life-extension remained out of reach for the vast majority of HIV+ 
patients (138).  While drug development over the last two decades has decreased the 
number and severity of these side effects, as well as substantially lowered the cost of 
anti-retroviral drugs, millions of people are still infected each year.  To date, six different 
human vaccine trials have taken place (139-142), with one ending early due to 
unexplained increases in HIV-1 susceptibility (143), and one showing modest protection 
of approximately thirty percent (144).  Therefore, the challenge remains to create an 
effective HIV-1 vaccine which prevents the transmission of all clades and, ultimately, 
eradicates this virus from the human population. 
 
HIV is a lentivirus which packages two identical single strand RNA transcripts into its 
capsid, along with several viral enzymes (Figure 56) (138, 145).  The surface 
glycoprotein (gp) 160 is composed of a transmembrane section, termed gp41, and a 
surface section, called gp120 (Figure 56) (138, 145, 146).  After gp120 attaches to its 
main receptor, CD4, on a host cell, a conformational change in the structure of the 
surface glycoprotein facilitates binding to a coreceptor, either CCR5 or CXCR4 (Figure 
57 A-B) (146).  Coreceptor binding then triggers an additional conformational change, 
allowing a section of gp41, called HR1, which is typically covered to become exposed 
and bind to the host cell surface (Figure 57 C) (146).  Once two gp160 glycoproteins 
have bound to the host cell surface, the viral capsid can then be deposited into the host 
cell (Figure 57 D) (145, 146).  Release of the capsid contents into the cytoplasm of the 
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Figure 56.  Structure of HIV virion.  HIV is a single strand RNA virus which carries two 
identical copies of its genome.  The RNA is surrounded by a capsid made from protein 
24 (p24).  Accessory proteins and enzymes are also packaged within the capsid with the 
RNA, including integrase (p31), reverse transcriptase (p51), and protease (p11).  The 
nuclear capsid is surrounded by a matrix made from p17.  The surface of the virus is 
covered in glycoproteins.  The surface portion is termed gp120, while the 
transmembrane section is gp41.  Together, these glycoproteins make gp160. 
 
 
host cell allows the viral reverse transcriptase enzymes to transcribe DNA from the viral 
RNA genome (Figure 57 E) (145, 147).  That DNA can then be transported into the host 
nucleus and integrated into the host genome via the viral integrase enzyme (Figure 57 
F) (147, 148).  Once integrated, the virus is now referred to as a provirus and can lay 
dormant for years, even decades, before beginning to replicate uncontrollably, leading to 
the decimation of the helper T cell response, and the patient to develop AIDS-related 
diseases (135, 147, 148).  Because genomic integration cannot be undone, an effective 
vaccine must produce antibodies which block viral entry into its host cell. 
 
The challenge for the immune system to produce such antibodies during an active 
infection is two-fold.  First, the virus infects and kills the cells (Th cells) which are 
responsible for helping B cells mutate and produce high affinity antibody.  Furthermore, 
the Th cells which are responsible for triggering the highest affinity antibodies, TFH cells, 
have recently been shown to contain the highest reservoir of virus of all the Th cell 
subsets.  Therefore, HIV-1 targets and removes the cells which could most effectively 
contribute to eliminating the virus.  Secondly, HIV-1 mutates at such a high rate the 
regions of gp120 and gp41 targeted by antibodies change just enough to facilitate viral 
escape from existing antibodies.  However, there are a few select regions on these  
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Figure 57.  Attachment and 
fusion of HIV to host cell.  A. 
HIV will first bind to a host cell via 
its main receptor, CD4, at a 
conserved binding site on gp120.  
B. Binding of CD4 to its site on 
the surface glycoprotein causes a 
conformational change in gp120 
that exposes the binding site for 
the coreceptor.  The coreceptor, 
either CCR5 or CXCR4, then 
binds its conserved site on 
gp120, called the V3 loop.  C. 
Binding of the coreceptor triggers a conformational change in the surface glycoproteins, 
revealing a portion of gp41 normally not exposed.  This domain of gp41 is called HR1.  
D. When two gp160 proteins have bound a host cell, fusion of gp41 to the cell surface 
allows transport of the viral capsid from the virion into the host cell.  E. Once the capsid 
enters the host cell, it releases its RNA and enzymes into the host cytoplasm.  Next, the 
reverse transcriptase (RT) will synthesize complementary DNA strands of the viral RNA 
using host cell nucleotides.  F. Finally, the viral DNA will traffic into the host cell nucleus 
along with the viral integrase enzymes.  Integrase will selectively splice viral DNA into 
the host genome.  Once this occurs, the virus is referred to as a provirus.  
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Figure 58.  Binding sites of broadly neutralizing antibodies to HIV.  Many anti-HIV 
antibodies have been isolated from the serum of infected patients which possess 
neutralizing capabilities.  The breadth of these antibodies is quite variable, but most can 
neutralize at least 30% of viruses.  The binding sites which these antibodies are directed 
to are not only crucial for virus attachment and fusion with host cells, but they are highly 
conserved among viruses as well, allowing these viruses to efficiently neutralize most 
virus they bind to.  Unfortunately, many of these binding sites are hidden and are not 
revealed until the virus begins to bind a host cell and the surface glycoproteins undergo 
conformational changes.  The antibodies b12, HJ16, VRC01, VRC02, VRC03, and 
CH103 have been shown to bind the CD4 binding site on gp120.  The V1 and V2 loops 
have been shown to be targeted by the PG9 and PG16 antibodies.  The V3 loop, which 
binds the viral coreceptor, has several characterized antibodies targeting it, including 
2G12, PGT121 – PGT123, and PGT125 – PGT128.  Finally, a conserved region on 
gp41 near the viral envelope has also been shown to be targeted by neutralizing 
antibodies.  The three with the highest affinity are 2F5, 4E10, and 10E8.  Figure adapted 
from Clapham PR and Lu S, Nature medicine, 2012. 
 
 
surface glycoproteins which are conserved.  These regions include the binding sites for 
CD4 and the coreceptors (Figure 58).  The difficulty with targeting these regions is due 
to their physical inaccessibility.  These areas are mainly shielded until the virus begins 
binding to a target cell, at which time the surface glycoproteins undergo conformational 
changes to facilitate infection (Figure 57).  It is then when the conserved regions are 
exposed and vulnerable to antibody binding.   
 
While the majority of HIV-1-infected individuals lack the ability to target these areas, a 
number of antibodies with known neutralizing capabilities have been characterized in a 
subset of infected patients (149-153).  These individuals’ immune systems have 
developed antibodies which target the CD4 binding site, the V3 loop (which binds 
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coreceptors), as well as a few conserved regions on gp41 (Figure 58) (149-153).  
Unfortunately, these antibodies usually take years to develop, and, by that point, an 
infected individual likely has millions of established proviruses.  Furthermore, the B cells 
from these patients have typically undergone five- to tenfold higher affinity maturation 
rates than cells from patients lacking these neutralizing antibodies (154).  This level of 
mutation is rarely seen in non-HIV+ people, and thus difficult to characterize (154).  
However, it seems indisputable that the GC must be involved in this affinity maturation, 
and, consequently, TFH cells likely play a pivotal role in aiding the development of 
neutralizing antibodies.  Therefore, any effective vaccine which is to elicit broadly 
neutralizing antibodies must not only target and stimulate B cell activity, but activate 
highly specific TFH cells as well.  
 
Because CD4+ T cells are the primary target for the virus, these cells have been largely 
ignored in the search for an effective vaccine.  While the importance of TFH cells in the 
humoral immune response has become clear in recent years, the role of TFH cells in an 
HIV vaccine strategy remains uncertain.  Furthermore, while much focus has been 
placed on serum antibody analysis in the development of HIV vaccines, little research 
has been done on evaluating the robustness of GC development with different 
vaccination approaches.  The GC has been shown to peak earlier in a secondary 
response than after a primary immunization (155), but nothing is known about the 
kinetics of the TFH response and the GC reaction with vaccines that require repeated 
immunizations. Therefore, it is critical to study the development of TFH cells and GCs to 
gain insights into effective HIV vaccine strategies.   
 
Currently, heterologous prime-boost vaccination strategies employing a DNA priming 
component are making headways in different disease fields, such as HIV, influenza, 
malaria and tuberculosis (156-159).  Previously, our collaborators have shown mice 
immunized with a DNA vector encoding gp120, followed by injection of recombinant 
gp120 protein, yield antibodies with higher specificity and avidity than either vaccine 
alone, and, more importantly, develop improved neutralizing antibodies against primary 
viral isolates (160-162).  Because TFH cells are crucial for the development of plasma 
cells secreting mutated high affinity antibodies from the GC, we hypothesized DNA 
priming causes more TFH cell differentiation, thereby triggering a more robust GC 
response. 
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MATERIALS AND METHODS 
 
Mice and immunizations 
 
Eight to ten week old C57BL/6 mice were obtained commercially from The Jackson 
Laboratory.  BCL6fl/fl mice were generated as described in Chapter 2 and mated to Cre-
ERT2 mice, which were also acquired from The Jackson Laboratory (stock # 007001).  
Mice were bred under specific pathogen-free conditions at the laboratory animal facility 
at the Indiana University School of Medicine (IUSM) and were handled according to 
protocols approved by the IUSM Animal Use and Care Committee. 
 
Pilot study mice were immunized i.m. with 1 x 109 sheep red blood cells (SRBC; 
Rockland Immunochemicals Inc., Gilbertsville, PA) in 100 uL of PBS.  A codon optimized 
JR-FL gp120 DNA vaccine construct in the pJW4303 vector was used for all DNA-based 
immunizations, as previously reported (161).  DNA vaccine plasmid was produced in 
HB101 bacterial cells then isolated and purified using the Qiagen Plasmid Mega Kit.   
 
Recombinant HIV-1 gp120 proteins were produced from Chinese Hamster Ovary (CHO) 
cells, as previously reported (161).  Mice were immunized i.m. with either 100 ug of DNA 
or 10 ug gp120 protein in ALUM (Sigma-Aldrich Corp., St. Louis, MO, USA).  A total of 
100 uL was injected, 50 uL per hind leg. 
 
Tamoxifen 
 
Mice were given i.p. injections of 4 mg Tamoxifen (Sigma-Aldrich Corp., cat. # T5648) in 
sunflower seed oil. 
 
Flow cytometry 
 
Total spleen or thymus cells were incubated with anti-mouse CD16/CD32 (Fcγ receptor) 
for 20 minutes, followed by surface staining for the indicated markers.  A fixable viability 
dye (eFluor 780, eBioscience) was used for all samples.  The following antibodies were 
used for staining GC B cells: α-mCD19 Alexa Fluor 700, clone eBio1D3 (eBioscience); 
α-mB220 PE, clone RA3-682 (BD Bioscience); α-mFas Biotin, cat. # 554256 (BD 
 124  
 
Bioscience); Streptavidin-PECy7 (Biolegned); α-mGL7 APC, clone GL7 (BD Bioscience); 
PNA FITC (Vector Laboratories Inc.).  The following antibodies were used to stain 
memory B cells: α-mCD19 Alexa Fluor 700, clone eBio1D3 (eBioscience); α-mB220 
PerCP, clone RA3-6B2 (Biolegend); α-mIgD FITC, clone 11-26C (eBioscience); α-mGL7 
APC, clone GL7 (BD Bioscience); α-mCD38 PE, clone 90 (eBioscience); α-mCD73 
PECy7, clone TY/11.8 (eBioscience).  The following antibodies were used to stain naïve 
and memory T cells: α-mCD3 Alexa Fluor 700, clone 500A2 (BD Bioscience); α-mCD4 
PECy7, clone RM4-5 (BD Bioscience); α-mCD8a APC, clone 53-6.7 (BD Bioscience), α-
mCD44 PE, clone IM7 (eBioscience); α-mCD62L FITC, clone MEL-14 (BD Bioscience).  
The following antibodies were used to stain TFH cells: α-mCD3 Alexa Fluor 700, clone 
500A2 (BD Bioscience); α-mCD4 PECy7, clone RM4-5 (BD Bioscience); α-mCXCR5 
PerCP-efluor 710, clone SPRCL5 (eBioscience); α-mPD-1 APC, clone 29F.1A12 
(Biolegend); α-mICOS FITC, clone C398.4A (eBioscience).   
 
Antibody analysis   
 
Antibody titers of gp120-specific IgG were measured by ELISA as previously reported 
(160).  Antibody avidity was measured via the NaSCN displacement method, as 
previously described (160).  This work was done by Dr. Shan Lu’s laboratory at the 
University of Massachusetts Medical School. 
 
RNA analysis   
 
Total spleen cells from Cre-ERT2 mice were lysed using Trizol three days after final 
immunizations.  Total RNA was isolated using an RNeasy mini kit (Qiagen).  cDNA was 
constructed using a Transcriptor First Strand cDNA synthesis kit (Roche).  Expression of 
BCL6 mRNA was quantified using SYBR Green analysis (Roche) with the following 
primers: 
 
BCL6 exon 2/3 forward (5’ – GCACTGGGCAAACACAACAT – 3’) 
BCL6 exon 2/3 reverse (5’ – AGCGTGCCGGGTAAACTG – 3’) 
BCL6 exon 8 forward (5’ – GAAGACCCACACTCGAATTCACT – 3’) 
BCL6 exon 8 reverse (5’ – CCCCACAGGTTTCACATTTGT – 3’) 
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Statistical Analysis   
 
All data analysis was done using SPSS Statistics 20 software.  Unless otherwise stated, 
ANOVA with Tukey post hoc analysis was used. 
 
 
RESULTS 
 
Immunization with gp120-encoding DNA yields a stronger GC response than 
gp120 protein 
 
To test the hypothesis that gp120-encoding DNA triggers stronger GC responses than 
gp120 protein alone, C57BL/6 mice were injected i.m. with either gp120-encoding DNA, 
gp120 protein, or empty vector DNA, three times, two weeks apart (Figure 59).  In our 
collaborators’ previous HIV-1 gp120 immunogenicity studies, the priming phase included 
three immunizations.  Traditionally, GC responses tend to peak between days seven and 
ten of the immune response.  In our initial experiments with this gp120 immunization 
scheme, we looked at these time points, only to find little evidence of an active GC (data 
not shown).  Also, to our knowledge, no data has been published demonstrating the  
 
 
 
Figure 59.  Experimental design for testing DNA vs. protein priming.  C57BL/6 mice 
were primed i.m. with either gp120-encoding DNA, gp120 protein, or empty vector, 3 
times, 2 weeks apart.  Some mice were sacrificed 3 and 7 days after final priming 
injections.  The remaining mice were rested for 4 weeks, then all groups were given 2 
booster shots of gp120 protein, 2 weeks apart.  Mice were then sacrificed 3 and 7 days 
after the final boosters. 
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Figure 60.  Germinal centers appear earlier 
with repeated immunizations.  C57BL/6 mice 
were immunized 3 times, 2 weeks apart, i.m. 
with SRBC or control mice were given PBS.  
Mice were sacrificed 3 and 7 days after final 
injections and analyzed for TFH and GC B 
populations.  PBS mice were sacrificed with 
day 3 mice.  TFH cells gated on CD3+ CD4+ 
CXCR5+ ICOS+ PD-1hi.  GC B cells gated on 
B220+ CD19+ Fas+ PNA+ GL7+.  Percent of 
total spleen; mean ± SE.  
 
 
kinetics of TFH cell differentiation with repeated immunizations.  Therefore, to determine 
the optimal time to analyze mice given multiple injections, we immunized C57BL/6 mice 
i.m. with SRBC three times, two weeks apart and sacrificed them at different times 
afterward.  Our data showed GC B cells and TFH cells peaking earlier, on day three, 
after final injections (Figure 60).  Therefore, we chose to analyze mice for the following 
experiments on days three and seven after final injections. 
 
With this information in mind, we then examined TFH cells and GC B cells after just the 
priming phase of the immunization scheme (Figure 61).  Mice which received gp120-
encoding DNA had increased TFH cells and significantly more GC B cells in the spleen 
three days after the last priming injections (Figure 61 A-B).  However, by day seven after 
the last priming injections, these amounts equaled that of mice primed with gp120 
protein.  Antibody analysis revealed priming with gp120 DNA induced significantly higher 
antigen-specific IgG titers, both three and seven days after final injections (day 28; 
Figure 61 C).  The avidity of these antibodies was somewhat higher on day three with 
gp120 DNA priming (Figure 61 D).  This data demonstrates priming with gp120 DNA 
alone, without booster injections, already triggered more robust GC responses and 
antigen-specific IgG production than does gp120 protein. 
 
 
Priming with gp120-encoding DNA enhances GCs and the proportion of TFH cells 
in spleen 
 
After initially priming with gp120-encoding DNA, gp120 protein, or empty vector DNA, all 
groups were rested for four weeks, then received two gp120 protein booster 
immunizations, two weeks apart (Figure 59).  TFH cells from spleen were elevated in  
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Figure 61.  Increased GC activity after gp120 DNA priming.  Mice were immunized 
according to Figure 59 and sacrificed 3 and 7 days after final priming injections 
immunizations.  A. TFH and GC B cell populations after priming only.  TFH cells gated 
on CD4+ CXCR5+ ICOS+ PD-1hi.  GC B cells gated on B220+ Fas+ PNA+ GL7+.  Percent 
of total spleen; mean ± SE.  B. Representative flow plots of TFH cells and GC B cells in 
(A) from day 3 after final immunization.  C. Serum anti-gp120-specific IgG titers after 
prime only; mean ± SE.  D. Anti-gp120-specific IgG affinity after prime only; mean ± SE.  
n = 3; *p < 0.05, **p < 0.01, ***p < 0.001.  C & D done in collaboration with Dr. Shan Lu. 
 
 
mice receiving gp120 DNA three days after the final injections, but tapered off by day 
seven (Figure 62 A-B).  GC B cell populations, however, remained significantly higher in 
mice primed with gp120 DNA on both day three and seven after final immunizations 
(Figure 62 A-B).  This data demonstrated the advantage of priming with gp120 DNA  
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Figure 62.  Enhanced GC B cells and TFH cell populations with gp120 DNA 
priming.  Mice were immunized as in Figure 59 and sacrificed 3 and 7 days after final 
gp120 protein booster injections.  A. TFH and GC B cell populations after prime-boost 
regimen.  Cells gated as in Figure 61.  Percent of total spleen; n = 3-5; mean ± SE. **p < 
0.01, ***p < 0.001  B. Representative flow plots of TFH cells and GC B cells in (A) from 
day 3 after final protein booster. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63.  Proportion of TFH cells increased with gp120 DNA priming.  Mice were 
immunized as in Figure 59 and sacrificed 3 and 7 days after final gp120 protein booster 
injections.  A. Percent EM T cells (CD3+ CD4+ CD44hi CD62L−) in gp120 DNA and 
protein primed mice after protein boosters.  Percent of total spleen; n = 5-6; mean ± SE.  
B. Ratio of TFH to EM cells.  n = 5-6; mean ± SE. **p < 0.01 by t test. 
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rather than protein, as GC cell populations were increased and arose earlier in the 
immune response. 
 
When EM CD4+ T cells were analyzed in the spleen of these mice, no significant 
differences were seen on either day three or seven after final immunization (Figure 63 
A).  Because TFH cells are activated Th cells, phenotypically they are included in the EM 
population of CD44+ CD62L− cells.  Therefore, we analyzed the proportion of TFH cells 
within this EM population.  On day three, the proportion of TFH cells within the EM 
population was significantly higher with gp120 DNA priming than with protein alone 
(Figure 63 B).  By day seven, however, the proportion of TFH cells from gp120 protein 
priming caught up to the levels from gp120 DNA priming.  Therefore, after boosting with 
gp120 protein, mice primed with DNA showed a clear advantage in TFH and GC B cell 
development.  
 
Priming with gp120 DNA improves GC activity 
 
Like EM T cells, neither priming method yielded significantly higher percentages of 
splenic memory B cells (Figure 64 A).  Therefore, we were interested in what percentage 
of these memory cells were of GC origin.  Recent literature has shown CD73 to be an 
accurate marker for defining former GC B cells (163).  When the fraction of memory B 
cells of GC origin was examined, we saw significantly higher percentages with gp120 
DNA priming both three and seven days after final immunization (Figure 64 B).  Titers of 
anti-gp120 IgG with DNA priming were significantly higher three days after final 
immunizations, as was the avidity (Figure 64 C-D).  It was not until day seven that the 
antibodies of mice primed with gp120 protein equaled the levels seen in gp120 DNA 
mice.  Not only was the functionality of these B cells increased with gp120 DNA priming, 
but, again, the increase in antibody secretion occurred earlier.   
 
While analyzing memory B cell populations, we observed a decrease in this cell 
population from day three to day seven, even though the memory cells of GC origin 
expanded during the same period with both immunization methods.  Therefore, we 
utilized the surface markers CD38 and GL7 to differentiate memory B cells (MB: CD38+ 
GL7−) from transitional B cells (TB: CD38+ GL7+) (Figure 65 A-B).  ln terms of B cell 
kinetics, it was interesting to observe that regardless of which priming method was used,  
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Figure 64.  Priming with gp120-encoding DNA improves GC activity.  Mice were 
immunized and sacrificed as in Figure 59.  A. Memory B cells (gated as CD19+ IgD− 
GL7− CD38+) in mice primed with gp120-encoding DNA or gp120 protein.  Percent of 
total spleen; mean ± SE.  B. Memory B cells originating from the GC.  Gated as CD19+ 
IgD− GL7− CD38+ CD73+.  Percent of memory B cells; n = 4-6; mean ± SE.  *p < 0.05, 
**p < 0.01 by t test.  C. Serum anti-gp120-specific IgG titers after boosting.  Mean ± SE.  
D. Avidity of serum anti-gp120-specific antibodies after boosting.  Mean ± SE. n = 4-6; *p 
< 0.05, ***p < 0.001  
 
 
 
 
 
 
 
 
 
 
 
Figure 65.  Dynamics of transitional B cells during repeated immunizations.  Mice 
were immunized and sacrificed as in Figure 59.  A. Transitional B cells (gated on CD19+ 
IgD− GL7+ CD38+); percent of total spleen; mean ± SE.  B. Representative flow plots of 
day 3 and day 7 from mice primed with gp120 DNA.  Quadrants show memory B cells 
(MB) (top left) and transitional B cells (TB) (top right).  
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B cells seem to be differentiating out of a memory B cell phenotype into a transitional cell 
state between days three and seven, while memory cells of GC origin retain their 
phenotype and proliferate.  Thus, while not increasing overall memory B cell numbers, 
priming with gp120 DNA significantly increased the percentage of memory cells of GC 
origin.  Furthermore, in the context of repeated immunizations, between days three and 
seven, memory B cells in all mice decreased, while those with a transitional cell 
phenotype increased, demonstrating a transition from a memory to a more active cell 
state.  
 
Deletion of BCL6 results in a significant increase of gp120-specific IgG 
 
Previously, we have generated a mouse wherein exons 7 – 9 of the BCL6 gene are 
flanked with loxP recombination sites (BCL6fl/fl) (See Chapter 2).  In this study we 
created a new cKO mouse model in which BCL6fl/fl mice were mated to mice expressing 
a Cre recombinase fused to a human estrogen receptor (Cre-ERT2).  Under control of 
the estrogen receptor, we can functionally delete BCL6 by administering tamoxifen to 
these mice.  Unlike our earlier cKO mouse, in which Cre was under the control of the 
CD4 promoter, BCL6fl/fl CreERT2 mice will have BCL6 functionally deleted in all cells once 
 
 
 
  
Figure 66.  Experimental design for deletion of BCL6.  ERT2-Cre BCL6fl/fl mice were 
primed with either gp120-encoding DNA or gp120 protein, followed by 2 booster shots of 
gp120 protein.  Some ERT2-Cre BCL6fl/fl mice also received 5 i.p. injections of tamoxifen 
(T) (4 mg in sunflower seed oil) between the prime and boost injections to delete BCL6.  
Mice were sacrificed 3 days after final injections. 
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Figure 67.  Deletion of BCL6 in 
tamoxifen treated mice.  Total 
spleen cells from ERT2-Cre BCL6fl/fl 
mice were analyzed for deletion of 
BCL6.  RNA from total spleen was 
analyzed via qPCR for BCL6 
transcripts.  Transcript levels were 
normalized to mice not given 
tamoxifen (dotted line at 1.0).  Exons 
2-3 and Exon 8 are shown.   
 
 
tamoxifen is administered.  As in the initial experiments, mice were primed with either 
gp120-encoding DNA or gp120 protein, three times, two weeks apart (Figure 66).   
 
 
During the four week rest period, half of the mice received i.p. injections of tamoxifen 
every day, for five days.  Twelve days after the final tamoxifen injection, mice were given 
the first of two gp120 protein booster injections.  Administration of tamoxifen effectively 
and functionally deleted BCL6 from mice (Figure 67).  Since the most drastic changes in 
GC dynamics were seen three days after final immunizations in our earlier studies, we 
chose this time point to analyze these mice.  Once again, gp120 DNA triggered 
significantly higher TFH and GC B cell populations in the spleen of mice not treated with 
tamoxifen (Figure 68 A-B).  As expected, deletion of BCL6 severely and significantly 
reduced the TFH and GC B cell populations (Figure 68 A-B).  Surprisingly, deletion of 
GCs led to an increase in gp120-specific IgG, (Figure 68 C).  Priming with gp120 DNA, 
followed by functional deletion of BCL6 significantly enhanced antigen-specific IgG titers 
compared to all other groups.  Furthermore, the avidity of these antibodies was 
increased as well (Figure 68 D).  This data verifies the necessity of BCL6 for GC 
development, while demonstrating the dispensability of these structures for antibody 
secretion and affinity maturation in the context of repeated immunizations. 
 
 
DISCUSSION 
 
While a number of research publications have shown the protective advantage of 
incorporating a DNA priming step into heterologous prime-boost vaccination strategies, 
few studies have looked into the mechanism by which DNA priming affords this 
advantage.  Furthermore, almost nothing is known about the role of the TFH cell and the  
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Figure 68.  GCs are lost with deletion of BCL6.  Cre-ER BCL6fl/fl mice were 
immunized as in Figure 66 and sacrificed 3 days after final protein booster injections.  
Some mice were given tamoxifen injections between prime and boost injections to delete 
BCL6.  A. TFH cells (gated as in Figure 61) in spleen of mice either untreated or given 
i.p. tamoxifen injections before boosting.  Representative flow plots of each treatment 
condition.  B. GC B cells (gated as in Figure 61) in spleen after prime-boost regimen with 
representative flow plots of each treatment condition.  Percent of total spleen; n = 3-4; 
mean ± SE.  C. Serum anti-gp120-specific IgG titers after boosting.  D. Avidity of anti-
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gp120-specific antibodies after boosting.  Mean ± SE. n = 3-4; *p < 0.05, **p < 0.01, ***p 
< 0.001  
 
 
GC response in prime-boost vaccinations.  Here, we demonstrate, using an HIV gp120 
vaccine scheme, priming with gp120-encoding DNA yields increased TFH and GC B cell 
populations compared to priming with gp120 protein.  Furthermore, this increase occurs 
at an earlier time-point after immunization.  The early antibody response induced by 
DNA priming was seen after the priming phase, as well as following the boost injections.  
While literature exists explaining the possible different mechanisms of antigen 
processing and presentation with plasmid vector vaccines (159, 164), it is not yet clear 
how the protein from these plasmids affords an advantage.   
 
Human trials of HIV-1 DNA vaccines consisting only of injections of HIV-1-encoding DNA 
(i.e. not prime-boost approaches) have been disappointing for eliciting the production of 
antibodies (165, 166).  More recently, several prime-boost HIV-1 vaccines have been 
tested in humans that use a pure DNA component, as well as protein, and these 
systems have succeeded in provoking a significant antibody response (167-169).  
Studies with cancer vaccines in humans have also supported the utility of DNA priming 
in a prime-boost system (170).  Thus, understanding how DNA priming can augment 
immunity in a prime-boost vaccination system is warranted. 
 
Memory cell development is considered critical for an effective vaccine.  We found no 
apparent increase in memory T cell populations after DNA priming.  However, when 
looking at the proportion of effector Th cells which are TFH cells, we saw that gp120 
DNA priming lead to more activated CD4+ T cells becoming TFH cells, rather than other 
Th cell subsets.  For B cells, priming with DNA effectively enhanced GC memory B cell 
outcomes, in this case by triggering the development of more CD73+ memory B cells, 
which are derived from the GC.  This data, combined with the earlier peak in antigen-
specific IgG, would suggest that priming with gp120 DNA not only triggers more memory 
B cell development from GCs, but that those memory cells underwent affinity maturation 
and differentiated into plasma cells more quickly than with protein priming.  The 
decrease in memory B cell populations between days three and seven, and the 
concurrent increase in transitional cells (Figure 65), shows an interesting trend in terms 
of B cell kinetics.  It would be worthwhile to investigate how repeated immunizations 
 135  
 
affect the timing of this cell transition; perhaps the increased number of immunizations is 
decreasing the time necessary to make this transition. 
 
To investigate the necessity of GCs in the context of repeated immunizations, our 
inducible Cre mouse model allowed us to delete BCL6, the master transcription factor for 
GCs, after priming the mice.  Our data suggests that once memory B cells are formed in 
the priming stage, further formation of GCs actually limits the antibody production of 
antigen-specific IgG-secreting B cells.  Since we observed more memory B cells of GC 
origin developing with gp120 DNA priming (Figure 64 B), we reasoned that during 
protein booster injections, forming GCs limits the antibody-secreting potential of these 
memory cells, as they appear to be better able to differentiate into antibody-secreting 
plasma cells independent of the constrains of the GC.  How these memory cells 
underwent additional affinity maturation, as evident by their increased avidity, outside the 
GC is not understood at this time.  It is possible these B cells are interacting with Th cells 
outside the B cell follicle.   
 
These results have highly significant implications for the field of B cell immunology, HIV-
1 vaccine development, and AIDS therapy.  When and where B cells can undergo 
affinity maturation needs to be fully understood to design an optimal immunization 
schedule that elicits high-affinity, broadly neutralizing antibodies by a prophylactic HIV-1 
vaccine.  Further studies are warranted to determine how much of a role repeated 
immunizations play in extra-follicular antibody development.  At what point GCs are no 
longer needed to develop antigen-specific antibodies with high avidity is of great 
importance to the vaccine field.  Our findings also have potential impact for the design of 
immune therapy strategies for HIV-1 infected people.  Published works have 
demonstrated TFH cells as being a major target and reservoir for HIV-1 (171-173).  
Therefore, it is undesirable to stimulate these cells when treating infected patients.  
However, if there is a way to trigger high-affinity antibody production without involving 
TFH cells, patients could increase their antibody-mediated protection without activating 
the production of new virus from TFH cells. 
 
In conclusion, the key goal of this study was to provide insight into how DNA priming 
provides an advantage in the antibody response, and here we have pinpointed, for the 
first time, the ability of DNA priming to augment the GC reaction, as well as to transiently 
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increase TFH cells.  Thus, the improved antibody response in a heterologous prime-
boost vaccination system with DNA priming can be explained by increased TFH and GC 
function.  At the same time, we have found that the GC reaction appears to limit antibody 
production in the boost phase.  These results should prompt a reevaluation of HIV 
vaccine design.  
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FUTURE DIRECTIONS 
 
Part I – Elucidating the role of BCL6 in repressing DNA methylation 
 
Determining the methylation status of BCL6-deficient naive CD4+ T cells 
 
Using our new cKO mouse model, we were able to determine a relationship between 
BCL6 and Dnmt3b, which is responsible for de novo methylation of DNA.  While we were 
able to establish the presence of Dnmt3b at the PD-1 promoter before immunization, it 
remains undetermined what the genome-wide methylation status is of naïve Th cells in 
BCL6fl/fl CreCD4 mice is.   
 
To investigate this aim, naïve CD4+ T cells should be isolated from naïve BCL6+/+ CreCD4 
and BCL6fl/fl CreCD4 mice via FACS.  Unstimulated naïve cells can then be lysed and 
assessed for DNA methylation via MeDIP analysis.  Briefly, methylated DNA 
immunoprecipitation works by targeting methylated DNA with a methyl cytosine (5-mC)–
specific antibody.  Following this immunoprecipitation, captured DNA can be assessed 
for total quantity, via Nanodrop technology, or sequenced to identify specific genes being 
modified, also known as MeDIP-seq. 
 
In addition to naïve unactivated cells being analyzed, sorted naïve Th cells can also be 
activated in vitro with anti-CD3 and anti-CD28 antibody stimulation.  These cells can be 
harvested over time, such as days three and seven, to track changes in methylation 
overtime using the same analysis tools stated above.  In this way, we can analyze the 
role BCL6 has in suppressing methylation machinery in the cell at different points after 
activation. 
 
To model this experiment in vivo, our cKO mice should first be bred onto an OT-II 
background.  This will cause all the TCRs of CD4+ cells in the mouse to be specific for 
OVA, and, thus, after immunization, have equal opportunities to become activated.  After 
sorting naïve CD4+ T cells from mice to use as a baseline for methylation status, an 
additional set of mice should be immunized and sacrificed at various time points after.  
Naïve (CD44− CD62L+) and effector (CD44+ CD62L−) cells should be isolated from these 
mice.  Analysis of effector cells can shed light on the changing methylation status of cells 
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over time, while analyzing naïve Th cells may provide interesting insights into changes in 
DNA methylation due to environmental cues without cellular activation. 
 
Determine the types of methylation modifications in BCL6-deficient Th cells 
 
While several types of methylation modifications exist, one of the most frequent is 5-
methylcytosine (5mC) (129).  This modification is associated with closed chromatin, and, 
thus, gene repression.  After DNA has been methylated de novo, how it becomes 
demethylated is currently a controversial topic in the field of epigenetics.  The first way in 
which this occurs, which is not contested, is via passive demethylation.  When a cell 
divides and the DNA replicates, the 5mC areas become hemimethylated because the 
new complementary DNA strand is without modifications.  Dnmt1 identifies these areas 
and methylates the new DNA strand in daughter strands, thus returning it to a fully 
methylated state.  If Dnmt1 fails to recognize a hemimethylated area of DNA, that 
segment will become passively demethylated with subsequent cell divisions. 
 
What is controversial is the current proposal that certain enzymes can actively target and 
demethylate 5mC (129).  In this model, TET enzymes can oxidize 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC).  This modified cytosine has been shown to 
be a crucial intermediate in demethylation activity.  Additionally, TET can further oxidize 
5hmC into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC).  These modified bases 
are then targeted for removal by thymine DNA glycosylase (TDG).  TDG, which plays a 
critical role in base excision repair, will remove the methylated cytosine, generating an 
abasic site.  This is followed by replacement with an unmethylated cytosine by DNA 
polymerase.    
 
One reason the type of methylation present in cKO Th cells should be assessed is 
because TET1 and TDG are significantly up-regulated in microarray analysis (Figure 69 
A).  Therefore, not only is DNMT3b increased in the absence of BCL6, but the 
machinery which modifies those methylation modifications put in place by Dnmt3b are 
increased also.  Furthermore, TET1 transcript levels were also found to be increased in 
total Th cells in our time course experiment (Figure 69 B).  For these reasons, not only 
should the total methylation status of DNA in cKO Th cells be assessed, but the type of 
methylation should be addressed as well. 
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Figure 69.  Tet1 and Tdg are up-regulated in the absence of BCL6.  A. Naïve Th 
cells from BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice, cultured, and assessed via 
microarray as described in Chapter 3.  B. BCL6+/+ CreCD4 and BCL6fl/fl CreCD4 mice were 
immunized with SRBC and sacrificed 1, 3, and 5 days after.  Total Th cells were lysed ex 
vivo and analyzed for tet1 transcript.  Levels normalized to Day 1 +/+ (dotted line at 1.0).  
**p < 0.01 by t test. 
  
 
To determine whether the methylation modifications are 5mC, 5hmC, 5fC, or 5caC, a 
ChIP analysis can be performed, as antibodies against these methylation forms are 
available for commercial purchase.  After IP, the captured DNA can be quantified for 
total concentration (Nanodrop) or analyzed for the presence of gene promoters, via 
qPCR or genome wide sequencing (ChIP-seq).  This data can help shed light on the 
current controversy surrounding active DNA demethylation. 
 
An additional reason why the increased expression of TET1 and TDG is interesting is 
the finding that once activated, BCL6-deficient Th cells proved to be more proliferative 
than their WT counterparts.  Perhaps the increased activity of TET1 and TDG in these 
cells is leading to more gene activity via demethylation once the cells are activated. 
 
Determine the physical relationship between BCL6 and Dnmt3b 
 
At this point, we know that Dnmt3b is up-regulated in the absence of BCL6, but how 
BCL6 represses the methyltransferase has not been determined.  Therefore, using 
several different analyses, we can determine at what level BCL6 is repressing Dnmt3b.  
First, by immunoprecipitating for BCL6, using ChIP analysis, we can determine whether 
BCL6 directly binds the Dnmt3b promoter.  To do this, mice should be immunized with 
SRBC and TFH cells sorted to ensure the highest expression of BCL6.  Also, qPCR 
promoters will need to be designed to span the entire Dnmt3b promoter. 
A. B.
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Through its zinc fingers, BCL6 also has the capability to bind RNA.  Therefore, BCL6 
may be repressing translation of Dnmt3b by bindings its transcripts.  To test this, RNA 
immunoprecipitation (RIP) can be employed (174).  Like ChIP analysis, samples are IP 
for a protein of interest and the RNA it associates with is isolated and analyzed.  In this 
way, we can test if BCL6 binds to Dnmt3b mRNA. 
 
Finally, to determine if BCL6 is repressing Dnmt3b by direct protein-protein interactions, 
TFH cells can also be co-IP for BCL6, followed by Dnmt3b.  This standard procedure will 
reveal if these repressors interact on the protein level.  
 
While data using mouse Th cells is crucial for establishing targets of interest, it is also 
important to test these theories in human models.  Using human tonsil samples, we can 
sort TFH cells and test BCL6-Dnmt3b interactions in these cells using the above 
techniques.  If we can identify this association in human T cells, our data could have 
great contributions for the study of human T cell activation. 
 
Effects of BCL6 on the cell cycle 
 
When a naïve Th cell is activated, in addition to up-regulating surface markers and 
secreting cytokines, it will enter the G1 phase of the cell cycle and, ultimately, divide.  
Because we saw decreased activation of naïve Th cells and increased proliferation of 
already activated cells in fl/fl mice, it remains to be investigated what affects BCL6 has 
on the cell cycle.  As discussed in Chapter 5 of this thesis, the chromatin in BCL6-
deficient Th cells appears to be more methylated than its WT counterpart.  Therefore, 
this increased epigenetic modification may be affecting a cell’s ability to enter the cell 
cycle and replicate. 
 
In addition to our methylation findings, further analysis of our microarray data revealed 
significant increases in the expression of genes which play a role in cell cycle 
progression (Figure 70 A).  Nek6 becomes activated during M phase and its inhibition 
will trigger apoptosis.  It associates with Kif11, which plays a role in organizing spindles 
prior to cell division.  Jub was also significantly increased and, in addition to playing roles 
in cell activation and proliferation, it activates Aurora A (aurka) which facilitates mitosis.   
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Figure 70.  Cell cycle genes are up regulated in the absence of BCL6.  A. 
Microarray analysis was done as in Chapter 3.  B. Time course experiment as described 
in Figure 69 B.  C. Naïve CD4+ T cells were isolated via bead separation and activated in 
vitro with anti-CD3 and anti-CD28 antibodies in Th0 media for 24 hours.  Cells were then 
lysed for RNA analysis.  Mean ± SE.  *p < 0.05, **p < 0.01, ***p < 0.001 by t test. 
 
 
Finally, cyclin D2 (ccnd2) plays a role in the transition from G1 to S phase.  When Th 
cells from our time course experiment were analyzed for jub and nek6 transcription, 
increased levels were found in the absence of BCL6 as well (Figure 70 B).  Also, when 
naïve Th cells were activated in vitro with antibodies for 24 hours, transcript levels of 
cyclin D2 were significantly decreased in the absence of BCL6 (Figure 70 C).  Therefore, 
it seems apparent that BCL6 is in some way, repressing cell cycle genes.   
 
This idea seems reasonable when you consider the role of BCL6 in B cells.  BCL6 is 
most highly expressed in the B cells of the GC.  Once there, it is beneficial to control the 
differentiation of these cells and limit it to those with the highest affinity.  Therefore, while 
cell machinery responsible for isotype class switching and somatic hypermutation is 
highly active in these cells, rampant cell differentiation would not be beneficial.  Only 
once these cells have been selected to become plasma cells, secreting the developed 
and mutated antibodies, is BCL6 down-regulated.  The same idea can be applied to TFH 
cells.  Patients with certain autoimmune diseases have been shown to have significantly 
more TFH cells in circulation than healthy controls.  Therefore, massive cell division of 
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TFH cells would be detrimental for human health and makes it possible that BCL6 works 
to limit the cell cycle in TFH cells. 
 
To test the ability for a cell to enter and complete cell cycling, a propidium iodide (PI) 
analysis can be done.  Once naïve Th cells from +/+ and fl/fl mice are activated in vitro 
with antibodies for twenty four hours, they can be fixed and stained with PI to check what 
part of the cell cycle they are currently in.  Using flow cytometry, this assay can 
differentiate cells which are in G0/G1 phase, S phase, and G2/metaphase.  Based on 
the genes which are up-regulated in the microarray, it is possible that BCL6-deficient 
cells are more likely to be going through mitosis than WT cells. 
 
Another way to test a cell’s ability to divide is via BrdU incorporation in vivo.  By injecting 
mice with BrdU before immunizing, we can assess a Th cell’s ability to divide with and 
without BCL6 using our cKO mouse model. 
 
 
Part II – Further investigate the limiting nature of GCs in a prime/boost vaccine 
scheme 
 
Reevaluate our vaccine strategy in a BCL6fl/fl CreCD4-ER model 
 
A noticeable caveat to our gp120 DNA-prime/protein boost vaccine scheme (Chapter 6) 
is that we deleted BCL6 in all cells in our animals, not just in T and B cells which make 
up GCs.  Therefore, deletion in other cells could be affecting antibody development via 
extrinsic factors.  Considering the extrinsic factors at play in BCL6 GL KO mice, which I 
have revealed in this thesis, this is a realistic concern.  Therefore, this vaccine 
experiment should be repeated with BCL6fl/fl CreCD4-ER mice (B6(129X1)-Tg(Cd4-
cre/ERT2)11 Gnri/J) (JAX cat. 022356).  Using this inducible cre model, we can restrict 
BCL6 deletion to T cells.  This will enable us to determine whether the altered antibody 
secretion we observed is due to the lack of GCs, deletion of BCL6 in B cells, or some 
other unidentified extrinsic factor. 
 
Evaluate somatic hypermutation rates in gp120 DNA-prime versus protein-prime B 
cells 
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While our analysis of antibodies using an HIV gp120 DNA prime versus gp120 protein 
prime demonstrated an advantage when the former was used, we did not test the 
mutation rate of immunoglobulin (Ig) genes in B cells.  Therefore, I propose isolating GC 
B cells and non-GC B cells from mice receiving either DNA or protein priming, and after 
they all receive protein boosts.  These cells can be lysed and their Ig genes cloned and 
sequenced. 
 
The complementary determining region of the Ig gene is the site most targeted for 
somatic hypermutation (175).  It undergoes mutation at the approximate rate of 0.05 – 1 
x 10-3 changes per base pair per cell division (175).  Using a database for germline 
sequences in mice (www.vbase2.org) we can determine the rate at which somatic 
hypermutation is taking place in B cells primed with gp120 DNA versus B cells primed 
with gp120 protein. 
 
Determine why GCs are limiting for antibodies resulting from a prime/boost 
vaccine scheme.   
 
As demonstrated in Chapter 6, once GCs were inhibited by injecting mice with tamoxifen 
(and thus deleting BCL6), antibody titers and affinity actually increased without the 
reassembly of these structures.  One way to determine the reason for this is to evaluate 
the somatic hypermutation rates with and without deletion of BCL6.  This can be done 
utilizing methods stated above.  Identifying whether B cells outside the GC undergo 
additional somatic hypermutation can shed light on why these cells seem to secrete 
higher quality antibodies.  If they cannot undergo additional mutations, then it is possible 
that additional booster shots may only be impeding the antibody response. 
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